https://flcube.com/abbvie-files-rinvoq-for-vitiligo-approval-in-us-and-eu/2026-02-04T20:32:52+08:00https://flcube.com/datroway-tnbc-sbla-gets-fda-priority-review-for-triple-negative-breast-cancer/2026-02-04T20:27:14+08:00https://flcube.com/bayer-nubeqa-gets-nmpa-approval-for-metastatic-prostate-cancer/2026-02-04T20:15:39+08:00https://flcube.com/daiichi-sankyo-discontinues-ds-9606-adc-delays-dato-dxd-data/2026-02-04T19:35:18+08:00https://flcube.com/insilico-medicine-doses-first-patient-in-men2501-phase-i-triggers-5m-menarini-milestone/2026-02-03T22:23:52+08:00https://flcube.com/primegenx-therapeutics-files-hong-kong-ipo-for-pumecitinib-platform/2026-02-03T22:19:23+08:00https://flcube.com/jumpcan-licenses-primegenx-pumecitinib-nasal-spray-for-allergic-rhinitis/2026-02-03T22:03:35+08:00https://flcube.com/zeiss-artevo-gets-nmpa-approval-for-china-ophthalmology-market/2026-02-03T21:52:19+08:00https://flcube.com/venglustat-gaucher-sanofi-meets-primary-endpoint-in-phase-3-leap2mono-study/2026-02-03T21:48:20+08:00https://flcube.com/arctic-vision-mdco-technology-merger-builds-ophthalmology-platform/2026-02-03T21:45:26+08:00https://flcube.com/eli-lilly-to-invest-3-5b-in-pennsylvania-plant-for-retatrutide-production/2026-02-03T21:42:52+08:00https://flcube.com/eli-lilly-mounjaro-fails-to-win-eu-approval-for-hfpef-heart-failure-indication/2026-02-03T21:34:17+08:00https://flcube.com/imfinzi-gastric-cancer-astrazeneca-secures-chmp-recommendation/2026-02-03T16:31:12+08:00https://flcube.com/chiesis-juxtapid-wins-nmpa-approval-for-rare-cholesterol-disorder-in-china/2026-02-03T16:25:45+08:00https://flcube.com/zonsen-peplib-signs-eli-lilly-deal-after-novartis-partnership/2026-02-03T16:18:13+08:00https://flcube.com/novartis-cosentyx-wins-nmpa-approval-for-non-radiographic-axial-spondyloarthritis/2026-02-03T16:14:20+08:00https://flcube.com/wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases/2026-02-03T16:10:14+08:00https://flcube.com/nmpa-releases-101st-batch-of-generic-reference-drugs/2026-02-02T22:50:19+08:00https://flcube.com/zenshine-pharma-files-for-hong-kong-ipo-with-357m-valuation/2026-02-02T22:48:33+08:00https://flcube.com/moderna-partners-with-recordati-on-mrna-3927-for-rare-propionic-acidemia/2026-02-02T22:42:46+08:00https://flcube.com/illumina-completes-350m-somalogic-acquisition-to-expand-proteomics-portfolio/2026-02-02T22:40:07+08:00https://flcube.com/microport-ep-medtechs-easyecho-ice-catheter-wins-nmpa-market-clearance/2026-02-02T22:37:11+08:00https://flcube.com/nhsa-targets-nrdl-fund-supervision-in-2026-crackdown/2026-02-02T22:34:24+08:00https://flcube.com/regeneron-q4-revenue-grows-3-to-3-9b-on-eylea-hd-and-dupixent-strength/2026-02-02T22:32:30+08:00https://flcube.com/vcare-pharma-partners-with-sun-novo-on-vc005-jak1-inhibitor-for-atopic-dermatitis/2026-02-02T22:25:29+08:00https://flcube.com/sciwinds-ecnoglutide-wins-nmpa-nod-as-first-camp-biased-glp-1-agonist/2026-02-02T22:11:54+08:00https://flcube.com/fda-opens-precheck-applications-to-strengthen-domestic-drug-manufacturing/2026-02-02T21:18:13+08:00https://flcube.com/abb-bio-techs-trivalent-influenza-vaccine-wins-nmpa-nod-for-all-ages/2026-02-02T21:12:33+08:00https://flcube.com/sanofi-rezurock-wins-eu-backing-for-graft-versus-host-disease/2026-02-02T21:05:25+08:00https://flcube.com/cms-d017-gets-nmpa-nod-for-pnh-clinical-trial/2026-02-02T20:59:50+08:00https://flcube.com/jj-akeega-gets-chmp-nod-for-brca-mutated-prostate-cancer/2026-02-02T18:49:50+08:00https://flcube.com/cde-seeks-feedback-on-103rd-batch-of-generic-reference-preparations/2026-02-02T18:38:04+08:00https://flcube.com/kyowa-kirin-reclaims-rocatinlimab-rights-from-amgen-in-strategic-shift/2026-02-02T17:08:59+08:00https://flcube.com/chiesi-fabry-drug-pegunigalsidase-alfa-wins-chmp-backing-for-extended-dosing/2026-02-02T17:02:31+08:00https://flcube.com/novo-nordisk-appoints-yan-cai-as-greater-china-president-amid-leadershipchange/2026-02-02T16:55:49+08:00https://flcube.com/china-medicals-opzelura-cream-gets-nmpa-approval-for-vitiligo/2026-01-30T14:10:02+08:00https://flcube.com/zhaoke-ophthalmologys-yuvezzi-gets-fda-nod-for-presbyopia/2026-01-30T14:01:57+08:00https://flcube.com/cspcs-sys-6055-car-t-gets-nmpa-nod-for-lymphoma-trials/2026-01-30T13:56:07+08:00https://flcube.com/astrazeneca-commits-14-4b-china-investment-in-cell-therapy-push/2026-01-30T13:49:39+08:00https://flcube.com/ascletis-asc40-phase-iii-success-in-acne-vulgaris/2026-01-30T13:36:46+08:00https://flcube.com/thermo-fisher-reports-q4-revenue-growth-on-ai-innovation/2026-01-30T13:31:14+08:00https://flcube.com/tyk-medicines-asandeutertinib-gets-china-priority-review-for-nsclc-brain-metastases/2026-01-30T13:23:47+08:00https://flcube.com/tyligand-bio-files-hong-kong-ipo-with-phase-ii-kras-g12d-inhibitor-tsn1611/2026-01-30T12:54:18+08:00https://flcube.com/genhouse-bio-files-hong-kong-ipo-with-phase-ii-shp2-inhibitor-gh21/2026-01-30T12:34:14+08:00https://flcube.com/cspc-pharma-signs-18-5b-astrazeneca-deal-for-weight-management-portfolio/2026-01-30T12:29:28+08:00https://flcube.com/sanofi-reports-9-9-sales-growth-to-eur-43-6b-driven-by-dupixent-and-china/2026-01-30T12:21:00+08:00https://flcube.com/united-labs-tul108-gets-fda-nod-for-antibiotic-resistance-trial/2026-01-29T22:03:46+08:00https://flcube.com/kanghua-to-acquire-nanoribo-in-phased-deal-for-mrna-platform/2026-01-29T21:42:44+08:00https://flcube.com/lisata-reclaims-certepetide-china-rights-amid-kuva-acquisition-cvr-milestone-triggered/2026-01-29T21:22:12+08:00https://flcube.com/wuxi-biologics-partners-with-sinorda-on-snd006-bispecific-antibody-for-autoimmune-diseases/2026-01-29T21:07:13+08:00https://flcube.com/neushen-therapeutics-raises-series-a-for-cns-drug-development/2026-01-29T20:57:31+08:00https://flcube.com/organon-completes-465m-jada-system-sale-to-laborie-medical/2026-01-29T20:52:10+08:00https://flcube.com/micurx-mrx-5-gets-fda-nod-for-phase-ii-ntm-lung-disease-study/2026-01-29T20:10:52+08:00https://flcube.com/huiyu-pharma-hyp-6589-gets-nmpa-nod-for-nsclc-osimertinib-combo/2026-01-29T20:04:47+08:00https://flcube.com/servier-oncology-revenue-drives-16-growth-us-sales-surge-70/2026-01-29T16:59:10+08:00https://flcube.com/changchun-high-techs-firsekibart-filing-accepted-for-non-infectious-uveitis/2026-01-29T16:50:34+08:00https://flcube.com/danaher-q4-revenue-grows-3-to-24-6b-on-biotech-and-diagnostics-innovation/2026-01-29T16:22:19+08:00https://flcube.com/distinct-healthcare-ipo-hong-kong-private-provider-seeks-36m-hkex-listing/2026-01-29T14:01:28+08:00https://flcube.com/merck-establishes-chongqing-china-branch-in-milestone-expansion/2026-01-29T13:55:05+08:00https://flcube.com/biogens-litifilimab-secures-fda-breakthrough-therapy-designation-for-lupus/2026-01-29T13:50:41+08:00https://flcube.com/seamless-therapeutics-partners-with-eli-lilly-on-1-12b-hearing-loss-recombinase-deal/2026-01-29T13:43:29+08:00https://flcube.com/sino-biopharms-tqa3605-meets-endpoint-in-hepatitis-b-phase-ii-trial/2026-01-28T22:12:52+08:00https://flcube.com/jj-darzalex-faspro-gets-fda-nod-for-ndmm-d-vrd-regimen/2026-01-28T22:09:32+08:00https://flcube.com/roche-ct-388-obesity-drug-shows-22-5-weight-loss-in-phase-ii-trial/2026-01-28T21:27:57+08:00https://flcube.com/fda-removes-suicide-warnings-from-glp-1-drugs-after-investigation-finds-no-causal-link/2026-01-28T21:05:04+08:00https://flcube.com/leqvio-gets-nmpa-nod-for-monotherapy-in-china-hypercholesterolemia/2026-01-28T21:01:05+08:00https://flcube.com/apeloa-partners-with-mindrank-on-ai-drug-development-platform/2026-01-28T20:54:37+08:00https://flcube.com/china-drug-administration-implementation-regulations-set-for-may-2026-launch/2026-01-28T20:49:42+08:00https://flcube.com/henlius-triple-combo-gets-nmpa-nod-for-advanced-solid-tumor-trials/2026-01-28T14:17:27+08:00https://flcube.com/ivd-medical-launches-nipah-virus-detection-kit-with-ai-early-warning-platform/2026-01-28T14:03:18+08:00https://flcube.com/betta-pharmaceuticals-bpi-572270-ras-inhibitor-gets-nmpa-nod-for-solid-tumor-trials/2026-01-28T13:56:34+08:00https://flcube.com/nanjing-leads-biolabs-secures-fda-fast-track-for-lbl-034-in-multiple-myeloma/2026-01-28T13:32:15+08:00https://flcube.com/nmpa-suspends-two-indian-pharma-apis-over-gmp-violations/2026-01-27T20:18:49+08:00https://flcube.com/zhaoke-ophthalmology-expands-brimochol-pf-presbyopia-distribution-to-singapore-and-vietnam/2026-01-27T19:56:16+08:00https://flcube.com/innovent-biologics-secures-fda-fast-track-for-ibi3003-trispecific-antibody-in-multiple-myeloma/2026-01-27T19:47:42+08:00https://flcube.com/insilico-medicine-partners-with-qilu-pharma-on-ai-drug-development/2026-01-27T19:42:37+08:00https://flcube.com/acrobiosystems-files-for-hong-kong-ipo-as-life-science-tools-leader/2026-01-27T19:36:38+08:00https://flcube.com/aucta-pharma-files-for-hong-kong-ipo-with-cns-and-rare-disease-pipeline/2026-01-27T18:09:30+08:00https://flcube.com/bio-heart-secures-indonesia-approval-for-iberis-rdn-system/2026-01-27T17:56:55+08:00https://flcube.com/bioarctic-partner-eisai-submits-ema-application-for-four-week-lecanemab-dosing-in-alzheimers/2026-01-27T17:49:53+08:00https://flcube.com/nuance-pharma-secures-nmpa-review-for-ensifentrine-copd-maintenance-therapy/2026-01-27T17:42:16+08:00https://flcube.com/ascp-launches-250k-grants-for-mcrc-biomarker-testing-with-pfizer-asco/2026-01-27T17:38:33+08:00https://flcube.com/boehringer-ingelheim-licenses-simceres-sim0709-bispecific-for-inflammatory-bowel-disease/2026-01-27T17:30:50+08:00https://flcube.com/visen-pharma-secures-nmpa-approval-for-skytrofa-in-pediatric-growth-hormone-deficiency/2026-01-27T12:32:02+08:00https://flcube.com/sunshine-lake-pharma-and-xtalpi-form-ai-drug-discovery-joint-venture/2026-01-27T12:14:39+08:00https://flcube.com/hanchorbio-partners-with-wuxi-biologics-on-next-gen-fusion-protein-manufacturing/2026-01-27T11:46:36+08:00https://flcube.com/ascletis-doses-first-patient-in-us-phase-ii-diabetes-study-for-oral-glp-1-asc30/2026-01-26T21:57:00+08:00https://flcube.com/knature-biopharm-files-hong-kong-ipo-backed-by-nad-mitochondrial-platform/2026-01-26T21:52:34+08:00https://flcube.com/sanofis-amlitelimab-hits-phase-iii-goals-in-atopic-dermatitis-targets-q4w-q12w-dosing-edge/2026-01-26T21:32:12+08:00https://flcube.com/microport-endovasculars-talos-stent-graft-secures-eu-ce-mdr-certification/2026-01-26T21:25:30+08:00https://flcube.com/huahui-healths-libevitug-wins-nmpa-approval-as-worlds-first-hdv-antibody-therapy/2026-01-26T21:13:58+08:00https://flcube.com/geneditbio-partners-with-ubrigene-on-lnp-ex-vivo-tech-for-cell-therapy-manufacturing/2026-01-26T21:07:36+08:00https://flcube.com/astrazenecas-soliris-wins-nmpa-approval-for-pediatric-myasthenia-gravis/2026-01-26T21:03:41+08:00https://flcube.com/merck-abandons-32-billion-revolution-medicines-acquisition-over-price-dispute/2026-01-26T21:00:09+08:00https://flcube.com/dizal-pharmaceutical-files-for-hong-kong-ipo-backed-by-astrazeneca-and-first-in-class-oncology-assets/2026-01-26T20:55:31+08:00https://flcube.com/zhongshengs-ray1225-wins-nmpa-approval-for-obesity-sleep-apnea-study-as-phase-iii-wraps-up/2026-01-26T20:47:43+08:00https://flcube.com/changchun-high-techs-gensci145-pi3k%ce%b1-inhibitor-cleared-by-nmpa-for-solid-tumor-study/2026-01-26T20:44:07+08:00https://flcube.com/eisai-biogens-leqembi-autoinjector-wins-fda-priority-review-for-weekly-alzheimers-dosing/2026-01-26T20:40:47+08:00https://flcube.com/healzen-inks-global-dac-partnership-second-tpd-deal-following-jj-alliance/2026-01-26T20:34:31+08:00https://flcube.com/daiichi-sankyo-secures-breakthrough-therapy-designation-for-cdh6-targeted-adc-raludotatug-deruxtecan-in-ovarian-cancer/2026-01-23T15:10:43+08:00https://flcube.com/novo-nordisk-expands-aspect-biosystems-partnership-for-diabetes-cell-therapy/2026-01-23T15:06:18+08:00https://flcube.com/sisram-medical-partners-with-fosun-pharma-subsidiary-on-local-production-base/2026-01-23T14:57:28+08:00https://flcube.com/bd-and-ypsomed-develop-neopak-xtraflow-5-5ml-prefilled-syringe-for-ypsomate-auto-injector/2026-01-23T14:50:46+08:00https://flcube.com/syngene-extends-bms-partnership-to-2035-expanding-crdmo-services/2026-01-23T06:47:54+08:00https://flcube.com/primegenx-therapeutics-files-for-hong-kong-ipo-with-jak-stat-pipeline/2026-01-23T06:37:10+08:00https://flcube.com/jj-reports-94-2-billion-full-year-2025-revenue-driven-by-oncology-and-immunology-growth/2026-01-23T06:15:59+08:00https://flcube.com/abbvie-secures-second-china-approval-for-risankizumab-in-ulcerative-colitis/2026-01-23T06:11:38+08:00https://flcube.com/bio-sincerity-pharma-tech-secures-greater-china-priority-rights-for-delims-semaglutide-and-tirzepatide-portfolio/2026-01-23T06:07:56+08:00https://flcube.com/taigen-and-joincare-partner-on-tg-4318-dpp1-inhibitor-for-bronchiectasis-in-greater-china/2026-01-23T05:58:03+08:00https://flcube.com/china-isotope-radiation-corporation-signs-commercial-deal-for-pluvicto-chinas-first-psma-radioligand-therapy/2026-01-22T21:21:43+08:00https://flcube.com/matwings-technology-partners-with-leading-us-biotech-on-aiacclbio-platform-for-biopharmaceutical-pipeline/2026-01-22T21:16:04+08:00https://flcube.com/amcellgene-licenses-mesenchymal-stem-cell-therapy-for-aclf-to-advanced-regeneration-in-first-chinese-stem-cell-outbound-deal/2026-01-22T21:12:50+08:00https://flcube.com/huadong-medicine-secures-exclusive-china-commercialization-rights-for-linaprazan-glurate-p-cab-from-sinorda/2026-01-22T21:04:00+08:00https://flcube.com/enhertu-wins-china-nmpa-approval-for-second-line-her2-positive-gastric-cancer/2026-01-22T20:52:30+08:00https://flcube.com/astrazenecas-imfinzi-wins-china-approval-for-endometrial-cancer-securing-seventh-indication/2026-01-22T20:44:36+08:00https://flcube.com/heartcare-medicals-intracranial-drug-eluting-stent-gets-nmpa-filing-nod/2026-01-22T11:09:42+08:00https://flcube.com/shanghai-heartcare-medical-secures-taiwan-approval-for-homegrown-femoral-artery-occluder/2026-01-22T11:04:30+08:00https://flcube.com/abbotts-tactiflex-duo-wins-ce-mark-for-atrial-fibrillation-treatment-in-europe/2026-01-22T11:00:03+08:00https://flcube.com/lillys-sofetabart-wins-fda-breakthrough-status-for-platinum-resistant-ovarian-cancer/2026-01-22T10:57:08+08:00https://flcube.com/ascletis-selects-asc37-as-clinical-candidate-for-monthly-triple-agonist-therapy/2026-01-22T10:53:32+08:00https://flcube.com/novavax-licenses-matrix-m-adjuvant-to-pfizer-in-530m-deal/2026-01-22T10:46:59+08:00https://flcube.com/henliuss-hlx701-gets-nmpa-nod-for-phase-ib-ii-advanced-crc-combination-study/2026-01-22T10:41:44+08:00https://flcube.com/bioray-pharmaceutical-files-hkex-ipo-backed-by-first-in-class-autoimmune-and-oncology-pipeline/2026-01-22T10:19:13+08:00https://flcube.com/bms-partners-with-microsoft-on-ai-powered-nsclc-detection-platform/2026-01-22T09:53:43+08:00https://flcube.com/bayer-partners-with-vanderbilt-in-5-year-deal-to-accelerate-cardio-renal-drug-discovery/2026-01-22T09:49:06+08:00https://flcube.com/hangzhou-diagens-biotechnology-files-hkex-ipo-for-medical-imaging-ai-platform/2026-01-22T09:43:37+08:00https://flcube.com/gsk-acquires-rapt-therapeutics-for-2-2-billion-adding-ozureprubart-for-food-allergy-protection/2026-01-22T09:23:25+08:00https://flcube.com/alteogen-licenses-alt-b4-hyaluronidase-to-tesaro-for-285m-subcutaneous-dostarlimab-deal/2026-01-22T02:02:05+08:00https://flcube.com/shanghai-pharmas-inkt-cell-therapy-b023-gets-nmpa-nod-for-advanced-solid-tumors/2026-01-22T01:56:07+08:00https://flcube.com/biokins-iza-bren-adc-receives-nmpa-filing-acceptance-for-escc-worlds-first-egfrxher3-bispecific/2026-01-22T01:51:03+08:00https://flcube.com/kawin-technology-withdraws-hepatitis-b-filing-for-peginterferon-alfacon-2-after-nmpa-feedback/2026-01-22T01:44:23+08:00https://flcube.com/eyebright-medical-to-acquire-control-of-delta-medical-in-143-m-sports-medicine-deal/2026-01-22T01:38:01+08:00https://flcube.com/astrazeneca-to-delist-from-nasdaq-shift-direct-nyse-listing-in-share-structure-unification/2026-01-22T01:31:35+08:00https://flcube.com/mersons-bemejing-wins-first-cnmr-overseas-version-drug-price-certificate/2026-01-21T15:19:26+08:00https://flcube.com/insilico-licenses-nlrp3-inhibitor-ism8969-to-hengtai-in-64m-cns-drug-deal/2026-01-20T20:51:39+08:00https://flcube.com/ocumensions-ot-703-dme-implant-enrolls-195-patients-in-china-real-world-study/2026-01-20T20:46:28+08:00https://flcube.com/aim-vaccines-pcv20-gets-nmpa-clinical-approval-challenging-pfizers-monopoly/2026-01-20T20:41:29+08:00https://flcube.com/shionogi-boosts-viiv-stake-to-21-7-in-2-1-billion-deal-doubles-down-on-hiv-focus/2026-01-20T20:35:00+08:00https://flcube.com/grand-pharmaceutical-files-tlx591-cdx-psma-diagnostic-for-prostate-cancer-in-china/2026-01-20T20:27:48+08:00https://flcube.com/d3-bios-kras-programs-advance-fda-clears-phase-i-g12d-inhibitor-d3s-003-and-phase-ii-g12c-erk-combo/2026-01-20T20:21:32+08:00https://flcube.com/aideas-adc205-hiv-combo-gets-nmpa-nod-for-clinical-trials-targeting-2-8b-market/2026-01-20T20:18:42+08:00https://flcube.com/blue-sails-lithonic-ivl-system-wins-ce-mark-for-coronary-calcified-lesions/2026-01-20T20:10:59+08:00https://flcube.com/shionogis-fetroja-wins-china-nmpa-approval-for-complicated-utis-targets-resistant-gram-negative-infections/2026-01-20T20:07:36+08:00https://flcube.com/chiesis-raxone-begins-lhon-treatment-in-china-first-world-approved-therapy/2026-01-20T20:03:25+08:00https://flcube.com/easydiagnosis-bio-to-acquire-51-of-ailex-medical-in-5-1m-deal-gains-ivd-platform/2026-01-20T19:16:53+08:00https://flcube.com/astrazeneca-secures-full-global-rights-to-abelzetas-c-car031-in-630m-car-t-deal/2026-01-20T00:19:43+08:00https://flcube.com/novartiss-ianalumab-wins-fda-breakthrough-therapy-designation-for-sjogrens-disease/2026-01-20T00:14:03+08:00https://flcube.com/medtronic-and-precision-neuroscience-form-first-brain-device-alliance-to-access-neural-data/2026-01-20T00:01:05+08:00https://flcube.com/akesos-gumokimab-nmpa-filing-for-ankylosing-spondylitis-expands-il-17a-franchise/2026-01-19T23:24:13+08:00https://flcube.com/harbour-biomed-boosts-spruce-stake-to-3-8-advancing-spr202-for-adrenal-disease/2026-01-19T22:45:17+08:00https://flcube.com/dualitys-db-1317-adc-receives-ind-approval-for-adam9-targeted-solid-tumor-therapy/2026-01-19T22:41:47+08:00https://flcube.com/biogens-high-dose-spinraza-wins-eu-approval-for-5q-sma-after-japan-nod/2026-01-19T16:49:03+08:00https://flcube.com/inventisbio-files-for-hong-kong-ipo-betting-on-oncology-and-metabolic-pipeline/2026-01-16T22:22:40+08:00https://flcube.com/boston-scientific-to-acquire-penumbra-in-14-5-billion-deal-bolsters-thrombectomy-leadership/2026-01-16T20:19:26+08:00https://flcube.com/gan-lees-insulin-glargine-wins-ethiopia-approval-challenging-sanofis-dominance/2026-01-16T20:10:07+08:00https://flcube.com/zelgens-zggs18-zg005-cleared-by-nmpa-for-advanced-solid-tumor-studies/2026-01-16T20:06:26+08:00https://flcube.com/jj-medtech-partners-with-ced-medical-to-accelerate-neurovascular-intervention-solutions/2026-01-16T20:03:09+08:00https://flcube.com/signet-therapeutics-completes-preclinical-study-for-sigx2649-pan-tead-inhibitor-for-solid-tumors/2026-01-16T20:01:07+08:00https://flcube.com/vitalgens-vgn-r08b-gene-therapy-earns-fda-orphan-drug-designation-for-gaucher-disease/2026-01-16T19:58:06+08:00https://flcube.com/cardiac-bio-solutions-launches-mycardia-at-china-production-with-shenzhen-ebulent/2026-01-16T14:40:15+08:00https://flcube.com/bio-thera-solutions-licenses-bat2206-stelara-biosimilar-to-gedeon-richter-in-110m-deal/2026-01-15T23:02:43+08:00https://flcube.com/jiangsu-aidea-raises-rmb-185-m-via-private-placement-to-boost-nanda-pharma-stake-to-73-4/2026-01-15T22:58:44+08:00https://flcube.com/huadong-medicines-dr10624-wins-fda-nod-for-masld-study-first-triple-agonist-to-enter-clinic/2026-01-15T22:54:47+08:00https://flcube.com/fresenius-kabi-licenses-tq-therapeutics-cell-tech-for-automated-t-cell-isolation-in-cell-therapy/2026-01-15T22:42:40+08:00https://flcube.com/bmss-mavacamten-shows-significant-lvot-reduction-in-first-adolescent-ohcm-phase-iii-study/2026-01-15T22:37:20+08:00https://flcube.com/abm-therapeutics-licenses-mek1-2-inhibitor-abm-168-to-mosaica-medicines-for-global-development/2026-01-15T22:26:04+08:00https://flcube.com/wuxi-xdc-acquires-tot-bio-in-357m-deal-to-bolster-adc-cdmo-leadership/2026-01-15T22:13:46+08:00https://flcube.com/fosun-kairos-secures-greater-china-rights-to-elpasbios-allojoin-for-knee-osteoarthritis/2026-01-15T22:05:39+08:00https://flcube.com/sino-biopharmaceutical-buys-hygieia-pharma-for-up-to-rmb-1-2-b-adding-sirna-platform-for-chronic-diseases/2026-01-15T21:41:01+08:00https://flcube.com/nhsa-releases-nrdl-value-assessment-guidelines-prioritizing-8-drug-categories-for-real-world-evaluation/2026-01-15T21:35:38+08:00https://flcube.com/jjs-tecvayli-shows-71-pfs-reduction-in-phase-3-majestec-9-for-multiple-myeloma/2026-01-15T19:51:54+08:00https://flcube.com/immvira-bio-files-for-hong-kong-ipo-with-phase-ii-oncolytic-immunotherapy-mvr-t3011/2026-01-15T19:47:08+08:00https://flcube.com/exegenesis-bio-files-for-hong-kong-ipo-with-ai-powered-gene-therapy-pipeline/2026-01-15T16:28:02+08:00https://flcube.com/sunshine-lake-pharma-launches-ai-powered-protac-platform-to-target-undruggable-proteins/2026-01-15T14:36:55+08:00https://flcube.com/qyuns-qx030n-partner-caldera-raises-112-5-million-for-ibd-bispecific/2026-01-15T14:00:09+08:00https://flcube.com/leads-biolabs-opamtistomig-secures-fda-fast-track-for-ep-nec-as-first-4-1bb-bispecific/2026-01-15T13:37:13+08:00https://flcube.com/wuxi-biologics-secures-mhra-gmp-certification-for-ophthalmic-biologic-manufacturing-facilities/2026-01-14T22:45:16+08:00https://flcube.com/nvidia-and-eli-lilly-launch-1-billion-ai-co-innovation-lab-to-transform-drug-development/2026-01-14T22:00:15+08:00https://flcube.com/astrazeneca-acquires-modella-ai-to-embed-multi-modal-foundation-models-in-oncology-rd/2026-01-14T21:48:56+08:00https://flcube.com/xellsmart-raises-rmb-400-m-in-series-b-b-and-c1-for-ipsc-parkinsons-therapy-backed-by-3sbio-and-crhc-fund/2026-01-14T21:45:10+08:00https://flcube.com/wuxi-apptec-projects-2025-revenue-of-6-51-billion-net-profit-surges-103-on-divestments/2026-01-14T21:40:38+08:00https://flcube.com/fosun-kairos-inks-vitalgen-tech-deal-to-develop-in-vivo-car-t-for-autoimmune-diseases/2026-01-14T21:36:07+08:00https://flcube.com/immuneoncos-imm2510-advances-to-phase-ii-iii-in-endometrial-cancer-after-axion-bio-deal-termination/2026-01-14T21:30:14+08:00https://flcube.com/henliuss-hanbeitai-bevacizumab-biosimilar-bla-accepted-by-fda-for-multiple-solid-tumors/2026-01-14T21:27:07+08:00https://flcube.com/u-yin-pharmas-eht102-gene-therapy-scores-ind-approval-under-nmpas-30-day-review-for-dfnb9-hearing-loss/2026-01-14T21:23:43+08:00https://flcube.com/genhouse-bio-raises-rmb-300-million-in-cross-over-round-led-by-green-pine-capital/2026-01-14T14:17:52+08:00https://flcube.com/haichang-biotechs-hc016-receives-fda-orphan-drug-designation-for-osteosarcoma/2026-01-14T13:55:06+08:00https://flcube.com/iktos-and-servier-forge-eur-1-billion-ai-drug-discovery-collaboration/2026-01-14T13:41:23+08:00https://flcube.com/sanofis-teizeild-wins-eu-approval-as-first-disease-modifying-therapy-for-type-1-diabetes/2026-01-13T22:07:16+08:00https://flcube.com/cspcs-prusogliptin-metformin-fdc-nda-accepted-by-nmpa-for-type-2-diabetes-targeting-60-m-underserved-patients/2026-01-13T22:04:06+08:00https://flcube.com/lifetechs-cs-stent-system-wins-nmpa-fast-track-for-aortic-arch-aneurysms-eliminates-cerebral-ischemia-risk/2026-01-13T21:55:30+08:00https://flcube.com/immuneoncos-timdarpacept-receives-nmpa-nod-for-atherosclerosis-study-expanding-cd47-platform/2026-01-13T21:51:35+08:00https://flcube.com/merck-and-abbiskos-pimicotinib-nda-accepted-by-fda-for-tgct-building-on-china-approval/2026-01-13T21:16:55+08:00https://flcube.com/hisoar-pharma-invests-rmb-150-million-in-wanbangdes-wp205-for-als-securing-15-global-revenue-share/2026-01-13T21:11:38+08:00https://flcube.com/fda-approves-zycubo-as-first-therapy-for-pediatric-menkes-disease-targeting-ultra-rare-copper-deficiency-disorder/2026-01-13T21:06:21+08:00https://flcube.com/abbvie-commits-100-billion-us-investment-and-trumprx-expansion-for-tariff-relief/2026-01-13T20:58:21+08:00https://flcube.com/bayer-ag-acquires-cardiac-amyloidosis-imaging-tracers-from-attralus-including-phase-iii-at-01-with-fda-breakthrough-designation/2026-01-13T20:47:01+08:00https://flcube.com/bmss-camzyos-meets-primary-endpoint-in-phase-iii-scout-hcm-study-for-adolescent-ohcm/2026-01-13T20:43:15+08:00https://flcube.com/nhsa-launches-6th-vbp-tender-for-medical-consumables-in-china-targeting-drug-coated-balloons/2026-01-13T20:39:57+08:00https://flcube.com/summit-therapeutics-submits-ivonescimab-bla-to-fda-for-egfr-mutated-nsclc-post-third-gen-tki/2026-01-13T20:32:09+08:00https://flcube.com/chinas-nhsa-launches-pre-communication-pilot-for-reference-drugs-targeting-category-1-innovative-drugs/2026-01-13T20:27:57+08:00https://flcube.com/remegen-licenses-rc148-bispecific-to-abbvie-for-up-to-5-6-billion-in-milestones/2026-01-13T14:19:19+08:00https://flcube.com/broncus-medical-secures-nmpa-fast-track-for-bronctarget-copd-system-targeting-9-million-refractory-patients-in-china/2026-01-13T14:09:55+08:00https://flcube.com/boehringer-ingelheim-jazz-launch-phase-i-her2-breast-cancer-combo-with-zongertinib-zanidatamab/2026-01-13T13:59:41+08:00https://flcube.com/thermo-fisher-scientific-partners-with-nvidia-in-280-million-ai-deal-to-automate-laboratory-operations/2026-01-13T13:51:02+08:00https://flcube.com/scineuro-pharmaceuticals-licenses-alzheimers-bbb-antibody-platform-to-novartis-in-1-5-billion-deal/2026-01-13T13:43:52+08:00https://flcube.com/carsgen-therapeutics-enters-phase-i-collaboration-with-dispatch-bio-for-ct053-car-t-in-solid-tumors/2026-01-13T13:25:10+08:00https://flcube.com/noetik-enters-50m-ai-collaboration-with-gsk-licensing-octo-vc-virtual-cell-models-for-nsclc-and-crc/2026-01-12T23:12:11+08:00https://flcube.com/alphamab-oncology-submits-envafolimab-for-first-line-biliary-tract-cancer-btc-as-worlds-first-subcutaneous-pd-l1/2026-01-12T22:51:50+08:00https://flcube.com/pfizers-braftovi-trio-achieves-64-response-rate-in-breakwater-cohort-3-for-braf-v600e-metastatic-colorectal-cancer/2026-01-12T22:46:52+08:00https://flcube.com/insilico-medicine-doses-first-patient-in-phase-iia-study-of-ai-designed-ism5411-for-inflammatory-bowel-disease/2026-01-12T22:43:22+08:00https://flcube.com/lynk-pharmaceuticals-reports-positive-phase-iii-data-for-zemprocitinib-in-rheumatoid-arthritis-best-in-class-jak1-inhibitor-shows-79-acr20-response/2026-01-12T22:29:23+08:00https://flcube.com/lifetech-scientific-secures-nmpa-approval-for-g-iliac-pro-upgraded-iliac-branch-device-for-aortic-aneurysm-repair/2026-01-12T22:25:50+08:00https://flcube.com/mirxes-partners-with-thailands-n-health-to-launch-mirna-cancer-screening/2026-01-12T22:13:13+08:00https://flcube.com/santens-upneeq-wins-japan-approval-for-acquired-ptosis/2026-01-12T22:09:58+08:00https://flcube.com/biocytogen-licenses-adc-programs-to-acepodia-in-option-deal/2026-01-12T21:52:32+08:00https://flcube.com/simcere-pharma-to-spin-off-zaiming-unit-for-hong-kong-ipo/2026-01-12T21:48:10+08:00https://flcube.com/nona-biosciences-partners-with-link-cell-on-car-t-discovery-using-hcab-platform/2026-01-12T21:32:19+08:00https://flcube.com/hengruis-quadruple-prostate-cancer-combo-wins-nmpa-ind-for-phase-2-study/2026-01-12T21:12:58+08:00https://flcube.com/shanghai-pharma-receives-nmpa-approval-for-myasthenia-gravis-oral-solution/2026-01-12T21:06:21+08:00https://flcube.com/fda-announces-flexible-cmc-pathway-for-cell-and-gene-therapies-to-accelerate-development/2026-01-12T21:02:03+08:00https://flcube.com/huadong-medicines-dr10624-wins-breakthrough-designation-for-severe-hypertriglyceridemia/2026-01-12T20:59:41+08:00https://flcube.com/dongcheng-pharmas-psma-pet-agent-18f-spiritide-nda-accepted-by-nmpa/2026-01-12T20:55:39+08:00https://flcube.com/novartis-to-build-23-billion-rlt-facility-in-florida-expanding-cancer-therapy-capacity/2026-01-12T20:51:18+08:00https://flcube.com/pierre-fabre-partners-with-iktos-on-ai-driven-oncology-drug-discovery/2026-01-12T20:47:52+08:00https://flcube.com/nhsa-launches-personal-healthcare-insurance-cloud-pilot-program/2026-01-12T20:44:48+08:00https://flcube.com/china-expands-medical-insurance-personal-account-pooling-nationwide/2026-01-12T20:42:05+08:00https://flcube.com/haisco-licenses-copd-drug-hsk39004-to-airnexis-for-1-06-billion/2026-01-12T17:04:42+08:00https://flcube.com/novartis-secures-exclusive-rights-to-zonsen-peplibs-radioligand-asset/2026-01-12T16:34:19+08:00https://flcube.com/boan-biosimilar-prolia-wins-bolivia-approval-targets-global-markets/2026-01-12T14:31:37+08:00https://flcube.com/johnson-johnson-strikes-tariff-exemption-deal-with-trump-administration/2026-01-12T13:56:32+08:00https://flcube.com/hybio-pharmaceutical-licenses-semaglutide-to-vitamedic-for-brazil-market/2026-01-11T21:29:17+08:00https://flcube.com/merck-in-talks-to-acquire-revolution-medicines-for-28-32-billion-in-oncology-push/2026-01-11T21:10:26+08:00https://flcube.com/genrix-bios-gr1803-nda-accepted-for-bcma-targeted-multiple-myeloma-therapy/2026-01-11T21:05:52+08:00https://flcube.com/remegens-rc48-wins-fourth-breakthrough-therapy-designation-for-gastric-cancer-combo/2026-01-11T20:59:33+08:00https://flcube.com/merck-initiates-phase-3-trial-for-calderasib-keytruda-qlex-in-kras-g12c-nsclc/2026-01-11T20:44:45+08:00https://flcube.com/takeda-licenses-halozymes-enhanze-technology-for-vedolizumab-in-global-deal/2026-01-11T14:01:46+08:00https://flcube.com/hansoh-pharmaceuticals-ameile-wins-fifth-nmpa-indication-for-egfr-mutated-nsclc/2026-01-11T13:56:01+08:00https://flcube.com/eisai-china-and-xuanwu-hospital-forge-strategic-cooperation-for-drug-rd/2026-01-11T13:52:21+08:00https://flcube.com/imunopharms-im19-car-t-wins-nmpa-ind-for-second-line-nhl-therapy/2026-01-10T23:39:32+08:00https://flcube.com/indupro-partners-with-lilly-on-950m-oncology-deal-using-proximity-guided-platform/2026-01-10T21:55:07+08:00https://flcube.com/medilink-licenses-b7h3-adc-yl201-to-roche-in-850-million-global-deal/2026-01-10T21:49:51+08:00https://flcube.com/shanghai-micurxs-contezolid-patent-extended-through-2033-securing-market-exclusivity/2026-01-10T21:45:19+08:00https://flcube.com/lillys-taltz-zepbound-combo-meets-primary-endpoint-in-psoriatic-arthritis/2026-01-10T21:37:45+08:00https://flcube.com/nmpa-issues-new-rules-to-strengthen-pharmaceutical-contract-manufacturing-oversight/2026-01-09T16:48:36+08:00https://flcube.com/betta-pharmaceuticals-partners-with-westlake-university-on-pharma-innovation/2026-01-08T20:54:56+08:00https://flcube.com/viva-biotech-and-cms-forge-ai-powered-drug-development-alliance/2026-01-08T20:49:14+08:00https://flcube.com/hisun-and-ecnu-forge-ai-drug-discovery-partnership/2026-01-08T20:43:32+08:00https://flcube.com/nmpa-issues-priority-review-guidelines-for-clinically-urgent-overseas-drugs/2026-01-08T20:34:08+08:00https://flcube.com/hengruis-retlirafusp-%ce%b1-wins-nmpa-approval-for-first-line-gastric-cancer/2026-01-08T14:01:03+08:00https://flcube.com/pfizer-partners-with-cartography-on-850-million-tumor-antigen-discovery-deal/2026-01-08T13:53:31+08:00https://flcube.com/sanofis-redemplo-wins-nmpa-approval-as-first-sirna-for-familial-chylomicronemia/2026-01-08T13:42:58+08:00https://flcube.com/bayers-cevatertinib-wins-breakthrough-therapy-designation-for-her2-mutant-nsclc/2026-01-08T13:32:14+08:00https://flcube.com/immuneonco-terminates-axion-licenses-regains-global-rights-to-imm2510-and-imm27m/2026-01-08T13:24:08+08:00https://flcube.com/hutchmeds-sovleplenib-meets-phase-3-primary-endpoint-in-waiha-targets-nda-filing/2026-01-08T13:20:58+08:00https://flcube.com/structure-therapeutics-licenses-glp-1-patents-to-roche-for-100-million-upfront/2026-01-08T01:02:03+08:00https://flcube.com/sichuan-biokins-bl-b01d1-adc-wins-priority-review-for-escc-in-china/2026-01-08T00:56:07+08:00https://flcube.com/ikarovec-and-vectorbuilder-sign-1-billion-aav-capsid-deal-for-amd-gene-therapy/2026-01-08T00:52:42+08:00https://flcube.com/zai-labs-repotrectinib-wins-nmpa-snda-for-ntrk-fusion-positive-solid-tumors/2026-01-08T00:47:38+08:00https://flcube.com/mabwell-partners-with-sentonix-on-neurodegenerative-disease-drug-discovery-alliance/2026-01-08T00:43:49+08:00https://flcube.com/amgen-acquires-dark-blue-therapeutics-for-840-million-to-expand-aml-portfolio/2026-01-08T00:38:25+08:00https://flcube.com/xtalpis-rtx-117-wins-nmpa-ind-for-cmt-therapy/2026-01-08T00:26:00+08:00https://flcube.com/ascentages-protac-btk-degrader-apg-3288-wins-fda-ind-for-b-cell-malignancies/2026-01-08T00:23:02+08:00https://flcube.com/takeda-and-protagonist-submit-rusfertide-nda-for-polycythemia-vera/2026-01-07T21:02:26+08:00https://flcube.com/sanofis-tzield-wins-fda-priority-review-for-pediatric-t1d-expansion/2026-01-07T20:57:02+08:00https://flcube.com/novo-nordisk-lilly-cut-china-prices-for-wegovy-mounjaro-by-up-to-80/2026-01-07T20:52:00+08:00https://flcube.com/lilly-nears-1-billion-deal-for-ventyxs-ibd-pipeline/2026-01-07T20:47:57+08:00https://flcube.com/nimbus-therapeutics-partners-with-eli-lilly-on-1-3-billion-obesity-drug-deal/2026-01-07T16:21:23+08:00https://flcube.com/yifan-pharmaceuticals-f-652-wins-nmpa-ind-for-gvhd-therapy/2026-01-06T22:36:05+08:00https://flcube.com/nmpa-releases-draft-102nd-reference-preparations-list-for-generic-drugs/2026-01-06T22:27:22+08:00https://flcube.com/mabwells-synusight-licenses-pet-tracer-18f-fd4-to-abli-for-parkinsons-trials/2026-01-06T22:17:11+08:00https://flcube.com/earendil-labs-partners-with-sanofi-on-2-56-billion-bispecific-antibody-deal-for-autoimmune-diseases/2026-01-06T22:00:24+08:00https://flcube.com/ark-biopharmas-azstarys-approved-in-china-for-adhd-first-new-methylphenidate-in-20-years/2026-01-06T21:52:41+08:00https://flcube.com/hengruis-hrs9531-and-ar-protac-win-nmpa-ind-approval-for-clinical-trials/2026-01-06T21:07:39+08:00https://flcube.com/genhouse-bios-mat2a-inhibitor-gh31-wins-nmpa-and-fda-clinical-trial-approvals/2026-01-06T13:56:36+08:00https://flcube.com/touchstone-medical-partners-with-inspur-to-advance-healthcare-ai-and-medical-robots/2026-01-06T13:48:07+08:00https://flcube.com/yifan-pharmaceutical-licenses-act001-for-sclc-brain-metastases-across-12-asian-markets/2026-01-06T11:22:58+08:00https://flcube.com/humanwell-healthcares-hw221043-receives-nmpa-approval-for-advanced-solid-tumor-trials/2026-01-06T11:02:10+08:00https://flcube.com/bio-sincerity-partners-with-xellar-on-ai-organoid-chip-drug-discovery-platform/2026-01-06T00:04:31+08:00https://flcube.com/frontier-biotechs-fb7013-wins-nmpa-ind-for-masp-2-sirna-in-iga-nephropathy/2026-01-05T23:10:01+08:00https://flcube.com/insilico-medicine-partners-with-servier-on-888-million-ai-oncology-deal/2026-01-05T23:03:40+08:00https://flcube.com/kelun-biotechs-sac-tmt-wins-breakthrough-therapy-designation-for-first-line-nsclc/2026-01-05T22:51:49+08:00https://flcube.com/kangtai-biological-co-founds-beijing-laboratory-to-advance-synthetic-immunology-and-vaccine-manufacturing/2026-01-05T22:38:43+08:00https://flcube.com/kelun-biotechs-itgb6-adc-skb105-wins-nmpa-ind-approval/2026-01-05T22:33:58+08:00https://flcube.com/huadong-medicine-licenses-mc2s-pad-based-biomee-skincare-for-greater-china/2026-01-05T22:27:06+08:00https://flcube.com/cms-unveils-balance-model-to-expand-glp-1-access-for-medicare-medicaid/2026-01-05T22:17:37+08:00https://flcube.com/geneditbios-geb-101-wins-fda-ind-approval-as-worlds-first-corneal-gene-therapy/2026-01-05T21:52:07+08:00https://flcube.com/mercks-winrevair-wins-china-nmpa-approval-for-pulmonary-arterial-hypertension/2026-01-05T20:40:42+08:00https://flcube.com/aspen-holdings-sells-asia-pacific-business-to-bgh-capital-for-aud-2-37-billion/2026-01-04T16:41:37+08:00https://flcube.com/china-approves-record-76-innovative-drugs-in-2025-as-out-licensing-hits-130-billion/2026-01-04T16:35:38+08:00https://flcube.com/china-supreme-court-upholds-novo-nordisk-semaglutide-patent-validity/2026-01-04T16:30:05+08:00https://flcube.com/insilico-medicine-and-hisun-pharma-nominate-pcc-in-8-months-via-ai-platform/2026-01-04T15:02:06+08:00https://flcube.com/genmab-discontinues-acasunlimab-to-focus-on-late-stage-portfolio/2026-01-04T14:54:10+08:00https://flcube.com/nhc-releases-fourth-batch-generic-drugs-catalogue-prioritizing-innovation-and-fertility-support/2026-01-04T14:28:19+08:00https://flcube.com/tarlatamab-enters-china-via-hainan-pilot-zone-as-first-sclc-immunotherapy/2026-01-04T14:20:37+08:00https://flcube.com/china-state-council-approves-revised-drug-administration-regulations-accelerating-innovation-review/2026-01-04T14:03:28+08:00https://flcube.com/aosaikang-licenses-adlai-nortyes-pan-ras-inhibitor-an9025-for-china-in-100-million-deal/2025-12-31T21:41:49+08:00https://flcube.com/hutchmeds-savolitinib-nda-accepted-by-nmpa-for-met-amplified-gastric-cancer-with-priority-review/2025-12-31T21:32:03+08:00https://flcube.com/neurogen-pharma-invests-rmb-80-million-in-gba-medical-park-for-neurology-expansion/2025-12-31T21:08:47+08:00https://flcube.com/zelgen-licenses-zg006-to-abbvie-for-1-2-billion-in-milestones-ex-china/2025-12-31T20:59:51+08:00https://flcube.com/sirius-therapeutics-doses-first-phase-ii-patient-for-srsd216-sirna-hyperlipoproteinemia-therapy/2025-12-31T14:05:30+08:00https://flcube.com/ribo-life-science-raises-hk1-6-billion-in-hong-kong-ipo-for-sirna-pipeline/2025-12-31T10:56:03+08:00https://flcube.com/broncus-medical-acquires-valgen-stake-from-venus-for-15-million/2025-12-30T21:28:40+08:00https://flcube.com/cspc-pharmaceutical-receives-ind-approvals-for-glp-1-gip-agonist-and-triple-combo-diabetes-drug/2025-12-30T21:20:25+08:00https://flcube.com/hengruis-hrs-6257-receives-ind-approval-for-novel-pain-therapy-in-china/2025-12-30T21:06:21+08:00https://flcube.com/jiangsu-hengruis-rezvilutamide-clears-nmpa-hurdle-moves-into-phase-iii-prostate-cancer-trial/2025-12-30T21:03:20+08:00https://flcube.com/hengrui-nmpa-approves-four-clinical-trials-advancing-oncology-and-metabolic-pipeline/2025-12-30T21:03:20+08:00https://flcube.com/hansoh-pharma-licenses-hengruis-shr6508-for-rmb-220-million-to-expand-renal-portfolio/2025-12-30T21:03:19+08:00https://flcube.com/recbios-rec610-shingles-vaccine-nda-accepted-by-nmpa-challenging-gsks-shingrix/2025-12-30T20:59:00+08:00https://flcube.com/edge-medical-raises-hk1-2-billion-in-hong-kong-ipo-to-fund-surgical-robot-pipeline/2025-12-30T20:39:50+08:00https://flcube.com/jjs-jnj-5939-fails-phase-2b-efficacy-endpoint-triggers-early-termination-of-atopic-dermatitis-trial/2025-12-30T20:16:20+08:00https://flcube.com/hutchmeds-fanregratinib-wins-nmpa-priority-review-for-fgfr2-cholangiocarcinoma/2025-12-30T16:49:12+08:00https://flcube.com/buchang-pharmaceuticals-signs-exclusive-malaysia-deal-for-efparepoetin-ckd-anemia-drug/2025-12-30T16:26:46+08:00https://flcube.com/easton-pharmaceutical-doses-first-patient-in-phase-i-ii-trial-of-hp-001-for-relapsed-multiple-myeloma/2025-12-30T16:17:23+08:00https://flcube.com/haihe-biopharmas-risovalisib-enters-china-spark-project-for-pediatric-pik3ca-disorders/2025-12-30T13:59:41+08:00https://flcube.com/sino-biopharmaceuticals-tdi01-enrolls-first-ipf-patient-in-worlds-first-rock2-inhibitor-phase-iii-trial/2025-12-30T13:52:25+08:00https://flcube.com/tj-biopharma-and-jumpcan-secure-be-trial-approval-for-localized-eftansomatropin-in-china/2025-12-30T13:46:44+08:00https://flcube.com/luye-pharma-divests-25-nanjing-luye-stake-in-rmb-1-1-billion-complex-option-deal/2025-12-29T21:12:25+08:00https://flcube.com/transcenta-licenses-hicb-platform-to-eirgenix-for-continuous-biomanufacturing/2025-12-29T20:45:09+08:00https://flcube.com/boan-biotech-ships-first-batch-of-boyoujing-aflibercept-biosimilar-in-china/2025-12-29T20:38:05+08:00https://flcube.com/bdgene-doses-first-patient-with-bd920-crispr-gene-therapy-for-hpv-16-hsil/2025-12-29T20:30:27+08:00https://flcube.com/nmpa-releases-2025-priority-approval-directory-for-eight-high-end-medical-device-categories/2025-12-29T20:22:51+08:00https://flcube.com/jenscare-scientific-submits-ce-mark-application-for-jensclip-tmvr-system-in-eu/2025-12-29T19:29:59+08:00https://flcube.com/tj-biopharma-partners-with-zhejiang-lab-to-develop-ai-driven-ultra-long-acting-growth-hormone/2025-12-29T16:51:55+08:00https://flcube.com/sino-biopharmaceuticals-tqh3906-achieves-90-pasi-75-response-in-phase-2-psoriasis-trial/2025-12-29T14:00:54+08:00https://flcube.com/hbm-holdings-and-lannacheng-biotech-forge-strategic-alliance-for-next-generation-rdcs-in-precision-oncology/2025-12-29T13:47:12+08:00https://flcube.com/kleos-health-and-bioinno-bioscience-forge-china-partnership-for-exosome-drugs-in-orthopedics/2025-12-29T13:40:10+08:00https://flcube.com/astrazeneca-and-ionis-eplontersen-wins-china-approval-for-attrv-pn-as-first-gene-silencing-therapy/2025-12-29T13:03:06+08:00https://flcube.com/astrazeneca-secures-nmpa-approval-for-fasenra-in-egpa-demonstrating-superior-steroid-sparing-effect/2025-12-29T12:54:48+08:00https://flcube.com/innovent-biologics-secures-nmpa-approval-for-tabosun-as-first-neoadjuvant-dual-io-therapy-for-msi-h-dmmr-colon-cancer/2025-12-29T12:51:19+08:00https://flcube.com/wantai-biological-secures-nmpa-approval-for-first-oral-hiv-self-test-kit-in-china/2025-12-29T12:48:18+08:00https://flcube.com/allist-pharmaceuticals-secures-breakthrough-therapy-designation-for-furmonertinib-in-egfr-pacc-mutated-nsclc/2025-12-29T12:44:51+08:00https://flcube.com/unipath-bronchoscopic-robot-wins-nmpa-approval-expanding-medbots-surgical-portfolio/2025-12-29T12:32:02+08:00https://flcube.com/livzons-lecankitug-accepted-by-nmpa-as-first-domestic-dual-il-17a-f-psoriasis-drug/2025-12-29T12:28:57+08:00https://flcube.com/novo-nordisks-sogroya-wins-nmpa-approval-for-pediatric-growth-hormone-deficiency/2025-12-29T12:13:43+08:00https://flcube.com/jjs-amivantamab-subcutaneous-wins-china-approval-for-nsclc/2025-12-29T12:02:04+08:00https://flcube.com/hybio-pharmaceutical-dr-reddys-forge-peptide-api-partnership/2025-12-29T11:42:48+08:00https://flcube.com/ndrc-expands-foreign-investment-in-healthcare-with-2025-catalogue/2025-12-29T11:36:51+08:00https://flcube.com/nmpa-issues-internet-pharma-info-rules-requiring-record-filing-display/2025-12-23T23:18:06+08:00https://flcube.com/shionogi-acquires-radicava-als-business-for-2-5-billion-from-tanabe-pharma/2025-12-23T22:53:14+08:00https://flcube.com/novo-nordisks-wegovy-wins-china-cardiovascular-approval-in-weight-loss-market-expansion/2025-12-23T22:41:54+08:00https://flcube.com/aosaikangs-delafloxacin-wins-nmpa-approval-as-first-fluoroquinolone-for-china-infections/2025-12-23T21:13:13+08:00https://flcube.com/coherent-biopharma-licenses-pdc-cbp-1018-to-multivalent-in-2-billion-prostate-cancer-deal/2025-12-23T21:08:07+08:00https://flcube.com/3sbios-rhtpo-wins-nmpa-approval-for-liver-disease-thrombocytopenia-before-surgery/2025-12-23T20:59:58+08:00https://flcube.com/gileads-seladelpar-wins-china-hainan-approval-for-pbc-treatment/2025-12-23T20:53:33+08:00https://flcube.com/alphamab-jskn003-adc-fda-breakthrough-therapy-targets-ovarian-cancer/2025-12-23T16:20:41+08:00https://flcube.com/cde-reference-standards-101st-batch-seeks-public-feedback/2025-12-23T16:13:11+08:00https://flcube.com/jemincare-jmx-2005-pad-injection-secures-nmpa-clinical-trial-approval/2025-12-23T14:03:46+08:00https://flcube.com/jj-tremfya-pediatric-psoriasis-ec-approval-targets-first-il-23-indication/2025-12-23T12:53:46+08:00https://flcube.com/takeda-zasocitinib-tyk2-phase-iii-shows-positive-psoriasis-results/2025-12-23T11:49:51+08:00https://flcube.com/lilly-imlunestrant-breast-cancer-ember-3-shows-38-risk-reduction/2025-12-23T11:43:13+08:00https://flcube.com/iview-gvb-2001-gene-therapy-treats-first-poag-patient-successfully/2025-12-23T11:36:15+08:00https://flcube.com/novartis-msd-sanofi-trumprx-deal-targets-medicaid-pricing/2025-12-23T11:07:41+08:00https://flcube.com/novabios-treg-therapy-np001-doses-first-als-patient-in-china-trial/2025-12-22T22:08:37+08:00https://flcube.com/grand-pharmaceuticals-tlx591-cdx-rdc-wins-china-phase-iii-for-prostate-cancer-diagnosis/2025-12-22T21:31:16+08:00https://flcube.com/minimed-diabetes-files-for-ipo-seeking-nasdaq-listing-as-mmed/2025-12-22T20:51:56+08:00https://flcube.com/simcere-zaiming-licenses-adc-sim0613-to-ipsen-in-1-06-billion-deal/2025-12-22T20:40:02+08:00https://flcube.com/mercks-pimicotinib-wins-china-approval-as-first-class-1-therapy-for-tgct/2025-12-22T18:49:49+08:00https://flcube.com/gsks-nucala-wins-china-approval-as-first-il-5-biologic-for-copd/2025-12-22T18:44:00+08:00https://flcube.com/epi-003-wins-fda-ind-as-first-lnp-epigenetic-therapy-for-hepatitis-b/2025-12-21T21:35:45+08:00https://flcube.com/sanegenebios-inhbe-sirna-wins-china-ind-for-obesity-as-first-rnai-target/2025-12-21T21:30:13+08:00https://flcube.com/fosun-pharma-partners-with-clavis-bio-in-362-5m-strategic-collaboration/2025-12-21T21:14:39+08:00https://flcube.com/leadingtac-raises-rmb-200m-series-b-to-advance-protein-degradation-pipeline/2025-12-20T22:02:31+08:00https://flcube.com/transthera-nda-accepted-for-tinengotinib-in-cholangiocarcinoma-after-fgfr-inhibitor/2025-12-20T21:54:54+08:00https://flcube.com/bio-thera-nda-for-vegf-a165-antibody-targets-2b-wet-amd-market-in-china/2025-12-20T20:51:28+08:00https://flcube.com/novo-nordisk-submits-cagrisema-nda-for-20-weight-loss-in-obesity/2025-12-19T21:50:05+08:00https://flcube.com/neurodawns-y-4-wins-fda-fast-track-for-first-in-class-neuropathic-pain-combo/2025-12-19T21:39:12+08:00https://flcube.com/baiyunshan-to-acquire-zhejiang-pharma-industry-for-500-5m-expanding-distribution-network/2025-12-19T21:26:53+08:00https://flcube.com/rona-therapeutics-sirna-rn5681-submitted-to-australian-ethics-committee/2025-12-19T14:07:00+08:00https://flcube.com/grand-pharmaceutical-rdc-gpn01530-wins-fda-phase-i-ii-nod-for-fap-tumor-diagnosis/2025-12-18T23:34:32+08:00https://flcube.com/dualitybios-db-1310-wins-ftd-as-first-her3-adc-for-hr-her2-breast-cancer/2025-12-18T23:09:55+08:00https://flcube.com/yabaos-glx002-wins-nmpa-approval-for-pah-clinical-trial-first-modified-bosentan/2025-12-18T23:03:36+08:00https://flcube.com/biostar-technologies-doses-first-patient-in-us-pivotal-trial-for-utedelone-in-breast-cancer-brain-mets/2025-12-18T22:57:28+08:00https://flcube.com/asieris-apl-2401-fgfr2-3-inhibitor-wins-nmpa-nod-for-phase-1-solid-tumor-trial/2025-12-18T22:43:29+08:00https://flcube.com/innocares-soficitinib-wins-nmpa-approval-for-phase-2-3-tyk2-urticaria-study/2025-12-18T22:35:34+08:00https://flcube.com/insilico-medicine-debuts-on-hkex-in-2-3b-ipo-valuing-ai-drug-platform-at-1-5b/2025-12-18T22:24:54+08:00https://flcube.com/china-mandates-specialty-departments-in-primary-care-by-2030/2025-12-18T22:06:13+08:00https://flcube.com/sirnaomics-partners-on-42m-small-nucleic-acid-fund-in-hangzhou/2025-12-18T21:19:27+08:00https://flcube.com/hainan-opens-first-wholly-foreign-owned-hospital-ahead-of-free-trade-port-launch/2025-12-18T21:02:59+08:00https://flcube.com/hutchmeds-hmpl-a251-attc-dosed-in-global-phase-1-for-her2-tumors/2025-12-18T20:59:16+08:00https://flcube.com/hbm-bms-multi-specific-antibody-deal-targets-1-billion-milestones/2025-12-18T16:33:50+08:00https://flcube.com/antengene-xpovio-snda-malaysia-approval-expands-dlbcl-indication/2025-12-18T14:05:45+08:00https://flcube.com/everest-lerodalcibep-pcsk9-fda-approval-targets-china-launch/2025-12-18T13:37:18+08:00https://flcube.com/cryofocus-gerd-system-secures-nmpa-approval-in-china/2025-12-18T13:31:08+08:00https://flcube.com/sanofi-adel-alzheimers-deal-targets-phase-1-adel-y01-antibody/2025-12-18T13:09:53+08:00https://flcube.com/byterna-therapeutics-raises-angel-plus-round-for-cmrna-car-t-pipeline/2025-12-17T22:52:32+08:00https://flcube.com/gsks-exdensur-wins-fda-approval-as-first-twice-yearly-asthma-biologic/2025-12-17T22:47:22+08:00https://flcube.com/beijing-friendship-hospital-launches-cell-and-gene-therapy-center-for-liver-diseases/2025-12-17T22:41:52+08:00https://flcube.com/kelun-biotech-settles-with-medilink-in-multi-million-dollar-adc-revenue-sharing-deal/2025-12-17T22:20:38+08:00https://flcube.com/hansoh-licenses-egfr-drug-aumolertinib-to-glenmark-for-1b-in-milestones/2025-12-17T22:15:17+08:00https://flcube.com/fangzhou-and-huilun-partner-on-ai-driven-chronic-disease-management-platform/2025-12-17T22:04:05+08:00https://flcube.com/adagenes-muzastotug-wins-fda-fast-track-for-ctla-4-cancer-combo/2025-12-17T21:25:35+08:00https://flcube.com/aficamten-wins-china-approval-as-hcm-drug-in-global-first-for-sanofi/2025-12-17T19:20:30+08:00https://flcube.com/haisco-wins-nmpa-clinical-approval-for-four-category-1-drugs-advancing-pipeline/2025-12-17T19:12:41+08:00https://flcube.com/orelabrutinib-first-btk-inhibitor-to-hit-phase-3-in-lupus-as-innocare-nmpa-filing-cleared/2025-12-16T23:50:07+08:00https://flcube.com/saizeng-medical-licenses-tshr-antibody-to-yarrow-for-1-4b-in-graves-disease-deal/2025-12-16T23:39:08+08:00https://flcube.com/zhichengs-tavr-robotic-system-enters-nmpa-innovation-pathway/2025-12-16T23:20:09+08:00https://flcube.com/enhertu-wins-fda-approval-as-first-line-her2-breast-cancer-therapy/2025-12-16T23:06:10+08:00https://flcube.com/fda-removes-key-rwe-limitation-allowing-drug-and-device-submissions-without-individual-patient-data/2025-12-16T22:43:45+08:00https://flcube.com/sanofis-tolebrutinib-fails-phase-3-ppms-endpoint-halting-registration-plans/2025-12-16T22:28:13+08:00https://flcube.com/konruns-doses-first-patient-in-phase-2-esophageal-cancer-trial-for-kc1036/2025-12-16T22:20:17+08:00https://flcube.com/johnson-johnsons-tecvayli-gets-fda-priority-review-for-myeloma-combo/2025-12-16T22:13:07+08:00https://flcube.com/ubrigene-partners-with-circurna-on-circrna-manufacturing-for-global-trials/2025-12-16T22:06:34+08:00https://flcube.com/dren-bio-sanofi-forge-1-8b-b-cell-therapy-deal-with-us-co-promote-option/2025-12-16T21:58:30+08:00https://flcube.com/adaptive-licenses-tcr-data-to-pfizer-in-890m-deal-for-rheumatoid-arthritis/2025-12-16T21:42:28+08:00https://flcube.com/gsks-nucala-wins-chmp-nod-for-copd-in-europe/2025-12-15T22:32:21+08:00https://flcube.com/sobi-acquires-arthrosi-for-1-5-billion-to-add-gout-drug-to-portfolio/2025-12-15T22:24:06+08:00https://flcube.com/novo-nordisks-wegovy-7-2mg-gets-ema-positive-opinion-for-obesity/2025-12-15T22:16:57+08:00https://flcube.com/innovents-mazdutide-wins-macau-approval-for-weight-management/2025-12-15T22:08:06+08:00https://flcube.com/kyinno-biotechnology-closes-rmb-250m-series-b-for-bispecific-antibody-pipeline/2025-12-15T21:40:38+08:00https://flcube.com/cellular-origins-raises-40m-series-a-led-by-johnson-johnson-for-cell-therapy-manufacturing/2025-12-15T21:32:45+08:00https://flcube.com/akesos-cadonilimab-wins-fda-nod-for-global-phase-3-gastric-cancer-study/2025-12-15T21:23:28+08:00https://flcube.com/china-healthcare-fund-settlement-reform-targets-3-ratio-by-2028/2025-12-15T21:12:36+08:00https://flcube.com/junshi-biosciences-wins-fda-nod-for-egfr-her3-bispecific-adc-in-solid-tumors/2025-12-15T21:00:49+08:00https://flcube.com/henlius-serplulimab-nda-wins-priority-review-for-gastric-cancer-as-adjuvant-therapy/2025-12-15T20:52:30+08:00https://flcube.com/hanx-biopharma-prices-hkex-ipo-to-fund-bispecific-antibody-pipeline/2025-12-15T20:48:02+08:00https://flcube.com/china-unveils-elderly-nursing-plan-to-boost-90-nurse-coverage-by-2027/2025-12-15T20:40:27+08:00https://flcube.com/amgens-uplizna-scores-third-fda-indication-in-myasthenia-gravis/2025-12-15T20:34:55+08:00https://flcube.com/huadao-submits-china-car-t-application-for-refractory-lymphoma-in-1b-market/2025-12-15T20:26:07+08:00https://flcube.com/boai-nky-medical-holdings-partners-with-huadao-biopharma-for-car-t-therapy-incubator/2025-12-15T20:21:23+08:00https://flcube.com/peijia-medical-wins-nmpa-approval-for-taurustrio-tav-first-transfemoral-system-for-aortic-regurgitation/2025-12-14T22:23:56+08:00https://flcube.com/everest-medicines-licenses-lerodalcibep-pcsk9-inhibitor-in-339m-greater-china-deal/2025-12-14T21:26:37+08:00https://flcube.com/lillys-retatrutide-achieves-28-7-weight-loss-in-phase-3-obesity-osteoarthritis-trial/2025-12-14T21:17:45+08:00https://flcube.com/joincares-pixavir-marboxil-wins-nmpa-approval-as-first-single-dose-flu-treatment/2025-12-14T21:03:37+08:00https://flcube.com/indupro-secures-sanofi-investment-and-first-negotiation-rights-on-pd-1-agonist-program/2025-12-14T20:54:37+08:00https://flcube.com/innocares-zurletrectinib-wins-nmpa-nod-as-chinas-first-next-gen-trk-inhibitor/2025-12-13T23:48:50+08:00https://flcube.com/brii-biosciences-taps-openbench-ai-platform-to-accelerate-drug-discovery/2025-12-13T23:21:13+08:00https://flcube.com/gsk-terminates-ideaya-synthetic-lethality-partnership-returns-two-clinical-programs/2025-12-13T23:14:05+08:00https://flcube.com/bk-corporation-debuts-on-hkex-in-900m-ipo-backed-by-burn-drug-pipeline/2025-12-13T22:49:10+08:00https://flcube.com/obt-and-gsk-forge-multi-target-cancer-collaboration-using-ogap-platform/2025-12-13T22:29:12+08:00https://flcube.com/lilly-to-invest-over-6-billion-in-alabama-glp-1-manufacturing-hub-for-orforglipron/2025-12-13T22:22:43+08:00https://flcube.com/sino-biopharms-culmerciclib-wins-nmpa-approval-as-first-cdk2-4-6-inhibitor-for-breast-cancer/2025-12-13T22:17:16+08:00https://flcube.com/insilico-licenses-ai-designed-ism4808-phd-inhibitor-to-taigen-in-two-digit-million-dollar-greater-china-deal/2025-12-13T21:57:57+08:00https://flcube.com/lobemilast-y-3-nda-accepted-by-nmpa-as-first-multi-target-stroke-neuroprotectant/2025-12-12T23:01:18+08:00https://flcube.com/bleecker-bio-formation-licenses-lynks-cns-penetrant-tyk2-inhibitor-lnk01006-in-605-m-deal/2025-12-11T22:43:28+08:00https://flcube.com/shanghai-pharmas-sph3127-renin-inhibitor-wins-nmpa-approval-for-primary-hypertension/2025-12-11T22:33:55+08:00https://flcube.com/juncell-therapeutics-files-for-hkex-ipo-pioneering-chemo-free-til-therapy-for-solid-tumors/2025-12-11T22:26:32+08:00https://flcube.com/relation-therapeutics-and-novartis-forge-1-7-billion-alliance-for-ai-driven-atopic-disease-targets/2025-12-11T22:21:44+08:00https://flcube.com/sanofis-qfitlia-wins-china-approval-as-first-hemophilia-sirna-therapy/2025-12-11T22:15:22+08:00https://flcube.com/zealand-pharma-and-otr-therapeutics-seal-2-5-billion-metabolic-disease-partnership/2025-12-11T22:09:00+08:00https://flcube.com/innovents-pecondle-meets-phase-3-il-23-psoriasis-endpoints-with-quarterly-dosing/2025-12-11T00:00:25+08:00https://flcube.com/d3-bio-closes-108-m-series-b-to-advance-elisrasib-kras-g12c-phase-3-trials-globally/2025-12-10T23:41:42+08:00https://flcube.com/fosun-pharma-licenses-oral-glp-1r-agonist-yp05002-to-pfizer-in-2-1-billion-deal/2025-12-10T23:37:10+08:00https://flcube.com/qilu-pharmaceutical-secures-china-approval-for-panitumumab-n01-first-fully-human-anti-egfr-antibody-in-colorectal-cancer/2025-12-10T23:25:51+08:00https://flcube.com/innovent-doses-first-patient-in-phase-1-trial-of-ibi3011-chinas-first-anti-il-1rap-antibody-for-gout-flares/2025-12-10T23:12:03+08:00https://flcube.com/shanghai-henlius-secures-nmpa-approval-for-phase-ii-iii-hlx22-her2-trials-pioneering-novel-epitope-adc-combination-in-breast-cancer/2025-12-10T23:02:45+08:00https://flcube.com/shandong-boan-licenses-us-rights-for-denosumab-biosimilars-to-nanjing-kingfriend-in-75-million-deal/2025-12-10T22:35:56+08:00https://flcube.com/fda-waskyra-was-gene-therapy-first-cell-based/2025-12-10T22:02:03+08:00https://flcube.com/fda-omisirge-severe-aplastic-anemia-first-hsct/2025-12-10T21:52:01+08:00https://flcube.com/cygenta-horicin-msc-partnership-accelerates-cell-therapy-development/2025-12-10T21:31:26+08:00https://flcube.com/lees-pharm-staccato-obt-acquisition-bolsters-ucb-partnership/2025-12-10T18:13:55+08:00https://flcube.com/zhaoke-brimochol-pf-taiwan-license-targets-presbyopia-market/2025-12-09T16:40:38+08:00https://flcube.com/kexing-gb10-namd-injection-secures-nmpa-clinical-trial-approval/2025-12-09T14:01:10+08:00https://flcube.com/ignis-therapeutics-cenobamate-nmpa-approval-targets-epilepsy/2025-12-09T13:28:21+08:00https://flcube.com/ignis-therapeutics-solriamfetol-nmpa-approval-targets-osa-sleepiness/2025-12-09T13:21:58+08:00https://flcube.com/abbisko-absk043-nsclc-combo-shows-71-disease-control-at-esmo-asia/2025-12-08T22:26:43+08:00https://flcube.com/leads-biolabs-lbl-034-multiple-myeloma-ash-data-shows-82-orr/2025-12-08T22:20:16+08:00https://flcube.com/junshi-biosciences-roconkibart-psoriasis-nmpa-acceptance/2025-12-08T22:07:29+08:00https://flcube.com/cspc-syh2069-glp-1-gip-dual-agonist-wins-fda-nod-for-obesity/2025-12-08T22:00:16+08:00https://flcube.com/asieris-apl-1401-ulcerative-colitis-phase-1b-data-positive/2025-12-08T21:51:38+08:00https://flcube.com/balance-medical-eptfe-pericardial-membrane-gets-nmpa-nod-ends-import-reliance/2025-12-08T21:42:34+08:00https://flcube.com/shanghai-pharma-x842-deal-termination-with-sinorda/2025-12-08T21:32:34+08:00https://flcube.com/weixikang-lidocaine-tetracaine-cream-nmpa-clinical-trial-approval/2025-12-08T21:23:11+08:00https://flcube.com/anke-biotech-pa3-17-car-t-pediatric-indication-nmpa-accepted/2025-12-08T21:06:32+08:00https://flcube.com/mirxes-xtalpi-ai-platform-targets-asian-gi-cancers/2025-12-08T20:58:52+08:00https://flcube.com/sirnaomics-chempartner-galahead-nucleic-acid-deal/2025-12-08T20:51:14+08:00https://flcube.com/nhsa-2025-drug-lists-add-114-medical-insurance-drugs-19-commercial/2025-12-08T20:43:43+08:00https://flcube.com/otr-therapeutics-series-a-raises-100m-for-neurology-pipeline/2025-12-08T20:38:27+08:00https://flcube.com/sanofi-completes-vicebio-1-6b-acquisition-adds-rsv-vaccine-platform/2025-12-05T23:42:12+08:00https://flcube.com/juventas-car-t-lbcl-launch-marks-second-indication/2025-12-05T23:27:11+08:00https://flcube.com/bms-breyanzi-mzl-fda-approval-first-car-t/2025-12-05T22:38:45+08:00https://flcube.com/formosa-pharma-app13007-clobetasol-asean-deal-with-rxilient/2025-12-05T22:28:25+08:00https://flcube.com/novo-nordisk-semaglutide-alzheimers-biomarkers-fail-primary-endpoint/2025-12-04T21:46:33+08:00https://flcube.com/acotec-v-otter-microcatheter-secures-nmpa-approval-for-tace-procedures/2025-12-04T21:38:53+08:00https://flcube.com/youjia-bio-tongee-medical-nucleic-acid-drug-partnership-targets-diabetes/2025-12-04T21:29:47+08:00https://flcube.com/fosun-pharma-fxs0887-atr-inhibitor-gets-nmpa-phase-1-nod/2025-12-04T20:53:36+08:00https://flcube.com/transthera-tinengotinib-cholangiocarcinoma-priority-review-china/2025-12-04T20:45:30+08:00https://flcube.com/bio-sincerity-ucas-rd-center-pharma-synthesis/2025-12-04T20:35:30+08:00https://flcube.com/sino-biopharm-tqf3250-glp-1-capsule-wins-fda-clinical-approval-for-weight-loss/2025-12-04T20:30:43+08:00https://flcube.com/gene-mink-car-nk-bcma-therapy-wins-china-approval-for-multiple-myeloma/2025-12-04T19:38:45+08:00https://flcube.com/cspc-syh2056-fda-approval-targets-depression-with-5-ht2a-agonist/2025-12-04T19:25:30+08:00https://flcube.com/antengene-xpovio-snda-hong-kong-approval-expands-mm-dlbcl-indications/2025-12-04T19:18:28+08:00https://flcube.com/duality-db-1324-adc-fda-ind-approval-advances-gsk-partnership/2025-12-04T19:11:52+08:00https://flcube.com/nhsa-guangzhou-drug-list-conference-releases-2025-medical-insurance-formulary/2025-12-04T19:04:58+08:00https://flcube.com/simcere-deuremidevir-rsv-licensing-deal-targets-china-breakthrough/2025-12-04T19:00:09+08:00https://flcube.com/henlius-fovinaciclib-cdk4-6-breast-cancer-china-commercialization/2025-12-04T18:52:24+08:00https://flcube.com/hengrui-remimazolam-icu-sedation-nmpa-application-accepted/2025-12-03T22:57:31+08:00https://flcube.com/novo-nordisk-cagrisema-pediatric-obesity-trial-to-enroll-460-children/2025-12-03T22:50:28+08:00https://flcube.com/antengene-atg-022-cldn18-2-adc-gets-china-nod-for-keytruda-combo-in-gastric-cancer/2025-12-03T22:44:20+08:00https://flcube.com/msd-mk-2214-fast-track-alzheimer-data-positive/2025-12-03T22:34:40+08:00https://flcube.com/china-drug-price-registration-system-launches-with-first-batch-of-10-products/2025-12-03T22:24:34+08:00https://flcube.com/3sbio-hk3-1b-placement-funds-rd-pipeline-for-705-706-008/2025-12-03T22:20:53+08:00https://flcube.com/generate-gb-0895-asthma-phase-iii-trials-to-enroll-1600-patients/2025-12-03T22:13:42+08:00https://flcube.com/henlius-hlx14-denosumab-biosimilar-nda-accepted-by-china-cde/2025-12-03T21:48:52+08:00https://flcube.com/new-radiomedicine-series-d-raises-800m-yuan-for-radiopharmaceuticals/2025-12-03T21:34:06+08:00https://flcube.com/kura-ziftomenib-sale-triggers-135m-kyowa-kirin-payment/2025-12-03T21:17:39+08:00https://flcube.com/roche-cobas-liat-whooping-cough-test-secures-fda-clearance/2025-12-03T21:12:33+08:00https://flcube.com/henlius-hlx37-bispecific-nmpa-approval-targets-advanced-solid-tumors/2025-12-02T22:48:49+08:00https://flcube.com/leads-biolabs-lbl047-bispecific-secures-china-ind-approval-for-sle/2025-12-02T22:39:56+08:00https://flcube.com/shanghai-bao-pharma-ipo-hkex-raises-hk1-billion-for-biotech-pipeline/2025-12-02T22:27:20+08:00https://flcube.com/shanghai-bao-pharmaceutical-and-subsidiary-secure-commercialization-rights-deal-for-sj02-with-organon-china/2025-12-02T22:20:37+08:00https://flcube.com/abbisko-absk141-kras-g12d-inhibitor-secures-fda-ind-approval/2025-12-02T22:16:44+08:00https://flcube.com/abbvie-rinvoq-upadacitinib-cde-priority-review-alopecia-areata-china/2025-12-02T22:09:42+08:00https://flcube.com/lynk-pharma-lnk01006-fda-approval-targets-tyk2-for-cns-diseases/2025-12-02T21:36:50+08:00https://flcube.com/fda-prasad-outlines-new-vaccine-approval-process-after-covid-19-safety-analysis/2025-12-02T21:05:18+08:00https://flcube.com/china-health-life-expectancy-hits-79-years-as-hospitals-expand-and-expenditure-controlled/2025-12-02T20:56:25+08:00https://flcube.com/canbridges-maralixibat-wins-hong-kong-approval-for-pfic-cholestatic-pruritus/2025-12-02T20:37:36+08:00https://flcube.com/wuxi-biologics-crdmo-qatar-mou-establishes-first-middle-east-center/2025-12-02T20:30:05+08:00https://flcube.com/johnson-johnsons-nipocalimab-secures-eu-approval-for-myasthenia-gravis/2025-12-02T16:02:26+08:00https://flcube.com/regeneron-tessera-partner-on-tsra-196-gene-writing-therapy-for-aatd-with-275m-deal/2025-12-02T15:48:55+08:00https://flcube.com/chempartner-and-fosun-pharma-forge-cro-cdmo-alliance-to-accelerate-drug-development/2025-12-02T12:35:12+08:00https://flcube.com/microports-pulsemagic-pfa-catheter-secures-nmpa-approval-as-first-pressure-monitoring-device-in-china/2025-12-01T23:20:35+08:00https://flcube.com/humanwells-hws117-long-acting-fsh-secures-nmpa-clinical-trial-approval-for-assisted-reproduction/2025-12-01T23:15:04+08:00https://flcube.com/sanyou-bio-and-fatiabgen-forge-ai-stal-alliance-for-korea-and-global-markets/2025-12-01T23:07:05+08:00https://flcube.com/ascletis-pharma-advances-asc37-oral-triple-agonist-for-obesity-targets-q2-2026-fda-ind/2025-12-01T22:58:58+08:00https://flcube.com/mabwells-9mw1911-cuts-copd-exacerbations-by-30-in-phase-2a-fda-accepts-us-trial-application/2025-12-01T22:50:20+08:00https://flcube.com/imugene-and-jw-therapeutics-partner-to-evaluate-oncarlytics-car%e2%80%91t-combination-for-advanced-solid-tumors/2025-12-01T22:40:30+08:00https://flcube.com/humanwell-launches-rmb250m-ruicheng-venture-fund-for-health-tech/2025-12-01T22:08:29+08:00https://flcube.com/iregenes-nouvneu004-wins-fda-special-exemption-for-msa-cell-therapy/2025-12-01T16:32:23+08:00https://flcube.com/provivas-ptx-912-pd-1-il-2-fusion-gets-usd-30m-series-a-boost/2025-12-01T15:42:33+08:00https://flcube.com/pfizer-astellas-padcev-wins-fda-approval-for-perioperative-bladder-cancer/2025-11-29T22:00:02+08:00https://flcube.com/genscis-gensci142-wins-nmpa-nod-for-bacterial-vaginosis-clinical-trials/2025-11-29T21:35:32+08:00https://flcube.com/jiuzhou-pharmaceutical-wins-tentative-fda-approval-for-generic-janumet-xr/2025-11-28T23:41:06+08:00https://flcube.com/hengruis-ivarmacitinib-wins-nmpa-nod-for-vitiligo-clinical-trials/2025-11-28T23:17:18+08:00https://flcube.com/juventas-car-t-wins-second-china-approval-for-lymphoma-expands-hematology-franchise/2025-11-28T21:07:43+08:00https://flcube.com/gene-keys-inkt-cell-therapy-wins-nmpa-nod-for-ards-first-allogeneic-ready-to-use/2025-11-28T20:20:35+08:00https://flcube.com/innovents-picankibart-wins-nmpa-approval-for-psoriasis-as-il-23p19-inhibitor/2025-11-28T20:17:41+08:00https://flcube.com/trulive-medical-closes-series-c-raising-over-rmb-100m-for-cardiovascular-innovation/2025-11-28T16:05:47+08:00https://flcube.com/boan-biotechs-boyoujing-aflibercept-wins-nmpa-approval-for-retinal-diseases/2025-11-27T21:48:09+08:00https://flcube.com/sprint-bioscience-sells-trex1-program-to-gilead-for-14m-upfront/2025-11-27T21:39:37+08:00https://flcube.com/novo-nordisks-semaglutide-7-2-mg-snda-submitted-for-weight-management/2025-11-27T21:31:36+08:00https://flcube.com/cspcs-jmt206-wins-nmpa-nod-for-actrii-targeted-weight-management/2025-11-27T21:26:14+08:00https://flcube.com/microtechs-linx-cgm-wins-india-approval-expanding-asia-diabetes-monitoring/2025-11-27T21:16:54+08:00https://flcube.com/bio-hearts-iberirdn-wins-new-zealand-nod-as-only-dual-approach-renal-denervation-system/2025-11-27T21:07:19+08:00https://flcube.com/iaso-bios-fucaso-wins-hong-kong-approval-as-first-china-car-t/2025-11-27T20:57:31+08:00https://flcube.com/patronus-biotech-gates-foundation-grant-accelerates-malaria-vaccine-development/2025-11-27T16:13:28+08:00https://flcube.com/innova-therapeutics-acquires-enci-therapeutics-ivt-8086-cancer-program/2025-11-27T16:00:13+08:00https://flcube.com/sciclones-meropenem-vaborbactam-wins-gba-approval-as-first-antibiotic-under-medical-connect/2025-11-27T15:41:19+08:00https://flcube.com/novartis-remibrutinib-wins-nmpa-approval-for-chronic-spontaneous-urticaria/2025-11-26T21:40:02+08:00https://flcube.com/cms-ira-drug-pricing-round-2-delivers-62-average-cut-ozempic-falls-71/2025-11-26T21:06:25+08:00https://flcube.com/hengruis-three-oncology-assets-win-nmpa-clinical-trial-approval/2025-11-26T16:45:30+08:00https://flcube.com/humanwells-lisdexamfetamine-nda-accepted-by-nmpa-for-adhd-first-generic-potential/2025-11-26T16:26:58+08:00https://flcube.com/innovents-mazdutide-9mg-obesity-application-accepted-by-nmpa/2025-11-26T16:13:23+08:00https://flcube.com/fosuns-luvometinib-gets-nmpa-priority-review-for-pediatric-lch/2025-11-26T16:04:12+08:00https://flcube.com/kelonia-jnj-partnership-targets-in-vivo-car-t-for-multiple-myeloma/2025-11-26T15:39:53+08:00https://flcube.com/otsukas-voyxact-wins-fda-accelerated-approval-for-igan-first-april-blocker/2025-11-26T15:19:25+08:00https://flcube.com/wuzhong-pharma-faces-mandatory-delisting-after-csrc-violations/2025-11-26T14:17:35+08:00https://flcube.com/novartiss-itvisma-wins-fda-approval-as-first-gene-therapy-for-sma/2025-11-26T13:48:38+08:00https://flcube.com/novos-kyinsu-wins-eu-approval-for-type-2-diabetes-a-once-weekly-combo-first/2025-11-26T13:30:35+08:00https://flcube.com/novo-nordisks-semaglutite-alzheimers-failure-sends-stock-to-4-year-low/2025-11-25T20:28:03+08:00https://flcube.com/zelgens-zg006-wins-btd-for-neuroendocrine-carcinoma-as-first-dll3-trispecific/2025-11-25T20:22:56+08:00https://flcube.com/hengruis-ivarmacitinib-nda-accepted-for-non%e2%80%91radiographic-axial-spondyloarthritis/2025-11-25T20:13:32+08:00https://flcube.com/astrazenecas-durvalumab-wins-china-approval-for-stage-iii-nsclc-after-sequential-chemoradiotherapy/2025-11-25T19:55:30+08:00https://flcube.com/qihan-biotechs-qt-019b-universal-car-t-wins-implied-nmpa-approval/2025-11-25T19:45:14+08:00https://flcube.com/junshis-js001sc-subcutaneous-pd-1-meets-phase-3-endpoint-in-nsclc/2025-11-25T16:55:49+08:00https://flcube.com/rimag-partners-with-qingyang-government-on-ai-medical-imaging-infrastructure/2025-11-25T16:48:43+08:00https://flcube.com/biogen-dayra-partnership-targets-immunology-with-macrocyclic-peptides/2025-11-25T16:36:29+08:00https://flcube.com/cstones-sugemalimab-wins-eu-approval-for-stage-iii-nsclc-expanding-european-indication/2025-11-25T16:27:20+08:00https://flcube.com/salubris-sal0139-wins-nmpa-nod-for-hyperlipidemia-clinical-trial/2025-11-24T22:03:03+08:00https://flcube.com/zhongshengs-onradivir-granules-enroll-first-phase-3-pediatric-influenza-patient/2025-11-24T21:54:53+08:00https://flcube.com/hbm-and-astrazeneca-deepen-adc-tce-collaboration-as-astrazeneca-exercises-license-options/2025-11-24T21:47:55+08:00https://flcube.com/kelun-biotechs-sac-tmt-achieves-first-adc-io-nsclc-success/2025-11-24T21:40:50+08:00https://flcube.com/luyes-ly03017-wins-fda-nod-for-psychosis-trials-in-alzheimers-and-parkinsons/2025-11-24T21:03:36+08:00https://flcube.com/cspcs-syh2056-wins-nmpa-nod-for-depression-trials-as-fast%e2%80%91acting-5%e2%80%91ht2a-agonist/2025-11-24T20:07:40+08:00https://flcube.com/biokins-iza-bren-nda-accepted-for-nasopharyngeal-carcinoma-advancing-bispecific-adc/2025-11-24T20:00:22+08:00https://flcube.com/phrontline-raises-60m-series-pre%e2%80%91a-to-advance-bispecific-adc-pipeline/2025-11-24T19:51:26+08:00https://flcube.com/valo-health-partners-with-merck-on-3b-parkinsons-disease-discovery-deal/2025-11-24T15:42:19+08:00https://flcube.com/nmpa-issues-export-drug-certification-rules-expanding-scope-and-validity/2025-11-24T15:34:01+08:00https://flcube.com/bayers-hyrnuo-wins-fda-approval-for-her2-mutated-lung-cancer/2025-11-24T00:21:51+08:00https://flcube.com/johnson-johnson-china-pins-head-alex-he-to-depart-driving-leadership-transition-amid-key-nrdl-product-success/2025-11-24T00:17:06+08:00https://flcube.com/3sbios-mandi-spin-off-targets-hkex-ipo-as-hair-health-leader/2025-11-23T23:18:31+08:00https://flcube.com/ge-healthcare-to-acquire-intelerad-for-2-3b-expanding-cloud-enabled-imaging/2025-11-23T23:09:20+08:00https://flcube.com/sinovac-receives-nasdaq-delisting-notice-over-late-20-f-filing/2025-11-23T23:01:08+08:00https://flcube.com/pien-tze-huangs-pzh2108-cancer-pain-drug-enrolls-first-phase-iia-patient/2025-11-22T22:20:21+08:00https://flcube.com/abbott-to-acquire-exact-sciences-for-21b-entering-cancer-diagnostics-leadership/2025-11-21T22:00:20+08:00https://flcube.com/henlius-serplulimab-wins-btd-for-gastric-cancer-perioperative-treatment-a-china-first/2025-11-21T21:53:32+08:00https://flcube.com/fda-pilot-program-offers-meeting-minute-clarification-to-drug-sponsors/2025-11-21T21:47:04+08:00https://flcube.com/reprogenix-closes-rmb-500m-series-a-to-advance-diabetes-cell-therapy-pipeline/2025-11-21T21:39:22+08:00https://flcube.com/pfizers-hympavzi-wins-china-approval-as-first-weekly-non%e2%80%91factor-hemophilia-therapy/2025-11-21T21:34:09+08:00https://flcube.com/freenome-roche-cancer-screening-deal-worth-over-200m/2025-11-20T16:52:07+08:00https://flcube.com/nona-biosciences-licenses-hcab-platform-to-pfizer-for-antibody-discovery/2025-11-20T16:30:58+08:00https://flcube.com/rock-rocs-car-m-platform-secures-rmb-50m-series-a-for-macrophage-therapy/2025-11-20T16:16:26+08:00https://flcube.com/kelun-biotechs-trastuzumab-botidotin-her2-adc-launches-in-china-after-phase-3-win-vs-t-dm1/2025-11-20T15:55:49+08:00https://flcube.com/regenerons-libtayo-wins-ec-approval-for-adjuvant-cscc-68-risk-reduction/2025-11-20T15:12:07+08:00https://flcube.com/novartis-builds-23b-north-carolina-manufacturing-hub-adding-700-jobs/2025-11-20T14:57:41+08:00https://flcube.com/lynks-lnk01004-pan-jak-inhibitor-shows-easi-75-win-in-phase-2-atopic-dermatitis-trial/2025-11-20T14:27:38+08:00https://flcube.com/acotecs-jingyi-balloon-catheter-wins-nmpa-approval-for-complex-coronary-lesions/2025-11-19T21:21:50+08:00https://flcube.com/sino-biopharms-lm-350-cdh17-adc-wins-nmpa-nod-for-clinical-trials/2025-11-19T21:05:00+08:00https://flcube.com/cutias-cu-40105-topical-finasteride-spray-nda-accepted-by-nmpa-a-china-first/2025-11-19T20:55:41+08:00https://flcube.com/mirxes-and-walvax-form-rna-partnership-for-vaccines-and-precision-medicine/2025-11-19T20:45:53+08:00https://flcube.com/nmpa-releases-98th-rld-catalog-for-chemical-generics-adding-48-new-specifications/2025-11-19T20:34:28+08:00https://flcube.com/roches-lunsumio-sc-wins-eu-conditional-approval-for-follicular-lymphoma/2025-11-19T20:27:58+08:00https://flcube.com/roches-giredestrant-serd-achieves-idfs-win-in-phase-3-lidera-breast-cancer-trial/2025-11-19T14:29:19+08:00https://flcube.com/hengruis-hrs-6209-cdk4-inhibitor-wins-nmpa-nod-for-breast-cancer-combo-trial/2025-11-18T20:33:41+08:00https://flcube.com/gate-bioscience-closes-65m-series-b-to-advance-molecular-gates-to-clinic/2025-11-18T16:47:22+08:00https://flcube.com/hengruis-hrs-4642-kras-g12d-inhibitor-wins-nmpa-nod-for-phase-1b-2-solid-tumor-trials/2025-11-18T16:38:06+08:00https://flcube.com/takeda-launches-tcic-digital-healthcare-innovation-center-in-chengdu-a-china%e2%80%91first/2025-11-18T16:25:33+08:00https://flcube.com/biokins-iza-bren-adc-achieves-dual-pfs-os-endpoints-in-phase-3-esophageal-cancer-a-global-first/2025-11-18T15:17:01+08:00https://flcube.com/resight-therapeutics-secures-tens%e2%80%91millions-rmb-angel-round-to-accelerate-ipsc%e2%80%91derived-corneal-endothelial-cell-therapy/2025-11-18T15:03:25+08:00https://flcube.com/bms-and-jj-halt-phase-iii-milvexian-anticoagulant-trial-for-acute-coronary-syndrome-patients/2025-11-18T14:42:50+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approval-for-tegileridine-in-mechanically-ventilated-icu-patients/2025-11-18T11:32:52+08:00https://flcube.com/johnson-johnson-to-acquire-halda-therapeutics-for-3-05-b-deal-highlights-first%e2%80%91in%e2%80%91class-oral-riptac-hld%e2%80%910915/2025-11-18T11:23:07+08:00https://flcube.com/lundbecks-vyepti-secures-chinese-nda-expands-asian-footprint/2025-11-17T20:16:18+08:00https://flcube.com/suzhou-zelgen-biopharma-to-deregister-u-s-subsidiary-gensun-to-sharpen-rd-focus/2025-11-17T20:07:17+08:00https://flcube.com/akeso-secures-nmpa-approval-for-ak152-first-bispecific-antibody-targeting-alzheimers-in-china/2025-11-17T19:58:40+08:00https://flcube.com/msd-acquires-cidara-therapeutics-in-9-2%e2%80%91billion-deal-to-expand-antiviral-portfolio/2025-11-17T19:51:59+08:00https://flcube.com/abbisko-therapeutics-reports-durable-response-in-phase-3-maneuver-study-for-pimicotinib-absk021-in-tgct/2025-11-17T19:35:38+08:00https://flcube.com/zhejiang-jianfeng-group-secures-nmpa-approval-for-jfan%e2%80%911001-vinorelbine-combination-in-advanced-nsclc/2025-11-17T19:26:38+08:00https://flcube.com/serviers-vorasidenib-enters-chinas-spark-program-first-dual-idh-inhibitor-for-idh%e2%80%91mutant-glioma/2025-11-17T19:18:50+08:00https://flcube.com/pegbios-pb%e2%80%91119-paidakang-wins-nmpa-approval-for-type-2-diabetes-treatment/2025-11-17T15:06:17+08:00https://flcube.com/henlius-poherdy-hlx11-receives-full-fda-approval-for-all-pertuzumab-indications/2025-11-17T14:54:07+08:00https://flcube.com/hangzhou-bio%e2%80%91sincerity-pharma%e2%80%91tech-secures-nmpa-approval-for-bios2242-oral-solution-in-acute-ischemic-stroke/2025-11-17T14:46:08+08:00https://flcube.com/nmpa-launches-pilot-program-to-cut-review-time-for-overseas%e2%80%91manufactured-drug-supplementary-applications/2025-11-17T14:31:52+08:00https://flcube.com/fda-issues-boxed-warning-on-elevidys-delandistrogene-moxeparvovec%e2%80%91rokl-use-limited-to-ambulatory-dmd-patients-aged-4/2025-11-17T14:22:37+08:00https://flcube.com/zelgen-biopharmas-zg006-alveltamig-receives-fda-orphan%e2%80%91drug-designation-for-neuroendocrine-carcinomas/2025-11-17T14:05:36+08:00https://flcube.com/westvac-biopharma-west-china-hospital-secure-nmpa-clearance-for-chinas-first-acne-therapeutic-vaccine/2025-11-17T13:41:01+08:00https://flcube.com/brightgene-boosts-stake-in-geek-gene-to-12-8-with-rmb-50-m-injection-expanding-cell%e2%80%91therapy-portfolio/2025-11-17T13:23:03+08:00https://flcube.com/changchun-genescience-secures-nmpa-approval-for-gs3%e2%80%91007a-dry-suspension-green%e2%80%91lights-gensci140-adc-trials/2025-11-17T13:08:24+08:00https://flcube.com/brightgene-secures-nmpa-nod-for-bgm1812-obesity-trial-fda-grants-trial-clearance/2025-11-16T00:05:21+08:00https://flcube.com/changchun-genescience-secures-fda-approval-for-gensci143-bispecific-adc-targeting-b7%e2%80%91h3-psma-in-advanced-solid-tumors/2025-11-15T23:18:03+08:00https://flcube.com/qyuns-therapeutics-receives-nmpa-trial-approvals-for-qx027n-long%e2%80%91acting-bispecific-antibody-targeting-asthma-and-atopic-dermatitis/2025-11-15T22:52:06+08:00https://flcube.com/suzhou-zelgen-secures-nmpa-trial-approval-for-zg006-alveltamig-first%e2%80%91in%e2%80%91class-trispecific-antibody-for-advanced-neuroendocrine-carcinoma/2025-11-15T22:46:44+08:00https://flcube.com/adagene-licenses-safebody-platform-to-third-arc-bio-for-masked-cd3-t%e2%80%91cell-engagers/2025-11-14T16:08:02+08:00https://flcube.com/gan-lees-ondibta-receives-positive-chmp-opinion-eu-biosimilar-pathway-opened/2025-11-14T16:00:11+08:00https://flcube.com/corxel-secures-fda-ind-clearance-for-cx11-phase-2-trial-in-type-2-diabetes/2025-11-14T15:00:18+08:00https://flcube.com/pfizer-reduces-biontech-holding-by-54-7-while-collaboration-remains-intact/2025-11-14T14:50:28+08:00https://flcube.com/legend-biotech-reports-524-m-carvykti-sales-fda-updates-q3-loss/2025-11-13T23:35:39+08:00https://flcube.com/tonghua-dongbao-secures-dominican-republic-market-launch-for-insulin-aspart/2025-11-13T23:22:19+08:00https://flcube.com/bcht-receives-nmpa-approval-for-first-adult-dtap-vaccine-covering-pertussis-diphtheria-and-tetanus/2025-11-13T23:06:52+08:00https://flcube.com/eirgenix-secures-152-m-licensing-deal-for-eg1206a-breast%e2%80%91cancer-biosimilar-from-sandoz/2025-11-13T22:35:33+08:00https://flcube.com/humanwell-initiates-phase-2-trial-of-hw231019-tablets-for-post%e2%80%91abdominal-surgery-analgesia/2025-11-13T22:18:39+08:00https://flcube.com/bio%e2%80%91sincerity-secures-xpo1-inhibitor-deal-for-bios%e2%80%910629-aims-at-solid%e2%80%91tumor-expansion/2025-11-13T22:10:18+08:00https://flcube.com/bayer-reports-stable-q3-2025-sales-highlights-strong-nubeqa-and-kerendia-growth/2025-11-13T21:57:20+08:00https://flcube.com/fda-announces-new-plausible%e2%80%91mechanism-pathway-to-rapid-approvals-for-rare-disease-treatments/2025-11-13T21:40:02+08:00https://flcube.com/complete-genomics-and-sophia-genetics-join-forces-to-deliver-end%e2%80%91to%e2%80%91end-oncology-validation-on-mgis-t1-sequencing-platform/2025-11-13T21:28:20+08:00https://flcube.com/degron-therapeutics-msd-rd-and-the-next-generation-of-molecular-glue-degraders/2025-11-13T21:16:46+08:00https://flcube.com/adicon-holdings-crown-bioscience-and-global-lab-services-forge-new-integrated-platform-for-oncology-translational-research/2025-11-13T20:59:00+08:00https://flcube.com/abbvie-to-end-11%e2%80%91year-rd-alliance-with-alphabet%e2%80%91owned-calico-labs/2025-11-13T16:04:07+08:00https://flcube.com/chengda-biotechnology-imcas-and-beijing-key-laboratory-for-synthetic-immunology-forge-new-frontiers-in-vaccine-manufacturing/2025-11-12T23:56:28+08:00https://flcube.com/sun%e2%80%91novo-byterna-and-car%e2%80%91t-circrna-collaboration-propel-in%e2%80%91vivo-gene%e2%80%91therapy-frontiers/2025-11-12T23:19:07+08:00https://flcube.com/suzhou-forlong-biotech-shanghai-henlius-and-engineered-cytokine-immunotherapy-collaboration-announced/2025-11-12T22:54:16+08:00https://flcube.com/gempharmatech-memorial-sloan-kettering-and-neomab-platform-accelerate-discovery-of-fully-human-therapeutic-antibodies/2025-11-12T22:44:27+08:00https://flcube.com/jinling-pharmaceutical-nanjing-gulou-hospital-and-cd16a-tech%e2%80%91transfer-deal-bolsters-nk%e2%80%91cell-oncology/2025-11-12T22:36:18+08:00https://flcube.com/jacobio-pharma-oceanpine-capital-and-partner-acquire-majority-of-jacoray-fuelling-early%e2%80%91stage-cardio%e2%80%91oncology-rd/2025-11-12T22:14:17+08:00https://flcube.com/walvax-biotechnology-pharmaniaga-lifescience-forge-malaysia-partnership-for-pcv%e2%80%9113-production-and-distribution/2025-11-12T22:09:16+08:00https://flcube.com/shandong-buchangs-luzhou-unit-moves-to-secure-exclusive-distribution-of-epo%e2%80%91igg-fusion-in-vietnam/2025-11-12T21:59:42+08:00https://flcube.com/ankebio-and-persongen-ink-capital%e2%80%91increase-deal-secure-exclusive-greater%e2%80%91china-agency-for-pa3%e2%80%9117-car%e2%80%91t-therapy/2025-11-12T16:32:46+08:00https://flcube.com/chongqing-precision-biotech-wins-nmpa-approval-for-pcar%e2%80%9119b-chinas-first-humanised-cd19-car%e2%80%91t-therapy-for-pediatric-b%e2%80%91all/2025-11-12T16:22:06+08:00https://flcube.com/laekna-and-qilu-pharma-sign-exclusive-china-license-for-akt-inhibitor-lae002-afuresertib/2025-11-12T16:02:03+08:00https://flcube.com/nmpa-grants-marketing-authorisation-to-hefei-amvites-memantine-hydrochloride-odt-for-alzheimers-disease/2025-11-12T15:50:52+08:00https://flcube.com/shanghai-henlius-biotech-secures-uk-mhra-approval-for-denosumab-biosimilars-bildyos-bilprevda/2025-11-12T15:32:40+08:00https://flcube.com/novo-nordisk-announces-major-china-business-restructuring-effective-jan-1-2026/2025-11-12T15:24:11+08:00https://flcube.com/huadong-medicine-files-nda-for-roflumilast-cream-zoryve-first-pde%e2%80%914-topical-for-atopic-dermatitis-in-greater-china/2025-11-12T15:07:32+08:00https://flcube.com/gan-lee-transfers-medtech-control-to-hillhouse-investment-accelerating-drug-delivery-innovation/2025-11-11T20:58:47+08:00https://flcube.com/sanyou-biopharmaceuticals-yugong-biotech-forge-strategic-enzyme-development-alliance/2025-11-11T20:28:26+08:00https://flcube.com/grand-pharmaceutical-glenmark-specialty-secure-china-nmpa-approval-for-ryaltris-nasal-spray/2025-11-11T17:04:29+08:00https://flcube.com/lepu-biopharma-secures-fda-ind-clearance-for-cdh17%e2%80%91targeted-adc-mrg007/2025-11-11T16:56:20+08:00https://flcube.com/novartis-wins-fda-approval-for-remibrutinib-tablets-first-btk-inhibitor-for-chronic-spontaneous-urticaria/2025-11-11T16:49:12+08:00https://flcube.com/lyell-immunopharma-secures-global-rights-to-lyl273-car%e2%80%91t-therapy-major-step-toward-mcrc-treatment/2025-11-11T14:54:53+08:00https://flcube.com/dualitybio-secures-fda-fast%e2%80%91track-designation-for-egfr-her3-bispecific-adc-avzo%e2%80%911418/2025-11-11T14:41:58+08:00https://flcube.com/mabwell-partners-with-ping-an-health-to-launch-integrated-bone%e2%80%91health-autoimmune-care-platform/2025-11-11T14:29:58+08:00https://flcube.com/roche-announces-positive-phase-iii-results-for-fenebrutinib-in-relapsing-primary%e2%80%91progressive-multiple-sclerosis/2025-11-11T13:33:49+08:00https://flcube.com/simcere-launches-phase-ii-trial-of-t%e2%80%91reg%e2%80%91selective-il%e2%80%912-fusion-sim0278-for-moderate%e2%80%91to%e2%80%91severe-atopic-dermatitis-in-china/2025-11-11T13:08:00+08:00https://flcube.com/gaush-meditechs-subsidiary-secures-china-registration-for-integrated-ophthalmic-electrophysiology-system/2025-11-11T12:59:22+08:00https://flcube.com/brise-pharma-closes-rmb-200-m-series-a-to-fund-pivotal-phase-iii-trial-of-first%e2%80%91in%e2%80%91class-cgrp-small%e2%80%91molecule-analgesic-br005/2025-11-11T12:42:05+08:00https://flcube.com/mabwells-9mw3811-gains-nmpa-approval-to-launch-world%e2%80%91first-il%e2%80%9111%e2%80%91targeting-phase-2-trial-for-pathological-scarring/2025-11-11T12:31:36+08:00https://flcube.com/meiragtx-grants-eli-lilly-worldwide-rights-to-aav%e2%80%91aipl1-gene-therapy-for-lca4/2025-11-11T12:03:10+08:00https://flcube.com/innovent-biologics-sanegene-bio-usa-report-first%e2%80%91in%e2%80%91human-success-for-ibi3016-sirna-hypertension-therapy/2025-11-11T11:30:49+08:00https://flcube.com/hangzhou-bio%e2%80%91sincerity-secures-nmpa-approval-for-bios%e2%80%910625-tablet-first%e2%80%91in%e2%80%91class-ulcerative-colitis-therapy/2025-11-11T11:21:16+08:00https://flcube.com/cansinobio-licenses-isl%e2%80%913c%e2%80%91lnp-platform-to-panru-biotech-100-m-deal-to-accelerate-mrna-cancer-vaccines/2025-11-11T11:09:50+08:00https://flcube.com/eisai-china-and-beckman-coulter-launch-alzheimers-blood%e2%80%91test-collaboration-in-mainland-china/2025-11-10T23:40:57+08:00https://flcube.com/gilead-sciences-tro-delvy-fails-to-meet-primary-endpoint-in-ascent%e2%80%9107-metastatic-breast-cancer-trial/2025-11-10T23:25:41+08:00https://flcube.com/insilico-medicine-eli-lilly-forge-strategic-ai%e2%80%91driven-drug-discovery-alliance/2025-11-10T23:19:27+08:00https://flcube.com/sanegenebio-eli-lilly-sign-global-partnership-to-advance-rnai-therapies-for-metabolic-diseases/2025-11-10T23:09:50+08:00https://flcube.com/delinova-raises-nearly-rmb-60-million-in-seed-angel-financing-for-in%e2%80%91vivo-car%e2%80%91t-platform/2025-11-10T22:59:12+08:00https://flcube.com/organon-acquires-jada-system-from-laborie-for-usd-465-million/2025-11-10T22:38:10+08:00https://flcube.com/hbm-holdings-and-evinova-form-ai%e2%80%91powered-biologic-therapy-collaboration/2025-11-10T22:06:50+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-announces-hrs%e2%80%912430-injection-approval-for-clinical-trials/2025-11-10T21:59:37+08:00https://flcube.com/national-health-commissions-negative-behavior-list-for-medical-staff-internet%e2%80%91based-health-science-popularization-trial/2025-11-10T21:32:36+08:00https://flcube.com/novo-nordisk-rules-out-higher-bid-for-metsera-as-pfizer-seals-86-25-per-share-deal/2025-11-10T14:22:09+08:00https://flcube.com/aureka-biotechnologies-closes-multi%e2%80%91million%e2%80%91dollar-series-a-generative-antibody-platform-gains-5y-capital-qiming-backing/2025-11-10T13:56:18+08:00https://flcube.com/zhaoke-ophthalmology-indonesia-distribution-deal-brimochol-pf-eyes-on-market-expansion/2025-11-08T15:19:09+08:00https://flcube.com/shanghai%e2%80%91boehringer-ingelheim-mou-launches-stroke-prevention-initiative-strengthening-china-health-2030/2025-11-08T15:08:51+08:00https://flcube.com/boehringer-ingelheim-taps-beijing-friendship-hospital-for-mash-trials-expands-china-key-initiative/2025-11-08T15:00:28+08:00https://flcube.com/zai-lab-q3-2025-revenue-up-13-yoy-to-115-4-m-led-by-nuzyra-and-xacduo-zejula-slows/2025-11-08T14:54:59+08:00https://flcube.com/eisai-china-partners-with-shanghai-pharmaceuticals-holding-focus-on-oncology-neuroscience-and-sleep-disorders/2025-11-08T14:45:05+08:00https://flcube.com/nhsa-pilot-ai-review-accelerates-full%e2%80%91process-medical-insurance-assessment-in-7-chinese-provinces/2025-11-08T14:37:00+08:00https://flcube.com/us-fdas-cnpv-fast%e2%80%91track-program-expands-to-15-drugs-cutting-review-time-to-months/2025-11-08T14:27:38+08:00https://flcube.com/sichuan-biokin-launches-on-hkex-raises-hk3-3-b-in-389-share-offering-a-milestone-for-chinas-biotech/2025-11-08T14:22:03+08:00https://flcube.com/lifetech-scientific-secures-nmpa-approval-for-g%e2%80%91branch-taaa-stent%e2%80%91graft-system/2025-11-08T12:46:27+08:00https://flcube.com/viatris-posts-q3-2025-revenue-dip-highlights-emerging%e2%80%91market-branded-growth-and-aculys-pharma-acquisition/2025-11-08T10:33:53+08:00https://flcube.com/humanwell-healthcare-secures-nmpa-approval-to-launch-first-fixed%e2%80%91dose-combination-for-pulmonary-arterial-hypertension/2025-11-08T10:27:12+08:00https://flcube.com/eli-lilly-novo-nordisk-reach-u-s-deal-to-cut-obesity%e2%80%91drug-prices-unlock-medicare-medicaid-access/2025-11-08T10:16:52+08:00https://flcube.com/johnson-johnson-launches-ethicon-4000-3d-laparoscopic-stapler-in-china/2025-11-08T10:10:16+08:00https://flcube.com/cstone-pharmaceuticals-to-unveil-cs2015-data-at-2025-acaai-meeting/2025-11-07T13:26:38+08:00https://flcube.com/amacathera-signs-exclusive-global-license-with-pacira-biosciences-for-amt%e2%80%91143-up-to-230-m-deal/2025-11-07T13:19:13+08:00https://flcube.com/sanofis-cablivi-wins-china-nmpa-approval-first-nanobody-drug-for-attp/2025-11-07T13:02:50+08:00https://flcube.com/judge-rejects-pfizers-attempt-to-block-novo-nordisks-10-bn-bid-for-metsera/2025-11-07T12:52:29+08:00https://flcube.com/amgen-reports-12-yoy-sales-growth-in-q3-2025-raises-full%e2%80%91year-revenue-guidance/2025-11-07T12:41:17+08:00https://flcube.com/astrazeneca-posts-11-y-y-revenue-rise-to-43-24-bn-in-first-nine%e2%80%91months-of-2025/2025-11-07T11:40:25+08:00https://flcube.com/nhsa-concludes-2025-national-basic-medical-insurance-drug-catalogue-negotiation-and-commercial-insurance-innovative-drug-price-talks/2025-11-06T14:31:25+08:00https://flcube.com/xtalpis-ailux-strikes-345-million-partnership-with-eli-lilly-to-co%e2%80%91develop-bispecific-antibodies/2025-11-06T14:22:20+08:00https://flcube.com/hbms-subsidiary-nona-biosciences-teams-up-with-umoja-biopharma-to-co%e2%80%91develop-in%e2%80%91vivo-car%e2%80%91t-platforms/2025-11-06T14:13:26+08:00https://flcube.com/siemens-shanghai-gains-nmpa-clearance-for-prostate%e2%80%91cancer-ai-detection-software/2025-11-06T14:07:02+08:00https://flcube.com/shandong-jincheng-pharma-subsidiary-jincheng-taier-to-sell-proxyl-vaginal-capsule-tech-mah-rights-to-shanghai-hemony-for-rmb-50-m/2025-11-06T11:27:10+08:00https://flcube.com/sinotau-receives-fda-nda-approval-for-mk%e2%80%916240-tau-pet-imaging-agent/2025-11-06T00:24:21+08:00https://flcube.com/baheal-pharma-locks-csl-behring-albumin-rights-to-boost-chinas-blood-product-supply/2025-11-06T00:11:50+08:00https://flcube.com/prelude-therapeutics-revamps-pipeline-incyte-option-on-jak2v617f-kat6a-degrader-takes-center-stage-smarca2-paused/2025-11-05T23:21:13+08:00https://flcube.com/ucb-wins-fda-approval-for-kygevvi-in-rare-mitochondrial-disease-tk2d/2025-11-05T23:08:19+08:00https://flcube.com/dizal-highlights-breakthrough-findings-for-golidocitinib-and-birelentinib-at-ash-2025/2025-11-05T22:58:31+08:00https://flcube.com/jiangsu-vcares-vc004-joins-nmpas-spark-oncology-program/2025-11-05T22:52:11+08:00https://flcube.com/pfizers-q3-2025-results-covid%e2%80%9119-sales-slide-while-eliquis-soars/2025-11-05T22:44:26+08:00https://flcube.com/jiangsu-hengrui-secures-priority-review-for-hrs%e2%80%915965-in-chinas-rare%e2%80%91disease-portfolio/2025-11-05T22:36:16+08:00https://flcube.com/pluvicto-radioligand-therapy-receives-dual-nmpa-approvals-in-china/2025-11-05T22:05:45+08:00https://flcube.com/sichuan-biokin-secures-breakthrough-therapy-designation-for-her2%e2%80%91targeted-adc-t%e2%80%91bren/2025-11-05T21:58:14+08:00https://flcube.com/shenzhen-kangtai-biological-products-launches-phase-i-trial-for-infant-influenza-vaccine/2025-11-05T21:45:26+08:00https://flcube.com/4d-molecular-transfers-asia%e2%80%91pacific-gene%e2%80%91therapy-rights-to-otsuka-for-85-m-cash/2025-11-05T21:10:48+08:00https://flcube.com/novo-nordisk-reports-15-yoy-sales-growth-cuts-full%e2%80%91year-guidance/2025-11-05T20:59:32+08:00https://flcube.com/china-cde-opens-public-comment-on-100th-batch-of-reference-standards-for-chemical-generic-drugs/2025-11-05T15:42:20+08:00https://flcube.com/msd-secures-full-global-rights-to-mk%e2%80%918690-after-150-million-settlement-with-falk-pharma/2025-11-05T15:37:07+08:00https://flcube.com/chinas-national-health-commission-launches-silver%e2%80%91haired-healthcare-elderly%e2%80%91care-initiative/2025-11-05T15:32:16+08:00https://flcube.com/chinas-national-health-commission-issues-ai-healthcare-implementation-opinions-roadmap-for-24-standardized-applications/2025-11-05T15:28:39+08:00https://flcube.com/zhejiang-acea-pharma-secures-conditional-nmpa-approval-for-olgotrelvir-sodium-capsules-first-dual%e2%80%91target-covid%e2%80%9119-oral-antiviral-in-china/2025-11-05T15:23:43+08:00https://flcube.com/daiichi-sankyos-enhertu-wins-cde-acceptance-for-first%e2%80%91line-her2%e2%80%91positive-breast%e2%80%91cancer-indication-in-china/2025-11-05T14:50:06+08:00https://flcube.com/metsera-faces-escalating-bidding-war-as-novo-nordisks-10-b-offer-tops-pfizers-revised-proposal/2025-11-05T11:25:47+08:00https://flcube.com/roche-announces-a-55-m-partnership-with-manifold-bio-to-build-bbb-shuttles/2025-11-04T22:11:23+08:00https://flcube.com/eli-lilly-announces-phase-3-attain%e2%80%91pad-trial-for-oral-glp%e2%80%911-agent-orforglipron/2025-11-04T22:02:47+08:00https://flcube.com/green-valley-faces-bribery-fine-as-re%e2%80%91registration-deadline-passes/2025-11-04T21:56:55+08:00https://flcube.com/carsgen-therapeutics-shares-promising-early-results-for-allogeneic-car%e2%80%91t-products/2025-11-04T21:51:52+08:00https://flcube.com/guangzhous-12%e2%80%91step-plan-to-accelerate-innovative-drug-and-device-adoption/2025-11-04T21:44:19+08:00https://flcube.com/hengrui-gets-nmpa-green-light-for-rezvilutamide%e2%80%91hs%e2%80%9120093-combination-trial-in-prostate-cancer/2025-11-04T21:38:09+08:00https://flcube.com/cstone-receives-nmpa-approval-for-cs2009-phase-ii-trial-in-advanced-solid-tumors/2025-11-04T21:31:11+08:00https://flcube.com/nhsa-re%e2%80%91designs-drug%e2%80%91prescribing-surveillance-targeting-illicit-use-and-resale/2025-11-04T21:21:36+08:00https://flcube.com/amoy-diagnostics-announce-nmpa-approval-of-chinas-first-kras-g12c-companion-diagnostic/2025-11-04T21:12:20+08:00https://flcube.com/genans-biotechnology-receives-fda-fast%e2%80%91track-designation-for-ga001-injection-a-promising-gene%e2%80%91therapy-for-retinitis-pigmentosa/2025-11-04T20:59:21+08:00https://flcube.com/ascentage-pharma-unveils-promising-results-for-olverembatinib-and-lisaftoclax-at-the-67th-ash-annual-meeting/2025-11-04T20:52:14+08:00https://flcube.com/sanyou-biopharmaceuticals-and-liferiver-bio-tech-forge-automation%e2%80%91driven-alliance-to-accelerate-biologic-development/2025-11-04T20:42:59+08:00https://flcube.com/yangzi-state%e2%80%91owned-investment-group-perennial-real-estate-join-forces-to-build-jiangsus-first-foreign%e2%80%91owned-general-hospital/2025-11-04T20:28:15+08:00https://flcube.com/shanghai-circodes-hm2002-gains-china-nmpa-approval-for-refractory-angina/2025-11-03T15:10:44+08:00https://flcube.com/transthera-sciences-and-neurocrine-biosciences-ink-881-5-m-nlrp3-collaboration/2025-11-03T15:00:41+08:00https://flcube.com/betta-pharma-secures-exclusive-greater%e2%80%91china-rights-to-gensciences-long%e2%80%91acting-factor-viii-therapy/2025-11-03T14:38:22+08:00https://flcube.com/abbvie-posts-8-4-revenue-gain-in-q3-2025-eps-slumps-on-iprd-charges/2025-11-03T14:22:08+08:00https://flcube.com/astellas-pharma-posts-10-revenue-rise-and-54-core-operating%e2%80%91profit-surge-in-h1-fy2025/2025-11-03T14:02:42+08:00https://flcube.com/fda-issues-draft-guidance-to-accelerate-biosimilar-development-and-cut-costs/2025-11-03T13:55:02+08:00https://flcube.com/simnovas-dll3%e2%80%91targeted-car%e2%80%91t-snc115-wins-first%e2%80%91in%e2%80%91china-clinical%e2%80%91trial-approval-for-relapsed-sclc/2025-11-03T11:29:01+08:00https://flcube.com/akesos-ivonescimab-ak112-receives-fourth-breakthrough-therapy-designation-in-china-for-triple%e2%80%91negative-breast-cancer/2025-11-03T11:24:19+08:00https://flcube.com/cttq-deepens-partnership-with-shionogi-to-accelerate-naldemedine-launch-in-china/2025-11-03T11:18:12+08:00https://flcube.com/fda-cder-director-george-tidmarsh-placed-on-leave-amid-probe-over-drug%e2%80%91approval-program-concerns/2025-11-03T11:12:25+08:00https://flcube.com/lepus-minwei-licenses-mwn105-injection-to-denmarks-sidera-bio-up-to-1-01-b-in-milestones/2025-11-03T11:03:31+08:00https://flcube.com/sanofi-acquires-rare-disease-candidate-inbrx-101-in-1-7-billion-deal/2025-10-31T21:06:46+08:00https://flcube.com/transcenta-partner-inhibrx-reports-positive-chondragon-results-for-ozekibart-plans-fda-bla-filing-in-2026/2025-10-31T21:06:45+08:00https://flcube.com/transcenta-holding-announces-positive-phase-iii-results-for-inhibrxs-ozekibart-in-advanced-chondrosarcoma/2025-10-31T21:06:45+08:00https://flcube.com/boehringer-ingelheim-licenses-pre%e2%80%91clinical-small%e2%80%91molecule-program-from-kyowa-kirin-for-autoimmune-therapy/2025-10-31T20:53:01+08:00https://flcube.com/chengdu-maxvax-secures-series-d-financing-at-over-rmb-400-million-to-accelerate-shingles-and-rsv-vaccine-development/2025-10-31T20:45:57+08:00https://flcube.com/bms-reports-q3-2025-results-2-global-revenue-growth/2025-10-31T20:32:50+08:00https://flcube.com/gilead-sciences-reports-3-yoy-q3-2025-revenue-growth-hiv-sales-up-4/2025-10-31T15:58:44+08:00https://flcube.com/msd-reports-3-yoy-q3-2025-sales-growth-keytruda-drives-8-lift-verona-acquisition-strengthens-cardio%e2%80%91pulmonary-portfolio/2025-10-31T15:54:36+08:00https://flcube.com/eli-lilly-reports-54-yoy-revenue-surge-in-q3-2025-raises-full%e2%80%91year-guidance-to-63-b/2025-10-31T15:47:04+08:00https://flcube.com/jebel-pharma-reports-positive-phase-iii-results-for-jjh201501-antidepressant/2025-10-31T15:38:50+08:00https://flcube.com/shanghai-bio%e2%80%91hearts-iberis-rdn-system-gains-uk-mhra-approval-expands-global-commercial-reach/2025-10-31T15:00:08+08:00https://flcube.com/hightide-therapeutics-announces-positive-phase-iii-results-for-htd1801-in-type-2-diabetes/2025-10-31T12:27:35+08:00https://flcube.com/takeda-reports-3-9-yoy-revenue-decline-in-h1-2025-citing-neuroscience-slump-and-fx-headwinds/2025-10-31T11:43:32+08:00https://flcube.com/brightgene-submits-hkex-prospectus-aiming-for-main%e2%80%91board-listing/2025-10-31T11:35:43+08:00https://flcube.com/dizal-pharmaceutical-reports-73-revenue-growth-driven-by-sunvozertinib-and-golidocitinib/2025-10-31T11:31:08+08:00https://flcube.com/jw-therapeutics-regeneron-sign-expanded-tcr%e2%80%91t-collaboration-unlocking-50-million-in-funding/2025-10-31T11:19:02+08:00https://flcube.com/novo-nordisk-launches-9-billion-unsolicited-bid-for-metsera-triggering-battle-with-pfizer/2025-10-31T11:06:38+08:00https://flcube.com/thermo-fisher-secures-8-875b-clario-acquisition-enhancing-digital%e2%80%91trial-endpoint-suite/2025-10-30T23:07:25+08:00https://flcube.com/modex-therapeutics-locks-1-b-collaboration-with-regeneron-on-multispecific-antibody-technology/2025-10-30T23:01:17+08:00https://flcube.com/everest-medicines-secures-exclusive-rights-to-vis%e2%80%91101-in-greater-china-potential-2026-phase-3-launch/2025-10-30T22:20:44+08:00https://flcube.com/bayer-secures-fda-approval-for-elinzanetant-first-dual-nk-therapy-for-vms/2025-10-30T22:14:56+08:00https://flcube.com/ascletis-launches-asc36-a-once%e2%80%91monthly-injectable-targeting-obesity/2025-10-30T22:08:22+08:00https://flcube.com/pharmaron-expands-cro-footprint-with-82-5-acquisition-of-biortus-in-200-m-deal/2025-10-30T22:00:35+08:00https://flcube.com/sihuan-pharmaceutical-partners-with-abalone-bio-to-accelerate-obesity-therapeutics-development/2025-10-30T21:28:55+08:00https://flcube.com/medicare-negotiation-begins-535-generic-drugs-reviewed-for-2025-drug-catalogue/2025-10-30T17:15:18+08:00https://flcube.com/bayer-sells-avelox-moxifloxacin-business-to-hsg-for-up-to-e260-million/2025-10-30T17:04:14+08:00https://flcube.com/lepu-biopharma-secures-conditional-nmpa-approval-for-becotatug-vedotin-mgr003-in-recurrent-nasopharyngeal-carcinoma/2025-10-30T16:59:27+08:00https://flcube.com/eli-lilly-and-nvidia-forge-record%e2%80%91breaking-ai%e2%80%91powered-supercomputer-for-pharma/2025-10-30T16:51:29+08:00https://flcube.com/shanghai-ark-biopharma-launches-phase-ii-trial-of-ak0610-a-next%e2%80%91generation-rsv-prophylactic-antibody/2025-10-30T16:42:33+08:00https://flcube.com/novabridge-biosciences-completes-rebranding-launches-new-nbp-ticker-on-nasdaq/2025-10-30T16:33:08+08:00https://flcube.com/shanghai-junshi-biosciences-secures-first-canadian-approval-for-loqtorzi-toripalimab-in-nasopharyngeal-cancer/2025-10-30T15:51:51+08:00https://flcube.com/innocare-announces-first-patient-dosing-of-icp%e2%80%91b794-a-novel-b7%e2%80%91h3-targeting-adc/2025-10-30T15:39:55+08:00https://flcube.com/national-health-commission-unveils-fourth-drug-list-for-generic-development/2025-10-30T15:32:12+08:00https://flcube.com/biomarin-cuts-2027-revenue-target-amid-voxzogo-competition/2025-10-30T15:26:51+08:00https://flcube.com/gsk-reports-strong-q3-2025-results-beats-forecasts-with-8-revenue-growth/2025-10-29T20:44:14+08:00https://flcube.com/sihuan-pharmaceutical-secures-fast%e2%80%91track-designation-for-ng%e2%80%91350a-in-u-s-rectal-cancer-treatment/2025-10-29T17:49:01+08:00https://flcube.com/yzy-biopharma-y225-patent-secures-hemlibra-biosimilar-pathway-in-china/2025-10-29T17:40:58+08:00https://flcube.com/bioray-pharmaceutical-co-ltd-signs-mena%e2%80%91wide-licensing-deal-with-saudi-tabuk-pharmaceutical-manufacturing/2025-10-29T17:34:39+08:00https://flcube.com/iaso-biotherapeutics-partners-with-gc-cell-to-advance-equecabtagene-autoleucel-car%e2%80%91t-therapy-in-south-korea/2025-10-29T17:24:44+08:00https://flcube.com/gsk-secures-worldwide-exclusive-rights-to-empiricos-emp%e2%80%91012-a-first%e2%80%91in%e2%80%91class-sirna-for-copd/2025-10-29T14:54:16+08:00https://flcube.com/wuxi-apptec-signs-dual-mous-with-neom-and-saudi-ministry-of-health-to-advance-localized-drug-development/2025-10-29T14:43:49+08:00https://flcube.com/qyuns-therapeutics-partners-with-roche-for-global-rights-to-long%e2%80%91acting-bispecific-antibody-qx031n/2025-10-29T14:26:55+08:00https://flcube.com/jiangsu-aidea-secures-approval-to-launch-adc118-tablets-in-china-first-domestic-hiv-integrase-fdc/2025-10-29T14:20:42+08:00https://flcube.com/fosun-pharmaceutical-q3-2025-revenue-slips-5-5-amid-vbp-innovative-drugs-grow-18/2025-10-29T14:07:44+08:00https://flcube.com/junshi-biosciences-q3-2025-revenue-climbs-31-toripalimab-drives-growth-nmpa-approves-snda/2025-10-29T14:01:46+08:00https://flcube.com/fosun-pharmaceutical-announces-spin%e2%80%91off-and-hk-listing-of-adgenvax/2025-10-29T13:20:15+08:00https://flcube.com/fosun-pharma-target-fund-launches-with-rmb-1-billion-capital-led-by-china-resources-gp/2025-10-29T13:06:07+08:00https://flcube.com/alphamab-oncology-secures-fda-fast%e2%80%91track-designation-for-her2-bispecific-adc-jskn003-in-platinum%e2%80%91resistant-ovarian-cancer/2025-10-28T16:28:35+08:00https://flcube.com/ssy-group-limited-projected-to-win-12-products-in-chinas-eleventh-vbp-round/2025-10-28T16:15:50+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-acceptance-for-fluzoparib-in-first%e2%80%91line-therapy-of-dna%e2%80%91repair%e2%80%91defect-positive-mcrpc/2025-10-28T16:09:32+08:00https://flcube.com/nanjing-leads-biolabs-announces-first%e2%80%91patient-dose-of-lbl%e2%80%91024-a-novel-bispecific-antibody-for-biliary-tract-cancer/2025-10-28T16:00:08+08:00https://flcube.com/eisai-and-merck-present-5%e2%80%91year-survival-data-for-lenvatinib%e2%80%91pembrolizumab-in-advanced-endometrial-carcinoma-at-esmo-2025/2025-10-28T15:32:55+08:00https://flcube.com/polymed-biopharmaceuticals-completes-pre%e2%80%91a-funding-round-led-by-caleb-capital-fuels-protac%e2%80%91focused-pipeline/2025-10-28T13:50:29+08:00https://flcube.com/nmpa-releases-draft-measures-on-drug-quality-sampling-seeks-public-comments-by-nov-5/2025-10-28T13:36:59+08:00https://flcube.com/novartis-asciminib-enters-chinas-spark-program-for-pediatric-chronic-myeloid-leukemia/2025-10-28T13:29:32+08:00https://flcube.com/wuxi-apptec-sells-wuxi-clinical-and-medkey-to-hillhouse-for-rmb-2-8-billion/2025-10-28T13:19:18+08:00https://flcube.com/wuxi-apptec-reports-15-3-yoy-revenue-growth-in-q3-2025-net-profit-hits-rmb-4-22-billion/2025-10-28T13:11:10+08:00https://flcube.com/grand-pharma-launches-gpn00884-clinical-trial-to-tackle-pediatric-myopia-progression/2025-10-27T23:49:25+08:00https://flcube.com/novartis-strikes-usd-12b-deal-for-aviditys-rna-therapeutics-and-gene-targeted-pipeline/2025-10-27T23:39:05+08:00https://flcube.com/eli-lilly-to-acquire-adverum-biotechnologies-for-up-to-usd-261-7m-for-ixo-vec-access/2025-10-27T23:30:27+08:00https://flcube.com/alphamab-oncologys-jskn003-approved-for-phase-iii-trial-in-her2-positive-crc/2025-10-27T23:19:15+08:00https://flcube.com/astrazeneca-launches-sixth-global-rd-center-in-beijing-to-accelerate-china-investments/2025-10-27T22:49:43+08:00https://flcube.com/chiesi-group-launches-first-eb-wound-treatment-in-china/2025-10-27T22:44:00+08:00https://flcube.com/chugai-to-acquire-renalys-pharma-for-jpy-31-billion-to-expand-iga-nephropathy-treatment-portfolio/2025-10-27T22:10:16+08:00https://flcube.com/innovents-mazdutide-meets-phase-iii-endpoint-in-type-2-diabetes-and-obesity-trial/2025-10-27T22:03:06+08:00https://flcube.com/sunshine-guojian-reports-strong-q3-growth-and-advances-key-rd-programs/2025-10-27T21:56:42+08:00https://flcube.com/astellas-establishes-first-china-innovation-rd-center-in-beijing-biopark/2025-10-27T21:48:23+08:00https://flcube.com/novartis-transfers-lucentis-and-beovu-rights-to-cms-vision-in-china-deal/2025-10-27T21:31:46+08:00https://flcube.com/gsk-secures-global-rights-to-syndivias-adc-for-metastatic-prostate-cancer/2025-10-27T21:22:48+08:00https://flcube.com/zhifeis-ca111-injection-approved-for-clinical-trials-targeting-weight-loss-and-hypoglycemia/2025-10-27T21:05:38+08:00https://flcube.com/leo-pharma-submits-nda-for-anzupgo-in-china-for-chronic-hand-eczema/2025-10-27T20:55:02+08:00https://flcube.com/eli-lilly-partners-with-cipla-to-distribute-new-tirzepatide-brand-yurpeak-in-india/2025-10-25T00:05:06+08:00https://flcube.com/alphamab-announces-first-patient-dosed-with-jskn022-a-pd%e2%80%91l1-%ce%b1v%ce%b26-bispecific-adc/2025-10-24T23:59:18+08:00https://flcube.com/hansoh-pharmaceutical-submits-hs%e2%80%9110365-nda-to-nmpa-for-ret%e2%80%91positive-nsclc/2025-10-24T23:53:53+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approval-to-launch-phase-iii-trial-of-trastuzumab-rezetecan-in-her2%e2%80%91positive-breast-cancer/2025-10-24T23:47:09+08:00https://flcube.com/nmpa-expands-reference-listed-drugs-list-to-98-items-for-chemical-generic-drugs/2025-10-24T23:37:16+08:00https://flcube.com/gsk-secures-fda-approval-for-blenrep-in-multiple-myeloma/2025-10-24T23:33:22+08:00https://flcube.com/pfizer-rd-atlatl-forge-open-innovation-partnership-in-beijing/2025-10-24T23:25:21+08:00https://flcube.com/ribolifes-rbd1016-earns-ema-orphan-designation-with-ribogalstar-platform/2025-10-24T23:21:20+08:00https://flcube.com/astellas-china-secures-gba-approval-for-first%e2%80%91in%e2%80%91class-fezolinetant-veoza/2025-10-24T23:14:48+08:00https://flcube.com/sanofi-q3-2025-results-7-revenue-growth-dupixent-drives-pharma-upswing/2025-10-24T23:08:57+08:00https://flcube.com/shanghai-circode-biomed-secures-fda-orphan-designation-for-hm2003-injection-in-thromboangiitis-obliterans/2025-10-24T23:02:39+08:00https://flcube.com/huadongs-mefatinib-approved-by-nmpa-for-egfr%e2%80%91driven-nsclc/2025-10-24T22:55:54+08:00https://flcube.com/hengrui-launches-henagliflozin-triple%e2%80%91combination-metformin-for-type-2-diabetes/2025-10-24T22:48:58+08:00https://flcube.com/cspcs-syh2061-injection-receives-nmpa-clinical%e2%80%91trial-approval-for-iga-nephropathy/2025-10-24T22:43:26+08:00https://flcube.com/boehringer-ingelheims-nerandomilast-approved-by-china-nmpa-for-idiopathic-pulmonary-fibrosis/2025-10-23T20:37:54+08:00https://flcube.com/boehringer-ingelheim-partners-with-cbmed-to-accelerate-first-in-class-cancer-medicines-development/2025-10-23T20:35:38+08:00https://flcube.com/fosun-pharma-helsinn-partner-to-produce-fosnetupitant-for-akynzeo-in-china/2025-10-23T20:32:25+08:00https://flcube.com/padcev-yields-60-efs-reduction-in-mibc-astellas%e2%80%91pfizer-ev%e2%80%91303-study/2025-10-23T20:18:07+08:00https://flcube.com/abbvies-select%e2%80%91switch-study-confirms-upadacitinib-outperforms-adalimumab-in-ra/2025-10-23T20:10:01+08:00https://flcube.com/harbour-biomed-reports-phase-ii-success-of-porustobart-in-mss-mcrc/2025-10-23T19:56:39+08:00https://flcube.com/vbp-11th-finalizes-389-participants-3-7-billion-doses-set-for-centralized-procurement/2025-10-23T19:41:22+08:00https://flcube.com/roche-reports-7-yoy-revenue-growth-through-q3-2025-raises-full%e2%80%91year-guidance/2025-10-23T19:32:41+08:00https://flcube.com/novo-nordisk-board-shake%e2%80%91up-chairman-helge-lund-and-six-members-step-down-after-disagreement-with-foundation/2025-10-22T21:16:51+08:00https://flcube.com/innovent-and-takeda-forge-11-4-b-partnership-on-ibi363-ibi343-ibi3001-adc-therapies/2025-10-22T21:05:53+08:00https://flcube.com/galapagos-announces-exit-from-cell%e2%80%91therapy-business-after-strategic-review/2025-10-22T20:56:42+08:00https://flcube.com/gfh375-enters-phase-ib-ii-at-peking-university-genfleet-targets-kras-g12d/2025-10-22T20:42:33+08:00https://flcube.com/rani-therapeutics-and-chugai-forge-1-085-billion-collaboration-deal-for-innovative-oral-therapeutic/2025-10-22T20:33:20+08:00https://flcube.com/bireoccilib-outperforms-traditional-cdk4-6-in-bright%e2%80%913-xuanzhu-biopharma-announces-interim-phase-iii-results-at-esmo-2025/2025-10-22T20:22:19+08:00https://flcube.com/sichuan-biokin-secures-nmpa-approval-for-bl%e2%80%91m24d1-adc-targeting-relapsed-hematologic-and-solid-tumors/2025-10-22T20:15:06+08:00https://flcube.com/huadong-medicine-secures-fda-approval-for-dr10624-first%e2%80%91in%e2%80%91class-trispecific-agonist-for-severe-hypertriglyceridemia/2025-10-22T20:05:25+08:00https://flcube.com/astrazeneca-daiichi-sankyo-announce-11-2-pcr-gain-with-enhertu-in-destiny%e2%80%91breast11-at-esmo-2025/2025-10-22T19:58:50+08:00https://flcube.com/indetek-laboratory-secures-nmpa-approval-for-idt%e2%80%91001-gel-a-novel-film%e2%80%91forming-therapy-for-sstis/2025-10-22T19:52:53+08:00https://flcube.com/fosun%e2%80%91henlius-announces-26-8%e2%80%91month-median-os-for-hetronifly-plus-chemo-in-advanced-nsclc/2025-10-22T19:45:20+08:00https://flcube.com/novartis-announces-five%e2%80%91year-natalee-results-for-kisqali-in-hr-her2%e2%80%91-early-breast-cancer/2025-10-22T19:38:23+08:00https://flcube.com/novo-nordisk-secures-fda-approval-for-rybelsus-to-reduce-cardiovascular-risk-in-type-2-diabetes/2025-10-21T21:39:53+08:00https://flcube.com/sino-biopharmaceutical-announces-breakthrough-phase-iii-results-for-culmerciclib-in-hr-her2%e2%80%91-negative-breast-cancer/2025-10-21T21:34:55+08:00https://flcube.com/sichuan-biokin-launches-phase-iii-trial-of-t%e2%80%91bren-for-her2%e2%80%91mutant-nsclc/2025-10-21T21:29:14+08:00https://flcube.com/anhui-anke-announces-hua21-success-in-her2%e2%80%91positive-gastric-cancer/2025-10-21T21:23:00+08:00https://flcube.com/novartis-announces-first%e2%80%91in%e2%80%91class-phase-iii-data-for-lutetium%e2%80%91177-vipivotide-tetraxetan-in-psma%e2%80%91positive-metastatic-hormone%e2%80%91sensitive-prostate-cancer/2025-10-21T21:18:58+08:00https://flcube.com/boston-scientific-announces-nalu-medical-acquisition-to-expand-chronic%e2%80%91pain-portfolio/2025-10-21T21:13:42+08:00https://flcube.com/accord-plasma-completes-acquisition-of-prothya-biosolutions-expanding-european-plasma%e2%80%91derived-medicinal-product-pdmp-capabilities/2025-10-21T21:07:38+08:00https://flcube.com/changchun-high%e2%80%91tech-secures-nmpa-approval-for-gensci139-bispecific-adc-in-advanced-solid-tumors/2025-10-21T21:04:03+08:00https://flcube.com/salubris-shares-promising-jk06-adc-results-from-esmo-2025-clinical-presentation/2025-10-21T20:56:33+08:00https://flcube.com/advaccine-biotechnology-announces-private-placement-of-up-to-2-2-million-shares-to-raise-rmb-300-million-for-microneedle-vaccine-development/2025-10-21T20:48:02+08:00https://flcube.com/summit-therapeutics-plans-u-s-fda-bla-submission-for-ivonescimab-chemotherapy-in-egfr%e2%80%91mutated-nsclc/2025-10-21T20:43:13+08:00https://flcube.com/samsung-bioepis-announces-global-adc-collaboration-with-phrontline-biopharma-to-advance-tj108/2025-10-21T20:38:48+08:00https://flcube.com/shanghai-henlius-biotech-secures-fda-orphan-drug-designation-for-hlx43-in-thymic-epithelial-tumors/2025-10-20T20:08:14+08:00https://flcube.com/carsgen-announces-promising-phase-ib-results-for-satricabtagene-autoleucel-injection-in-post%e2%80%91surgery-pancreatic-cancer/2025-10-20T20:03:10+08:00https://flcube.com/cspc-pharmaceutical-secures-breakthrough-therapy-designation-for-jskn003-in-her2%e2%80%91positive-colorectal-cancer/2025-10-20T19:55:54+08:00https://flcube.com/akeso-announces-landmark-phase-iii-results-for-ivonescimab-in-first%e2%80%91line-sq%e2%80%91nsclc/2025-10-20T19:49:19+08:00https://flcube.com/wuhan-yzy-biopharma-announces-interim-phase-ii-results-for-m701-in-malignant-pleural-effusion/2025-10-20T19:39:01+08:00https://flcube.com/china-isotope-radiation-corp-signs-mou-with-brazils-cnen-for-long%e2%80%91term-isotope-supply/2025-10-20T19:34:42+08:00https://flcube.com/wuhan-healthgen-announces-star-market-ipo-of-oryzogen-shares/2025-10-20T19:27:32+08:00https://flcube.com/alphamab-oncology-announces-interim-phase-iii-results-for-anbenitamab-in-her2%e2%80%91positive-gastric-cancer/2025-10-20T19:21:03+08:00https://flcube.com/fosun-kairos-secures-series-a-financing-to-propel-cell%e2%80%91therapy-expansion/2025-10-20T19:09:47+08:00https://flcube.com/multitude-therapeutics-announces-early%e2%80%91stage-efficacy-signals-for-amt%e2%80%91116-a-first%e2%80%91in%e2%80%91class-cd44v9%e2%80%91targeting-adc/2025-10-20T19:01:37+08:00https://flcube.com/eli-lilly-announces-long%e2%80%91term-survival-benefit-of-abemaciclib-in-early-breast-cancer/2025-10-20T18:52:40+08:00https://flcube.com/merck-kgaa-secures-nmpa-approval-for-erbitux-in-braf%e2%80%91v600e-mcrc/2025-10-20T18:46:07+08:00https://flcube.com/novo-nordisk-secures-global-rights-to-zaltenibart-in-deal-with-omeros/2025-10-20T18:37:35+08:00https://flcube.com/boehringer-ingelheim-aimedbio-announce-global-adc-collaboration-to-target-broad%e2%80%91spectrum-cancers/2025-10-20T18:27:02+08:00https://flcube.com/pregene-partners-with-kite-to-pioneer-next-generation-in-vivo-therapies/2025-10-20T10:25:11+08:00https://flcube.com/aosaikangs-askgene-pharma-licenses-askg712-to-visara-for-macular-disease-treatment/2025-10-17T19:48:59+08:00https://flcube.com/kelun-biotechs-trastuzumab-botidotin-approved-by-nmpa-for-her2-positive-breast-cancer/2025-10-17T19:43:02+08:00https://flcube.com/huadong-medicine-secures-nmpa-approval-for-relmapirazin-injection-complementing-medibeacon-tgfr-device/2025-10-17T16:05:22+08:00https://flcube.com/kexing-biopharm-easton-biopharma-sign-exclusive-overseas-licensing-deal-for-apalutamide/2025-10-17T15:58:27+08:00https://flcube.com/sinclairs-maili-precise-receives-nmpa-acceptance-notice-for-class-iii-device/2025-10-17T15:51:10+08:00https://flcube.com/i%e2%80%91mab-announces-global-transformation-novabridge-rebranding-and-37-m-acquisition-of-vis%e2%80%91101/2025-10-17T15:11:52+08:00https://flcube.com/cstones-sugemalimab-receives-positive-ema-opinion-for-stage-iii-nsclc/2025-10-17T14:57:27+08:00https://flcube.com/viatris-acquires-aculys-pharma-to-secure-japanese-rights-for-pitolisant-and-spydia/2025-10-17T14:42:40+08:00https://flcube.com/gan-lee-pharma-fiocruz-sign-mou-to-advance-gzr4-and-gzr102-insulin-candidates/2025-10-17T14:24:41+08:00https://flcube.com/hansoh-pharma-grants-roche-exclusive-global-rights-to-cdh17%e2%80%91targeting-adc-hs%e2%80%9120110/2025-10-17T14:09:55+08:00https://flcube.com/shanghai-junshi-biosciences-secures-fda-approval-for-js207-phase-ii-iii-trial/2025-10-17T13:50:58+08:00https://flcube.com/astrazeneca-china-integrates-symbicort-and-breztri-sales-teams-in-new-organizational-shake%e2%80%91up/2025-10-17T13:18:16+08:00https://flcube.com/leads-biolabs-dianthus-therapeutics-announce-global-partnership-for-lbl%e2%80%91047-bispecific-fusion-protein/2025-10-17T13:06:37+08:00https://flcube.com/neurogen-pharma-secures-exclusive-rights-to-brexpiprazole-orally-disintegrating-film-from-bocimed/2025-10-16T17:07:09+08:00https://flcube.com/chia-tai-tianqing-secures-nmpa-approval-for-phase-iii-trial-of-tqb2868-anlotinib-in-first%e2%80%91line-mpdac-therapy/2025-10-16T16:59:21+08:00https://flcube.com/lepu-biopharma-enrolls-first-patient-in-phase-ii-trial-of-mrg006a-the-worlds-first-gpc3%e2%80%91targeting-adc/2025-10-16T16:54:02+08:00https://flcube.com/jacobio-pharmaceuticals-secures-80-equity-investment-in-jacoray-from-oceanpine-capital/2025-10-16T16:42:39+08:00https://flcube.com/zhejiang-authority-imposes-administrative-penalties-on-dahongying-pharma-for-substandard-fluorouracil-injection/2025-10-16T16:31:38+08:00https://flcube.com/help-therapeutics-secures-nmpa-approval-for-hicm388-chinas-first-cell%e2%80%91based-therapy-for-stemi/2025-10-16T16:18:38+08:00https://flcube.com/abbott-reports-q3-2025-revenue-of-11-369-b-up-6-9-yoy-strong-growth-across-nutrition-devices-segments/2025-10-16T16:12:00+08:00https://flcube.com/haihe-biopharma-grants-taiho-pharmaceutical-exclusive-license-for-risovalisib-in-japan/2025-10-16T16:03:18+08:00https://flcube.com/genesis-healthcare-mgi-sign-strategic-mou-to-accelerate-precision-medicine-in-japan/2025-10-16T15:57:36+08:00https://flcube.com/nuance-pharma-partners-with-stallergenes-greer-to-launch-actair-in-china/2025-10-15T23:15:34+08:00https://flcube.com/pfizer-ceo-bourla-highlights-benefits-of-china-biotech-collaborations-at-ny-gala/2025-10-15T23:05:47+08:00https://flcube.com/uni-bio-science-partners-with-sinovac-to-expand-teriparatide-injection-globally/2025-10-15T23:00:29+08:00https://flcube.com/adagene-expands-exelixis-collaboration-to-include-third-target-using-safebody-technology/2025-10-15T22:49:17+08:00https://flcube.com/ollin-biosciences-launches-with-100m-funding-to-advance-ophthalmology-pipeline/2025-10-15T22:41:27+08:00https://flcube.com/yanyin-tech-and-circode-biomed-forge-three-year-rna-drug-development-partnership/2025-10-15T22:36:34+08:00https://flcube.com/china-resources-double-crane-partners-with-rigerna-on-sirna-drug-rg008-for-chronic-metabolic-diseases/2025-10-15T22:29:40+08:00https://flcube.com/livzon-launches-chinas-first-oral-gnrh-antagonist-for-multiple-indications/2025-10-15T22:15:08+08:00https://flcube.com/pacific-shuanglins-controlling-stake-transferred-to-cnbg-in-rmb-4-7b-deal/2025-10-15T22:10:01+08:00https://flcube.com/jingze-bio-and-cms-subsidiary-partner-to-commercialize-key-products-in-reproduction-and-ophthalmology/2025-10-15T22:04:13+08:00https://flcube.com/yanyin-tech-and-changjiang-pharma-partner-to-advance-ai-in-drug-development/2025-10-15T21:47:07+08:00https://flcube.com/sino-biopharmaceuticals-partner-cttq-secures-breakthrough-therapy-designation-for-tq%e2%80%91b3234-capsule-in-china/2025-10-15T17:32:06+08:00https://flcube.com/pfizer-reports-positive-phase-3-her2climb%e2%80%9105-results-for-tukysa-tucatinib-in-first%e2%80%91line-her2-mbc/2025-10-15T17:25:22+08:00https://flcube.com/zennova-rapafusyn-forge-alliance-to-accelerate-non%e2%80%91degrading-molecular-glue-therapies/2025-10-15T17:18:07+08:00https://flcube.com/shenzhen-kangtai-secures-530-million-yuan-technology-transfer-for-klebsiella-pneumoniae-vaccine/2025-10-15T17:02:44+08:00https://flcube.com/eisai-biogen-secure-tga-approval-for-lecanemab-leqembi-in-early-alzheimers-disease/2025-10-15T16:45:45+08:00https://flcube.com/genscripts-probio-secures-rmb-479-7-m-license-payment-for-lm%e2%80%91299-boosting-sinobiopharmaceuticals-portfolio/2025-10-15T16:39:14+08:00https://flcube.com/chengdu-olymvax-biopharmaceuticals-delonix-bioworks-announce-joint-development-of-gene%e2%80%91engineered-pertussis-vaccine/2025-10-15T16:26:58+08:00https://flcube.com/jiudian-pharma-acquires-chengdu-peides-jij02-gel-advancing-a-novel-acne-treatment-into-phase-1/2025-10-15T16:03:40+08:00https://flcube.com/junshi-biosciences-reports-49-yoy-revenue-growth-in-h1-2025-raises-cash-reserves-to-rmb-3-49-b/2025-10-15T15:52:36+08:00https://flcube.com/johnson-johnson-reports-robust-q3-2025-sales-growth-boosts-full%e2%80%91year-outlook/2025-10-15T15:42:32+08:00https://flcube.com/kailera-therapeutics-secures-600-million-series-b-funding-from-bain-capital-private-equity-to-accelerate-global-obesity-pipeline/2025-10-15T13:12:01+08:00https://flcube.com/bio%e2%80%91thera-expands-canadian-partnership-with-intas-pharma-for-golimumab-biosimilar-bat2506/2025-10-15T13:03:05+08:00https://flcube.com/national-joint-procurement-office-announces-11th-round-vbp-astrazeneca-dapagliflozin-leads-demand/2025-10-15T12:54:44+08:00https://flcube.com/maxvax-biotech-secures-nmpa-acceptance-for-its-recombinant-herpes-zoster-vaccine/2025-10-15T12:49:04+08:00https://flcube.com/shandong-buchang-names-goodfellow-as-exclusive-philippine-distributor-for-efparepoetin-alfa-to-treat-ckd-anemia/2025-10-15T12:34:51+08:00https://flcube.com/zhaoke-ophthalmology-secures-exclusive-indonesian-distribution-deal-for-nvk002-a-novel-atropine%e2%80%91based-myopia-treatment/2025-10-15T12:16:28+08:00https://flcube.com/cspc-pharmaceutical-group-announces-nmpa-acceptance-of-efmedaglutide-alfa-injection-for-long%e2%80%91term-weight-management/2025-10-14T15:46:47+08:00https://flcube.com/ucb-biosciences-receives-nmpa-marketing-authorization-for-zilucoplan-zilbrysq-in-adult-generalized-myasthenia-gravis/2025-10-14T15:32:55+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-ind-approval-for-7mw4911-cdh17%e2%80%91targeting-adc-in-advanced-solid-tumors/2025-10-14T15:26:41+08:00https://flcube.com/gsk-receives-china-nmpa-approval-for-shingrix-in-immunocompromised-adults/2025-10-14T15:16:04+08:00https://flcube.com/arcutis-biotherapeutics-receives-fda-approval-for-zoryve-roflumilast-cream-in-children-2%e2%80%915-years-with-atopic-dermatitis/2025-10-14T15:10:16+08:00https://flcube.com/beone-medicines-receives-fda-breakthrough-therapy-designation-for-sonrotoclax-in-relapsed-mantle-cell-lymphoma/2025-10-14T14:54:42+08:00https://flcube.com/revir-therapeutics-secures-fda-orphan-drug-designation-for-rtx%e2%80%91117-targeting-charcot%e2%80%91marie%e2%80%91tooth-disease/2025-10-14T14:34:19+08:00https://flcube.com/everest-medicines-commences-global-phase-i-trial-of-universal-mrna-cancer-vaccine-evm14/2025-10-14T14:23:55+08:00https://flcube.com/boehringer-ingelheim-launches-trajenta-production-in-zhangjiang-china/2025-10-14T13:54:04+08:00https://flcube.com/amoytop-biotech-secures-nmpa-approval-for-pegbinterferon-combination-therapy-in-chronic-hepatitis-b/2025-10-13T17:44:58+08:00https://flcube.com/sihuan-pharma-invests-in-swiss-aesthetic-tech-company-suisselle-secures-permanent-exclusive-distribution-of-cellbooster-in-china/2025-10-13T17:39:42+08:00https://flcube.com/sino-biopharma-subsidiary-secures-breakthrough-therapy-designation-for-tqb2102-adc-targeting-her2%e2%80%91positive-colorectal-cancer/2025-10-13T17:30:04+08:00https://flcube.com/everest-medicines-receives-nmpa-approval-for-universal-oncology-vaccine-evm14/2025-10-13T17:22:20+08:00https://flcube.com/sichuan-kelun%e2%80%91biotech-wins-nmpa-approval-for-sacituzumab%e2%80%91tirumotecan-in-egfr%e2%80%91mutant-lung-cancer/2025-10-13T17:15:50+08:00https://flcube.com/beihai-biotech-secures-fda-ind-approval-for-first%e2%80%91in%e2%80%91class-peptide%e2%80%91drug-conjugate-bh1621/2025-10-13T17:09:35+08:00https://flcube.com/sichuan-biokins-systimmune-receives-250-million-triggered-by-phase-2-3-milestone-in-egfrxher3-adc/2025-10-13T17:04:44+08:00https://flcube.com/boehringer-ingelheim-secures-fda-approval-for-nerandomilast-jascayd-in-idiopathic-pulmonary-fibrosis/2025-10-13T16:52:25+08:00https://flcube.com/chinas-nmpa-approves-mufemilast-hemay005-hemeis-first-domestic-pde4-inhibitor/2025-10-13T16:39:37+08:00https://flcube.com/state-council-introduces-2026-regulations-governing-clinical-research-of-biomedical-new-technologies-in-china/2025-10-13T16:32:36+08:00https://flcube.com/bms-acquires-orbital-for-1-5-b-in-rna%e2%80%91based-immunotherapy-deal/2025-10-11T15:10:38+08:00https://flcube.com/peijia-medical-secures-nmpa-approval-for-geminione-teer-system/2025-10-11T15:00:59+08:00https://flcube.com/pegbio-signs-non%e2%80%91binding-term-sheet-with-uae%e2%80%91based-pdc-for-exclusive-middle-east-africa-license-of-visepegenatide/2025-10-11T14:53:28+08:00https://flcube.com/tigermed-completes-share-transfer-of-teddy-clinical-laboratory-to-frontage-laboratories-for-rmb-270-million/2025-10-11T14:48:02+08:00https://flcube.com/beone-medicines-terminates-patent-dispute-with-abbvies-pharmacyclics-over-btk-inhibitors/2025-10-11T14:43:46+08:00https://flcube.com/national-drug-alliance-moves-vbp-11th%e2%80%91round-information-disclosure-conference-to-27-oct-2025-in-shanghai/2025-10-11T11:27:46+08:00https://flcube.com/novo-nordisk-to-acquire-akero-therapeutics-for-5-2-billion-secures-future-value-with-efruxifermin/2025-10-10T17:20:31+08:00https://flcube.com/xingqi-pharma-secures-nmpa-approval-for-sq%e2%80%91129-a-novel-treatment-for-diabetic-macular-edema/2025-10-10T17:06:50+08:00https://flcube.com/shanghai-henlius-biotech-achieves-primary-endpoint-in-phase-3-trial-of-serplulimab-for-early%e2%80%91stage-gastric-cancer/2025-10-10T16:58:36+08:00https://flcube.com/jw-cayman-therapeutics-secures-nmpa-acceptance-for-carteyva-introducing-in%e2%80%91house-lentiviral-vector-production/2025-10-10T16:44:45+08:00https://flcube.com/acotec-scientific-receives-fda-510k-clearance-for-endovenous-radiofrequency-ablation-system/2025-10-10T16:37:15+08:00https://flcube.com/beijing-luzhu-biotechnology-completes-u-s-phase-1-trial-of-lz901-demonstrating-strong-safety-and-immunogenicity/2025-10-10T16:31:02+08:00https://flcube.com/huadong-medicine-secures-nmpa-trial-approval-for-hdm2017-a-cdh17%e2%80%91targeting-adc/2025-10-10T16:10:07+08:00https://flcube.com/chance-pharma-secures-exclusive-china-deal-with-huadong-medicine-for-cxg87-inhaler/2025-10-10T16:03:29+08:00https://flcube.com/takeda-shuts-down-cell%e2%80%91therapy-program-eyes-external-collaboration-for-%ce%b3%ce%b4-t%e2%80%91cell-platform/2025-10-10T15:42:12+08:00https://flcube.com/mirxes-secures-chinas-first-blood%e2%80%91test-approval-for-gastric%e2%80%91cancer-screening/2025-10-09T16:48:06+08:00https://flcube.com/jenscare-secures-lux%e2%80%91valve-approval-for-transjugular-tricuspid-replacement-in-greater-bay-area/2025-10-09T16:05:55+08:00https://flcube.com/roche-secures-fda-approval-for-tecentriq%e2%80%91lurbinectedin-combo-in-es%e2%80%91sclc/2025-10-09T15:52:32+08:00https://flcube.com/eli-lilly-to-invest-1b-in-india-launch-new-hyderabad-manufacturing-hub/2025-10-09T15:30:04+08:00https://flcube.com/walvax-biotech-wins-jordan-fda-approval-for-13%e2%80%91valent-pneumococcal-vaccine/2025-10-09T15:20:54+08:00https://flcube.com/northeast-pharma-secures-nmpa-approval-for-dcty0801-injection-targeting-egfrviii%e2%80%91positive-brain-gliomas/2025-10-09T15:13:26+08:00https://flcube.com/innocare-zenas-orelabrutinib-2-b-licensing-deal-fuels-ms-therapeutic-pipeline/2025-10-09T14:55:11+08:00https://flcube.com/hengrui-shr%e2%80%914298-ras-china-approves-two-novel-anti%e2%80%91tumor-drugs-for-clinical-trials/2025-10-09T14:44:48+08:00https://flcube.com/shanghai-fosun-secures-nmpa-approval-for-hlx43-hlx07-combination-in-advanced-solid-tumors/2025-10-09T14:33:25+08:00https://flcube.com/remegen-santen-announce-cde-acceptance-of-rc28%e2%80%91e-for-diabetic-macular-edema/2025-09-30T16:45:01+08:00https://flcube.com/astrazeneca-announces-dual%e2%80%91market-direct-listing-on-nyse-harmonising-global-share-structure/2025-09-30T16:40:42+08:00https://flcube.com/c%e2%80%91mer-medical-gilead-and-hanmi-sign-global-licensing-deal-for-first%e2%80%91in%e2%80%91class-p%e2%80%91glycoprotein-inhibitor-encequidar/2025-09-30T16:36:27+08:00https://flcube.com/nmpa-announces-import-of-commercial%e2%80%91scale-pre%e2%80%91approval-overseas-drugs/2025-09-30T16:29:08+08:00https://flcube.com/microport-announces-680-million-merger-with-crm-cayman-expanding-cardio%e2%80%91medical-footprint/2025-09-30T16:24:43+08:00https://flcube.com/shanghai-junshi-biosciences-announces-nearly-rmb-380-million-capital-increase-for-grit-biotechnology/2025-09-30T16:11:43+08:00https://flcube.com/accuredit-therapeutics-raises-75-m-series-a-secures-strategic-partners-for-gene%e2%80%91editing-platform/2025-09-30T15:57:38+08:00https://flcube.com/changchun-genescience-secures-china-approval-for-long%e2%80%91acting-fsh%e2%80%91ctp-injection/2025-09-30T14:49:54+08:00https://flcube.com/ipsen-launches-bylvay-in-china-for-rare-liver-disease/2025-09-30T14:30:18+08:00https://flcube.com/tj-biopharma-secures-series-c2-funding-to-accelerate-autoimmune-and-oncology-pipeline/2025-09-30T14:22:49+08:00https://flcube.com/full%e2%80%91life-technologies-raises-77-m-in-series-c-and-debt-funding/2025-09-30T14:17:00+08:00https://flcube.com/gsk-names-luke-miels-as-ceo-to-drive-growth/2025-09-30T14:10:54+08:00https://flcube.com/simnova-secures-fda-ind-for-car%e2%80%91nk-therapy-in-sle/2025-09-30T14:03:57+08:00https://flcube.com/sinopharm-secures-nmpa-approval-for-quadrivalenthpv-vaccine/2025-09-29T17:56:22+08:00https://flcube.com/hua-medicine-secures-hong-kong-nda-acceptance-for-dorzagliatin-first%e2%80%91in%e2%80%91class-glucokinase-activator/2025-09-29T17:45:27+08:00https://flcube.com/xinhua-pharma-wins-china-trial-approval-for-dual%e2%80%91mechanism-pah-drug-lxh%e2%80%911211/2025-09-29T17:38:53+08:00https://flcube.com/simcere-secures-fda-approval-for-adc-sim0609-in-advanced-solid-tumors/2025-09-29T17:31:48+08:00https://flcube.com/cms-wins-nmpa-green-light-for-phase%e2%80%913-trial-of-mg%e2%80%91k10-anti%e2%80%91il%e2%80%914r%ce%b1-in-chronic-urticaria/2025-09-29T17:19:20+08:00https://flcube.com/eisai-biogen-secure-leqembi-china-maintenance-approval/2025-09-29T17:09:39+08:00https://flcube.com/hanx-biopharmaceuticals-secures-nmpa-approval-for-hx044%e2%80%91hx008-pd%e2%80%911-therapy-combination-in-advanced-solid-tumors/2025-09-29T16:44:38+08:00https://flcube.com/novatim-partners-with-vrise-to-launch-kq%e2%80%912003-car%e2%80%91t-in-india/2025-09-29T16:33:48+08:00https://flcube.com/cms-announces-phase-3-success-of-ruxolitinib-cream-in-atopic-dermatitis/2025-09-28T11:40:34+08:00https://flcube.com/merck-names-kai-beckmann-as-incoming-ceo-signals-smooth-leadership-transition/2025-09-28T11:29:48+08:00https://flcube.com/trumps-new-pharmaceutical-tariffs-will-be-limited-to-15-for-eu-and-japan-white-house-says/2025-09-28T11:23:20+08:00https://flcube.com/beijing-unicets-qh104a-receives-chinese-nmpa-approval-for-cns-solid%e2%80%91tumor-clinical-trials/2025-09-28T11:16:32+08:00https://flcube.com/wolters-kluwer-and-the-chinese-academy-of-medical-sciences-sign-ai%e2%80%91driven-medical%e2%80%91information-collaboration/2025-09-28T11:05:28+08:00https://flcube.com/leo-pharma-secures-first-greater-bay-area-prescription-for-anzupgo-a-novel-topical-jak-inhibitor/2025-09-28T10:55:01+08:00https://flcube.com/shanghai-micurx-and-genscripts-probio-unit-sign-strategic-deal-to-accelerate-antibody%e2%80%91drug-conjugate-adc-development/2025-09-28T10:46:01+08:00https://flcube.com/nhsa-launches-100%e2%80%91day-medical%e2%80%91insurance-fraud-crackdown-campaign/2025-09-26T14:28:04+08:00https://flcube.com/cspc-pharma-secures-nmpa-approval-for-lecanemab-biosimilar-first-of-its-kind-in-china/2025-09-26T14:24:49+08:00https://flcube.com/trump-announces-100-tariff-on-branded-drugs-exempts-u-s-%e2%80%91built-pharmaceutical-factories/2025-09-26T14:14:17+08:00https://flcube.com/china-unveils-national-long%e2%80%91term-care-insurance-service-catalog-in-pilot-phase/2025-09-26T14:08:27+08:00https://flcube.com/sichuan-biokin-secures-second-breakthrough-therapy-designation-for-izalontamab-brengitecan-in-advanced-urothelial-carcinoma/2025-09-26T14:00:57+08:00https://flcube.com/fosun-pharmas-alovatinib-enters-chinas-pediatric-anti%e2%80%91tumor-spark-pilot/2025-09-26T13:48:39+08:00https://flcube.com/eli-lilly-halts-obesity-study-of-experimental-drug-bimagrumab-for-strategic-reasons/2025-09-26T13:16:44+08:00https://flcube.com/sanofi-injects-an-extra-usd-625-million-into-sanofi-ventures-to-boost-biotech-digital%e2%80%91health-innovation/2025-09-25T16:50:54+08:00https://flcube.com/illumina-partners-with-pharma-giants-on-pan%e2%80%91cancer-companion-diagnostics-using-trusight-oncology/2025-09-25T16:41:32+08:00https://flcube.com/astrazeneca-and-daiichi-sankyo-submit-priority%e2%80%91review-sbla-for-enhertu-as-first%e2%80%91line-therapy-for-her2%e2%80%91positive-breast-cancer/2025-09-25T16:05:39+08:00https://flcube.com/gan-lee-secures-3-b-rmb-supply-deal-for-insulin-glargine-in-brazils-national-pdp/2025-09-25T15:54:28+08:00https://flcube.com/microtech-medical-secures-nmpa-approval-for-equil-patch-insulin-pump-in-children-and-adolescents/2025-09-25T15:08:57+08:00https://flcube.com/biogen-receives-fda-complete%e2%80%91response-letter-on-high%e2%80%91dose-nusinersen-for-sma/2025-09-25T14:54:31+08:00https://flcube.com/eisai-and-biogen-secure-australian-tga-approval-for-lecanemab-in-early-alzheimers-disease/2025-09-25T14:45:28+08:00https://flcube.com/xtalpi-and-bio%e2%80%91sincerity-announce-ai%e2%80%91robotics-rd-partnership/2025-09-25T14:35:25+08:00https://flcube.com/prellis-biologics-and-eli-lilly-announce-ai%e2%80%91driven-antibody-discovery-collaboration/2025-09-25T14:17:01+08:00https://flcube.com/fosun-kairos-secures-nmpa-approval-for-second-car%e2%80%91t-product-fkc889-targeting-relapsed-refractory-b%e2%80%91cell-all/2025-09-25T14:00:34+08:00https://flcube.com/mabwell-bioscience-hits-phase-ii-milestone-with-first%e2%80%91patient-dose-of-9mw3011-the-only-anti%e2%80%91tmprss6-monoclonal-antibody-for-polycythemia-vera/2025-09-25T13:48:26+08:00https://flcube.com/burning-rock-secures-japanese-approval-for-oncoguide-oncoscreen-plus-cdx-enabling-capivasertib-therapy/2025-09-25T13:08:07+08:00https://flcube.com/fibrogen-launches-phase-2-dose%e2%80%91optimization-trial-for-cd46%e2%80%91targeted-adc-fg%e2%80%913246-in-metastatic-castration%e2%80%91resistant-prostate-cancer/2025-09-25T12:54:10+08:00https://flcube.com/dualitybio-initiates-global-phase-ia-ib-study-of-adam9%e2%80%91targeting-adc-db%e2%80%911317/2025-09-25T12:37:03+08:00https://flcube.com/trump-administration-expands-section-232-tariffs-on-robotics-industrial-machinery-and-medical-devices/2025-09-25T12:20:57+08:00https://flcube.com/hengrui-pharma-glenmark-partner-on-trastuzumab-rezecan-adc-for-her2%e2%80%91positive-lung-cancer/2025-09-25T12:01:48+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-acceptance-for-shr7280-oral-gnrh-antagonist/2025-09-24T15:23:45+08:00https://flcube.com/johnson-johnson-announces-international-withdrawal-of-linx-reflux-system/2025-09-24T15:06:46+08:00https://flcube.com/rm-bio%e2%80%91tech-secures-cde-approval-for-hf001-stem%e2%80%91cell-therapy-in-type-2-diabetes/2025-09-24T14:59:30+08:00https://flcube.com/jiangsu-hengruis-adebrelimab-new-indication-accepted-by-nmpa-for-stage-ii%e2%80%91iiib-nsclc/2025-09-24T14:21:38+08:00https://flcube.com/yantai-dongcheng-secures-nmpa-approval-for-225ac%e2%80%91lnc1011-alpha%e2%80%91particle-radiopharmaceutical-to-target-prostate-cancer/2025-09-24T14:12:31+08:00https://flcube.com/eli-lilly-announces-6-5-b-houston-facility-to-boost-synthetic%e2%80%91medicine-api-production/2025-09-24T14:06:14+08:00https://flcube.com/sino-biopharmaceutical-reports-first%e2%80%91patient-enrollment-for-lm%e2%80%912417-phase-i-trial/2025-09-24T13:59:32+08:00https://flcube.com/msd-teams-with-variational-ai-in-349-million-generative%e2%80%91ai-drug-discovery-deal/2025-09-24T13:47:44+08:00https://flcube.com/probio-and-immunofoco-forge-global-cgt-manufacturing-alliance/2025-09-23T16:42:52+08:00https://flcube.com/stealth-biotherapeutics-receives-fda-accelerated-approval-for-forzinity-in-barth-syndrome/2025-09-23T16:37:14+08:00https://flcube.com/china-drug-procurement-centralized-rules-shape-11th-round-of-vbp/2025-09-23T16:29:17+08:00https://flcube.com/genrix-bio-secures-exclusive-deal-for-vecantoxatug-and-silevimig-with-cms/2025-09-23T16:11:37+08:00https://flcube.com/roches-sc-lunsumio-gains-chmp-recommendation-for-relapsed-follicular-lymphoma/2025-09-23T16:04:03+08:00https://flcube.com/roches-giredestrant-yields-positive-pfs-results-in-evera-phase-iii-study/2025-09-23T15:52:41+08:00https://flcube.com/shanghai-sanyou-medicals-agloe-robot-enters-chinese-nmpa-special-review-for-innovative-spine-devices/2025-09-23T15:46:40+08:00https://flcube.com/eisai-secures-fda-fast-track-for-etalanetug-a-tau-antibody-targeting-mtbr/2025-09-23T15:40:14+08:00https://flcube.com/pfizer-to-acquire-metsera-for-4-9-b-expanding-its-obesity-cardiometabolic-pipeline/2025-09-23T15:30:56+08:00https://flcube.com/youcare-pharma-secures-fda-approval-for-ykyy013-a-novel-sirna-therapy-for-chronic-hepatitis-b/2025-09-23T15:21:11+08:00https://flcube.com/national-healthcare-security-administration-announces-nationwide-pilot-for-real%e2%80%91world-medical%e2%80%91insurance-value-evaluation/2025-09-23T15:14:30+08:00https://flcube.com/huadong-medicine-secures-fda-ind-approval-for-hdm2017-adc/2025-09-23T15:06:01+08:00https://flcube.com/sichuan-kelun%e2%80%91biotechs-a400-receives-nda-acceptance-in-china/2025-09-23T14:56:43+08:00https://flcube.com/visen-pharmaceuticals-secures-hainan-approval-for-palopegteriparatide/2025-09-23T13:39:39+08:00https://flcube.com/stone-pharmaceuticals-launches-cs2009-phase-ii-trial-in-australia/2025-09-23T12:05:28+08:00https://flcube.com/nanjing-leads-biolabs-secures-fda-ind-for-lbl%e2%80%91047-a-first%e2%80%91in%e2%80%91class-bispecific-fusion-protein/2025-09-23T11:23:22+08:00https://flcube.com/chinas-insilico-mabwell-and-chemexpress-forge-ai%e2%80%91driven-adc-collaboration/2025-09-22T15:46:29+08:00https://flcube.com/nhsa-completes-2025-drug-negotiation-review-car%e2%80%91t-therapies-clear-the-hurdle/2025-09-22T15:27:22+08:00https://flcube.com/shenzhen-salubris-submits-nmpa-nda-for-sal003-a-once%e2%80%91monthly-anti%e2%80%91pcsk9-biologic/2025-09-22T15:19:42+08:00https://flcube.com/biogen-acquires-alcyone-therapeutics-to-drive-thecaflex-drx-implant-development/2025-09-22T15:13:06+08:00https://flcube.com/henlius-organon-secure-eu-marketing-approval-for-bildyos-and-bilprevda-denosumab-biosimilars/2025-09-22T15:02:23+08:00https://flcube.com/innovent-secures-2nd-nmpa-approval-for-mazdutide-first-dual-glp%e2%80%911-gcgr-therapy-for-type-2-diabetes/2025-09-22T14:54:34+08:00https://flcube.com/ausperbio-secures-63-million-series-b2-financing-to-propel-ahb%e2%80%91137-development/2025-09-22T14:47:38+08:00https://flcube.com/pfizer-and-arvinas-pass-commercial-rights-of-vepdegestrant-to-third-party/2025-09-22T14:41:47+08:00https://flcube.com/guangdong-taienkang-secures-nmpa-approval-for-safinamide-generic/2025-09-19T15:48:13+08:00https://flcube.com/hengrui-pharma-secures-breakthrough-therapy-designation-for-shr%e2%80%911501-in-china/2025-09-19T15:25:52+08:00https://flcube.com/ge-healthcare-eyes-sale-of-china-unit-amid-revenue-decline/2025-09-19T15:00:43+08:00https://flcube.com/hengrui-pharma-secures-nmpa-approval-for-two-novel-immune%e2%80%91inflammatory-drugs/2025-09-19T14:54:11+08:00https://flcube.com/gensci-secures-exclusive-rights-to-alks-house-dust-mite-allergy-therapies-in-china/2025-09-18T20:47:59+08:00https://flcube.com/jiangsu-hengrui-secures-priority-review-for-trastuzumab-rezetecan-in-her2%e2%80%91positive-breast-cancer/2025-09-18T20:41:23+08:00https://flcube.com/chongqing-genrix-secures-nmpa-trial-approval-for-gr2301-il%e2%80%9115-antibody-in-vitiligo/2025-09-18T15:59:55+08:00https://flcube.com/suzhou-zelgen-secures-nmpa-approval-for-zggs34-trites-targeting-muc17%e2%80%91positive-solid-tumors/2025-09-18T15:54:48+08:00https://flcube.com/eli-lillys-orforglipron-outperforms-oral-semaglutide-in-achieve%e2%80%913-phase-3-trial/2025-09-18T15:42:23+08:00https://flcube.com/eisai-china-partners-with-dsm%e2%80%91firmenichs-i%e2%80%91health-to-bring-lacteol-to-mainland-china/2025-09-18T15:35:52+08:00https://flcube.com/biocytogen-eyes-a%e2%80%91share-listing-on-shanghais-star-market-to-fund-preclinical-rd-growth/2025-09-18T15:30:09+08:00https://flcube.com/jiangsu-hengrui-hrs%e2%80%915635-seeks-breakthrough-therapy-designation-for-chronic-hepatitis-b/2025-09-18T15:23:26+08:00https://flcube.com/roche-announces-2-4-b-acquisition-of-89bio-targeting-liver-and-cardiometabolic-therapies/2025-09-18T15:10:36+08:00https://flcube.com/eli-lillys-mounjaro-shows-promising-results-in-children-with-type-2-diabetes/2025-09-18T14:44:46+08:00https://flcube.com/siemens-healthineers-and-stryker-forge-neurovascular-robotics-alliance/2025-09-18T14:33:23+08:00https://flcube.com/china-cde-seeks-public-feedback-on-98th-batch-of-reference-standards-for-generic-drugs/2025-09-18T14:25:05+08:00https://flcube.com/mabwell-bioscience-teams-with-aditum-bio-to-launch-kalexo-bio-inc-targeting-1-b-in-cardio-sirna-deal/2025-09-18T12:19:50+08:00https://flcube.com/cook-medical-siemens-healthineers-partner-to-launch-first-radiation%e2%80%91free-imri-suite/2025-09-17T15:57:25+08:00https://flcube.com/eli-lilly-unveils-5-b-virginia-facility-to-scale-bioconjugate-antibody-production/2025-09-17T15:50:13+08:00https://flcube.com/astrazeneca-china-decentralises-medical-affairs-signals-shift-in-global-strategy/2025-09-17T15:36:13+08:00https://flcube.com/ascletis-pharma-reports-28%e2%80%91day-asc30-study-results-at-easd/2025-09-17T15:22:10+08:00https://flcube.com/hisun-pharma-secures-china-rights-to-ascentawits-first%e2%80%91in%e2%80%91class-drug-ast%e2%80%913424/2025-09-17T15:11:26+08:00https://flcube.com/guangdong-launches-5%e2%80%91year-plan-to-streamline-import-of-urgently-needed-drugs-and-medical-devices/2025-09-17T14:53:06+08:00https://flcube.com/gsk-to-invest-30-b-in-the-united-states-over-five-years-building-advanced-biopharma-facilities/2025-09-17T14:37:44+08:00https://flcube.com/novo-nordisk-to-file-us-approval-for-high%e2%80%91dose-wegovy-aiming-to-match-lillys-zepbound/2025-09-17T14:30:25+08:00https://flcube.com/suzhou%e2%80%91based-innobm-partners-with-qilu-pharmaceutical-on-bm601-metallic-embolic-microsphere/2025-09-17T14:18:29+08:00https://flcube.com/shanghai-henlius-biotech-negotiates-potential-sale-of-hlx43-adc-to-johnson-johnson-and-roche/2025-09-17T13:57:23+08:00https://flcube.com/shenzhen-mindray-eyes-1-b-hong-kong-ipo-with-huatai-jpmorgan-on-board/2025-09-17T13:43:44+08:00https://flcube.com/duoning-bio-secures-global-license-for-upstream-bios-biochemical-analyzer-portfolio/2025-09-17T13:34:51+08:00https://flcube.com/fovinaciclib-cdk4-6-breaks-ground-in-breast%e2%80%91cancer-therapy/2025-09-17T00:54:57+08:00https://flcube.com/cspcs-almb-0166-approved-for-phase-ii-trials-in-parkinsons-disease/2025-09-17T00:46:35+08:00https://flcube.com/nanjing-leads-biolabs-doses-first-patient-in-opamtistomig-melanoma-trial/2025-09-17T00:41:12+08:00https://flcube.com/astrazeneca-launches-ultomiris-in-china-for-gmg-and-nmosd-treatments/2025-09-17T00:35:52+08:00https://flcube.com/astrazeneca-pauses-gbp-200m-cambridge-rd-investment-amid-uk-funding-cuts/2025-09-17T00:30:43+08:00https://flcube.com/novo-nordisk-rybelsus-gains-cardio-benefit-from-soul-trial/2025-09-16T17:12:33+08:00https://flcube.com/guangzhou-baiyunshan-pharmaceutical-launches-phase-i-ii-trial-for-ret%e2%80%91targeted-bys10/2025-09-16T17:06:29+08:00https://flcube.com/sino-biopharmaceutical-secures-nmpa-approval-for-degarelix-generic-in-china/2025-09-16T16:58:59+08:00https://flcube.com/haisco-pharma-secures-nmpa-approval-for-anrikefon-in-hemodialysis%e2%80%91related-pruritus/2025-09-16T16:51:02+08:00https://flcube.com/monte-rosa-therapeutics-and-novartis-partner-on-degrader-development/2025-09-16T16:39:47+08:00https://flcube.com/shenzhen-kangtai-receives-nmpa-approval-for-sabin%e2%80%91strain-inactivated-polio-vaccine/2025-09-16T16:12:35+08:00https://flcube.com/bioray-biopharmaceutical-secures-nmpa-approval-for-bgm0504-in-overweight-obesity-trials/2025-09-16T15:53:59+08:00https://flcube.com/biocytogen-licenses-renmice-antibody-to-tubulis-boosting-adc-development/2025-09-16T15:41:00+08:00https://flcube.com/rona-therapeutics-rn3161-sirna-targets-inhbe-submits-australian-trial-application/2025-09-16T15:32:48+08:00https://flcube.com/bio-thera-partners-with-jamjoom-pharma-to-launch-bat2306-biosimilar-in-mena/2025-09-15T20:41:54+08:00https://flcube.com/zsco-invests-790-m-rmb-in-guobang-pharma-launches-strategic-partnership/2025-09-15T17:04:15+08:00https://flcube.com/cspc-pharmaceutical-group-secures-nmpa-approval-for-syh2066-in-rsv-trials/2025-09-15T16:43:52+08:00https://flcube.com/genrix-succeeds-with-telikibart-phase-3-targets-atopic-dermatitis/2025-09-15T16:36:24+08:00https://flcube.com/hitgen-and-bioage-launch-phase-i-study-of-bge%e2%80%91102-a-novel-nlrp3-inhibitor/2025-09-15T16:28:39+08:00https://flcube.com/lion-tcr-secures-fda-approval-for-liocyx%e2%80%91m004-launching-phase-ib-ii-trial-in-chronic-hepatitis-b/2025-09-15T16:12:47+08:00https://flcube.com/biokin-pharma-secures-breakthrough-therapy-designation-for-izalontamab-with-bms/2025-09-15T15:56:11+08:00https://flcube.com/siemens-healthineers-diagnostics-sale-blackstone-cvc-kkr-explore-e6-b-deal/2025-09-15T15:20:43+08:00https://flcube.com/baheals-24-take%e2%80%91over-of-tianjin-jikun-secures-rights-to-pulmonary-fibrosis-drug-jk1033/2025-09-15T15:09:29+08:00https://flcube.com/bms-sells-60-shanghai-stake-to-hillhouse-capital-shifting-focus-to-growth/2025-09-15T14:55:55+08:00https://flcube.com/nmpa-releases-96th-reference-listed-drugs-catalog-adding-42-new-generic-specifications/2025-09-15T14:45:52+08:00https://flcube.com/cspc-pharmaceutical-group-submits-anbenitamab-for-nmpa-approval-in-her2%e2%80%91positive-gastric-cancer/2025-09-12T15:51:17+08:00https://flcube.com/biontech-and-bms-reveal-promising-interim-results-for-pumitamig-in-es%e2%80%91sclc/2025-09-12T15:40:57+08:00https://flcube.com/summit-therapeutics-presents-2025-harmoni-study-results-at-world-lung-cancer-conference/2025-09-12T15:25:40+08:00https://flcube.com/guangzhous-bio%e2%80%91thera-solutions-secures-5-4-million-milestone-from-intas-pharma/2025-09-12T15:15:28+08:00https://flcube.com/fda-launches-aggressive-campaign-to-curb-misleading-drug-advertisements/2025-09-12T14:38:10+08:00https://flcube.com/msd-scrapes-1-billion-uk-expansion-shifts-life%e2%80%91science-research-to-the-us/2025-09-12T14:25:02+08:00https://flcube.com/fibrox-therapeutics-secures-ind-approval-for-fibrocell-in-lumbar-disc-degeneration/2025-09-12T13:37:52+08:00https://flcube.com/nmpa-unveils-30%e2%80%91working%e2%80%91day-pathway-to-accelerate-innovative-drug-trials/2025-09-12T13:19:32+08:00https://flcube.com/genrix-bio-secures-nmpa-approval-for-gr1803-bispecific-antibody-in-systemic-lupus-erythematosus/2025-09-11T17:07:55+08:00https://flcube.com/genfleet-therapeutics-surges-onto-hong-kong-main-board-raising-hk1-58-b/2025-09-11T17:00:25+08:00https://flcube.com/remedium-bio-teams-up-with-eli-lilly-to-push-gene%e2%80%91therapy-frontiers-for-diabetes-and-obesity/2025-09-11T16:51:06+08:00https://flcube.com/yoltech-raises-300-million-yuan-series-b-pushing-in%e2%80%91vivo-gene%e2%80%91editing-to-the-forefront/2025-09-11T16:35:41+08:00https://flcube.com/novartis-secures-tabrecta-approval-in-china-for-metex14-nsclc/2025-09-11T16:31:08+08:00https://flcube.com/china-to-add-hpv-vaccine-to-national-immunization-program-pledges-free-shots-for-eligible-girls/2025-09-11T16:25:58+08:00https://flcube.com/chinas-drug-evaluation-authority-issues-draft-rules-for-class-i-atmp-meetings/2025-09-11T13:47:31+08:00https://flcube.com/china-unveils-healthcare-foundation-strengthening-plan-to-bring-clinics-within-15%e2%80%91minute-reach/2025-09-11T13:42:51+08:00https://flcube.com/transthera-sciences-secures-china-phase-ii-trial-approval-for-tinengotinib%e2%80%91fulvestrant-combination/2025-09-11T13:35:34+08:00https://flcube.com/innovent-biologics-cowell-health-forge-strategic-alliance-to-boost-drug-access/2025-09-11T13:28:10+08:00https://flcube.com/taiji-group-secures-nmpa-approval-to-begin-clinical-trials-of-semaglutide-biosimilar/2025-09-11T13:23:06+08:00https://flcube.com/betta-pharmaceuticals-secures-nmpa-approval-for-mcla%e2%80%91129-ensartinib-combination-in-advanced-solid-tumors/2025-09-11T10:58:50+08:00https://flcube.com/qilu-pharmaceutical-fdstc-announce-strategic-partnership-to-boost-chinas-biomedical-innovation/2025-09-10T16:44:06+08:00https://flcube.com/corxel-and-wuxi-forge-cardiovascular-partnership-to-accelerate-drug-development/2025-09-10T16:33:20+08:00https://flcube.com/danaher-partners-with-beckman-to-advance-alzheimers-blood%e2%80%91biomarker-diagnosis/2025-09-10T16:15:35+08:00https://flcube.com/danaher-partners-with-huashan-hospital-to-develop-alzheimers-diagnostic-solutions/2025-09-10T16:06:48+08:00https://flcube.com/johnson-johnson-secures-fda-approval-for-inlexzo-a-ground%e2%80%91breaking-intravesical-system-for-bladder-cancer/2025-09-10T16:00:51+08:00https://flcube.com/chinas-11th-national-drug-vbp-draft-unveils-major-pricing-competition-reforms/2025-09-10T15:53:51+08:00https://flcube.com/kexing-biopharm-secures-global-rights-to-humanwell-puracaps-nintedanib/2025-09-10T15:46:28+08:00https://flcube.com/novo-nordisk-launches-company%e2%80%91wide-transformation-to-drive-diabetes-and-obesity-growth/2025-09-10T15:20:26+08:00https://flcube.com/iaso-biotherapeutics-cellbri-sign-global-cell%e2%80%91therapy-alliance/2025-09-10T15:09:21+08:00https://flcube.com/qilu-pharmaceutical-commences-phase-iii-trial-of-qls31905-for-advanced-pancreatic-cancer/2025-09-10T15:00:49+08:00https://flcube.com/novartis-expands-iptacopan-approval-to-iga-nephropathy-in-china/2025-09-10T14:51:02+08:00https://flcube.com/sihuan-pharma-secures-ind-for-dual%e2%80%91target-glp%e2%80%911-gcgr-drug-p052-injection/2025-09-09T14:47:04+08:00https://flcube.com/simcere-secures-nmpa-approval-for-cdh17%e2%80%91targeting-adc-sim0609-in-advanced-solid-tumors/2025-09-09T14:30:04+08:00https://flcube.com/daan-gene-secures-nmpa-approval-for-first-hivdna-diagnostic-kit/2025-09-09T14:15:15+08:00https://flcube.com/nmpa-releases-online-prescription-compliance-guidelines-to-tighten-drug-retail-oversight/2025-09-09T14:08:44+08:00https://flcube.com/sirnaomics-secures-hk138-m-investment-from-bloomage-biotech-expanding-oncology-and-aesthetic-pipelines/2025-09-09T14:02:04+08:00https://flcube.com/remegen-secures-china-cde-approval-for-telitacicept-in-sjogrens-syndrome-first-biologic-of-its-kind/2025-09-09T13:47:24+08:00https://flcube.com/shanghai-henlius-biotech-secures-fda-ind-approval-for-hlx17-a-pembrolizumab-biosimilar/2025-09-09T13:24:06+08:00https://flcube.com/kintor-pharmaceutical-completes-kt%e2%80%91939-tyrosinase-inhibitor-safety-trial-highlights-cosmetic-potential/2025-09-09T13:18:40+08:00https://flcube.com/grand-pharma-secures-ce-mark-for-sir%e2%80%91spheres-y%e2%80%9190-expanding-liver%e2%80%91cancer-treatment-portfolio/2025-09-09T13:05:19+08:00https://flcube.com/chongqing-genrix-bio-secures-nmpa-approval-for-gr2303-a-novel-tl1a%e2%80%91targeting-antibody-in-ibd/2025-09-09T11:26:52+08:00https://flcube.com/fosun-pharma-secures-foritinib-approval-for-alk%e2%80%91nsclc-trials-paving-way-for-targeted-therapy/2025-09-09T11:13:20+08:00https://flcube.com/duality-biotherapeutics-hits-pfs-milestone-with-db%e2%80%911303-bnt323-in-her2%e2%80%91positive-breast-cancer/2025-09-08T15:55:51+08:00https://flcube.com/innovent-biologics-announces-strong-phase-ii-results-for-tigulixostat-in-chinese-gout-patients/2025-09-08T15:40:39+08:00https://flcube.com/xwpharma-secures-205-m-valiloxybate-deal-with-avadel/2025-09-08T15:35:25+08:00https://flcube.com/fda-launches-green-list-to-shield-u-s-markets-from-unsafe-glp%e2%80%911-apis/2025-09-08T15:23:41+08:00https://flcube.com/innocare-pharma-secures-singapore-hsa-approval-for-orelabrutinib-in-relapsed-mzl/2025-09-08T15:18:43+08:00https://flcube.com/regenelead-secures-nmpa-approval-for-rgl%e2%80%91305-cell-therapy-in-advanced-malignant-tumors/2025-09-08T14:56:10+08:00https://flcube.com/takeda-secures-fda-approval-for-vonvendis-expanded-use-in-adult-and-pediatric-vwd/2025-09-08T14:47:52+08:00https://flcube.com/quantumpharm-xtalpi-secures-phase-i-approval-for-pep08-a-next%e2%80%91generation-prmt5-inhibitor/2025-09-08T14:39:12+08:00https://flcube.com/escugen-and-huahui-health-form-exclusive-partnership-to-develop-first%e2%80%91in%e2%80%91class-adc-for-solid-tumors/2025-09-08T14:02:25+08:00https://flcube.com/nhsa-releases-draft-regulations-to-tighten-medical-insurance-funds-oversight/2025-09-08T13:50:34+08:00https://flcube.com/gilead-terminates-2-3-b-collaboration-with-kite-pharma-over-off%e2%80%91the%e2%80%91shelf-cell-therapies/2025-09-08T13:45:43+08:00https://flcube.com/junshi-biosciences-js005-il%e2%80%9117a-antibody-shows-promise-in-phase-iii-psoriasis-trial/2025-09-08T11:33:46+08:00https://flcube.com/hengruis-hrs%e2%80%914729-glp%e2%80%911-triple-agonist-receives-nmpa-approval-for-masld-mash/2025-09-05T14:24:21+08:00https://flcube.com/hengruis-rss0393-pde4-inhibitor-approved-for-atopic-dermatitis-clinical-trial/2025-09-05T14:23:55+08:00https://flcube.com/innovents-xinbimin-igf%e2%80%911r-antibody-approved-in-macau/2025-09-05T13:35:17+08:00https://flcube.com/transthera-begins-phase-ii-tinengotinib-trial-with-akeso-bispecifics-for-advanced-hcc/2025-09-05T13:27:31+08:00https://flcube.com/simcere-launches-quviviq-new-insomnia-therapy-in-china/2025-09-05T13:17:30+08:00https://flcube.com/hengrui-licenses-hrs%e2%80%911893-to-braveheart-bio-in-75-m-deal-global-myosin-inhibitor/2025-09-05T12:03:57+08:00https://flcube.com/dongcheng-pharma-to-spin%e2%80%91off-lannacheng-for-hk-main-board-listing-radiopharma-focus/2025-09-05T11:56:29+08:00https://flcube.com/hengruis-shr%e2%80%91a2009-adc-gains-nmpa-approval-for-her3%e2%80%91targeted-tumor-therapy/2025-09-04T16:20:45+08:00https://flcube.com/haisco-pharmaceuticals-hsk47388-gears-up-for-new-autoimmune-trial-nmpa-approval/2025-09-04T16:12:17+08:00https://flcube.com/boji-medicals-fczr-approved-for-otomycosis-trials-first-liquid-eardrop-in-china/2025-09-04T15:47:59+08:00https://flcube.com/hengruis-hrs9531-injection-clears-nmpa-approval-hits-19-2-weight-loss-in-phase-3/2025-09-04T15:36:48+08:00https://flcube.com/biocytogen-merck-partner-on-antibody%e2%80%91conjugated-lipid-nanoparticles/2025-09-04T15:27:45+08:00https://flcube.com/argo-biopharma-novartis-expand-sirna-collaboration-for-cardiovascular-drugs/2025-09-04T15:20:52+08:00https://flcube.com/chempartner-toposcend-form-200-m-healthcare-fund-to-back-innovative-drugs/2025-09-04T15:12:31+08:00https://flcube.com/abbvie-secures-nmpa-priority-review-for-epcoritamab-in-relapsed-follicular-lymphoma/2025-09-04T14:40:40+08:00https://flcube.com/replicate-bioscience-teams-with-novo-nordisk-on-srrna%e2%80%91powered-metabolic-drugs/2025-09-04T14:29:33+08:00https://flcube.com/simcere-secures-nmpa-approval-for-deunoxavir-marboxil-first-pediatric-influenza-drug/2025-09-04T14:18:41+08:00https://flcube.com/fda-unveils-rdep-to-accelerate-rare-disease-therapy-development/2025-09-04T14:10:02+08:00https://flcube.com/aosaikang-launches-phase-iii-trial-of-ask202-with-leatinib-for-nsclc/2025-09-04T13:59:10+08:00https://flcube.com/abb-bio%e2%80%91tech-wins-nmpa-approval-for-first%e2%80%91ever-quadrivalent-influenza-subunit-vaccine/2025-09-04T13:44:55+08:00https://flcube.com/sanofis-tzield-earns-china-nmpa-approval-for-stage-2-type-1-diabetes/2025-09-04T10:24:30+08:00https://flcube.com/zenas-secures-300-m-royalty-deal-for-obexelimab-royalty-pharma-to-invest/2025-09-04T10:18:13+08:00https://flcube.com/enlaza%e2%80%91vertex-partner-on-45-m-multi%e2%80%91target-drug-discovery-collaboration/2025-09-03T15:31:58+08:00https://flcube.com/servier-secures-global-rights-to-darovasertib-for-uveal-melanoma-treatment/2025-09-03T15:20:52+08:00https://flcube.com/jt118-vaccine-receives-nmpa-approval-for-monkeypox-prevention/2025-09-03T15:04:31+08:00https://flcube.com/pfizer%e2%80%91biontech-receives-fda-approval-for-new-covid%e2%80%9119-vaccine-indication-for-high%e2%80%91risk-adults/2025-09-03T14:51:42+08:00https://flcube.com/nmpa-adds-35-new-reference%e2%80%91listed-drugs-to-95th-catalog-updates-31-existing-specs/2025-09-03T14:43:16+08:00https://flcube.com/hengrui-pharma-secures-nmpa-approval-for-hrs%e2%80%917172-targeting-ras%e2%80%91mutated-tumors/2025-09-03T14:33:43+08:00https://flcube.com/msd-reports-positive-phase-3-coralreef-lipids-results-for-oral-pcsk9-inhibitor-enlicitide/2025-09-03T13:59:06+08:00https://flcube.com/omass-therapeutics-teams-up-with-genentech-on-first%e2%80%91in%e2%80%91class-ibd-oral-small-molecule/2025-09-03T13:39:57+08:00https://flcube.com/arrowhead-partners-with-novartis-for-aro%e2%80%91snca-sirna-therapy/2025-09-03T13:30:09+08:00https://flcube.com/novatim-licenses-ky%e2%80%910301-nano%e2%80%91bispecific-adc-to-radiance-biopharma/2025-09-02T15:55:45+08:00https://flcube.com/zai-labs-tivdak-wins-hong-kong-approval-for-recurrent-cervical-cancer/2025-09-02T14:32:41+08:00https://flcube.com/fosun-launches-futuoning-first%e2%80%91in%e2%80%91class-cdk4-6-inhibitor-for-hr%e2%80%91positive-breast-cancer/2025-09-02T14:21:15+08:00https://flcube.com/fosun-secures-fda-approval-for-two-denosumab-biosimilar-formulations/2025-09-02T14:09:27+08:00https://flcube.com/haisco-secures-fda-clinical-trial-approval-for-first%e2%80%91in%e2%80%91class-bcl6-protac-hsk47977/2025-09-02T13:59:15+08:00https://flcube.com/santen-launches-tapcom-preservative%e2%80%91free-glaucoma-combo-in-china/2025-09-02T13:40:37+08:00https://flcube.com/chempartner-hayoo-forge-nucleic%e2%80%91acid-delivery-partnership-to-expand-extranodal-therapies/2025-09-02T13:25:13+08:00https://flcube.com/sino-biopharmaceuticals-benmelstobart%e2%80%91anlotinib-combo-secures-nmpa-nda-for-advanced-asps/2025-09-02T11:24:28+08:00https://flcube.com/hansoh-pharma-secures-second-fda%e2%80%91approved-indication-for-inebilizumab-in-igg4%e2%80%91related-disease/2025-09-02T11:10:40+08:00https://flcube.com/sanofis-wayrilz-fda-approval-brings-new-oral-btk-inhibitor-for-itp/2025-09-01T17:20:59+08:00https://flcube.com/eli-lilly-jd-health-form-digital-care-alliance-for-obesity-diabetes-and-alopecia/2025-09-01T16:11:28+08:00https://flcube.com/gileads-seladelpar-approved-for-pbc-treatment-in-beijing-pilot-zone/2025-09-01T16:00:13+08:00https://flcube.com/bioheng-therapeutics-receives-fda-rpdd-for-off%e2%80%91the%e2%80%91shelf-car%e2%80%91t-ctd402/2025-09-01T15:53:41+08:00https://flcube.com/kactus-biosystems-partners-with-bioheng-for-cell-therapy-raw-materials/2025-09-01T15:48:29+08:00https://flcube.com/jcbio-mgi-launch-koreas-first-dcs-lab-to-accelerate-multi%e2%80%91omics-innovation/2025-09-01T15:41:15+08:00https://flcube.com/ivd-medical-acquires-20-of-gofintech-in-hk3-14-b-deal/2025-09-01T15:30:42+08:00https://flcube.com/fosun-pharma-secures-china-rights-to-accropeutics-ac%e2%80%91201-jak-inhibitor/2025-09-01T15:17:06+08:00https://flcube.com/shenlian-bio-launches-phase-2-trial-for-ub%e2%80%91221-injection-in-chronic-urticaria/2025-09-01T15:00:49+08:00https://flcube.com/mabwells-9mw3811-receives-nmpa-phase-ii-approval-for-pathological-scar-treatment/2025-09-01T14:35:29+08:00https://flcube.com/suzhou-zelgen-secures-fda-approval-for-dual%e2%80%91targeted-therapy-trial-in-advanced-solid-tumors/2025-09-01T14:26:19+08:00https://flcube.com/mabwell-secures-first-overseas-approval-for-denosumab-biosimilars-in-pakistan/2025-09-01T14:19:41+08:00https://flcube.com/novo-nordisks-steer-study-wegovy-cuts-cardiovascular-risk-57-vs-tirzepatide/2025-09-01T14:05:10+08:00https://flcube.com/eisai-biogen-secure-fda-approval-for-lecanemab-auto%e2%80%91injector-home%e2%80%91based-alzheimers-therapy/2025-09-01T13:54:07+08:00https://flcube.com/packgene-cmri-announce-aav-screening-kit-for-global-gene-therapy-rd/2025-08-29T14:46:52+08:00https://flcube.com/suzhou-hemacell-receives-nmpa-ind-approval-for-first%e2%80%91in%e2%80%91class-megakaryocyte-injection-thrombocytopenia-treatment/2025-08-29T14:33:33+08:00https://flcube.com/everest-medicines-reports-48-yoy-revenue-growth-nefecon-launches-and-velsipity-production-milestone/2025-08-29T14:22:55+08:00https://flcube.com/luye-pharma-reports-1h-2025-revenue-growth-of-3-5-amid-oncology-and-cns-gains/2025-08-29T13:42:27+08:00https://flcube.com/shanghai-pharma-reports-2025-interim-results-1-6-revenue-rise-41-profit-surge/2025-08-29T13:35:28+08:00https://flcube.com/zennova-rapafusyn-forge-biocarier%e2%80%91powered-rapaglue-collaboration-2025/2025-08-29T13:17:55+08:00https://flcube.com/boehringer-ingelheim-sino-biopharma-secure-conditional-approval-for-zongertinib-in-china/2025-08-29T11:37:45+08:00https://flcube.com/innovent-biologics-revenue-soars-50-in-h1-2025-oncology-growth-fuels-glp%e2%80%911-expansion/2025-08-28T15:40:41+08:00https://flcube.com/nhsa-2025-drug-catalog-review-6-drugs-rejected-718-applications-reviewed/2025-08-28T15:34:20+08:00https://flcube.com/harbourbiomed-reports-327-revenue-surge-launches-hcab%e2%80%91based-elance-therapeutics/2025-08-28T15:29:05+08:00https://flcube.com/santen-receives-boao-lecheng-approval-for-ryjusea-a-preservative%e2%80%91free-atropine-eye-drop-for-pediatric-myopia/2025-08-28T15:11:22+08:00https://flcube.com/anglikang-secures-exclusive-rights-to-yafeis-imd%e2%80%911005-in-china/2025-08-28T15:01:35+08:00https://flcube.com/remegens-telitacicept-hits-primary-endpoint-in-phase-iii-iga-nephropathy-trial/2025-08-28T14:29:00+08:00https://flcube.com/immuneonco-secures-5-m-milestone-from-instil-bio-strengthening-axion-bio-collaboration/2025-08-28T13:34:35+08:00https://flcube.com/hitgens-2025-h1-report-shows-16-58-revenue-growth-and-391-profit-surge/2025-08-28T11:40:51+08:00https://flcube.com/shandong-boan-biotechnology-reports-8-yoy-revenue-growth-3%e2%80%91year-profit-trend/2025-08-28T11:39:12+08:00https://flcube.com/changchun-high-files-gensci134-clinical-trial-for-growth-hormone-deficiency/2025-08-27T15:23:12+08:00https://flcube.com/fosun-pharma-grants-sitala-global-license-for-fxs6837-up-to-190-m-milestones/2025-08-27T15:10:28+08:00https://flcube.com/regenerons-cemdisiran-beats-key-milestones-in-phase-iii-gmg-trial/2025-08-27T14:45:53+08:00https://flcube.com/gileads-yeytuo-gains-eu-marketing-authorization-for-twice%e2%80%91yearly-hiv%e2%80%911-prep/2025-08-27T14:37:04+08:00https://flcube.com/tyk-medicines-secures-exclusive-distribution-of-ty%e2%80%919591-in-mainland-china/2025-08-27T14:27:41+08:00https://flcube.com/fosun-pharma-reports-4-6-revenue-decline-in-2025-h1-innovative-drugs-drive-growth/2025-08-27T14:08:27+08:00https://flcube.com/c%e2%80%91mer-announces-acquisition-of-hong-kong-endoscopy-centre/2025-08-27T13:59:12+08:00https://flcube.com/junshi-biosciences-reports-49-revenue-growth-in-h1-2025/2025-08-27T13:37:52+08:00https://flcube.com/innogen-commences-phase-ii-trial-of-efsubaglutide-alfa-for-obesity-in-australia/2025-08-27T13:30:04+08:00https://flcube.com/humanwell-secures-nmpa-approval-for-remimazolam-icu-sedation/2025-08-27T13:21:26+08:00https://flcube.com/eisai-biogen-launch-lecanemab-in-austria-germany-first-cause%e2%80%91based-alzheimers-therapy/2025-08-27T13:14:17+08:00https://flcube.com/bioarctic-novartis-announce-braintransporter%e2%80%91enabled-neurodegeneration-collaboration-up-to-772-m-potential-pay%e2%80%91out/2025-08-26T15:32:52+08:00https://flcube.com/anke-biotech-secures-long%e2%80%91acting-fsh%e2%80%91ctp-approval-in-china/2025-08-26T15:21:20+08:00https://flcube.com/cloudbreak-pharma-profit-highlights-turnaround-in-ophthalmic-biotech/2025-08-26T15:09:44+08:00https://flcube.com/minova-rongzhi-funding-surge-series-b-backed-by-idg-capital/2025-08-26T14:56:57+08:00https://flcube.com/walvax-biotechnology-reports-19-5-revenue-drop-faces-hpv-vaccine-impairment/2025-08-26T14:36:51+08:00https://flcube.com/abbvie-acquires-bretisilocin-from-gilgamesh-in-1-2b-deal-for-mdd-treatment/2025-08-26T14:28:33+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-approval-for-hrs%e2%80%912162-and-hrs%e2%80%916093-clinical-trials/2025-08-26T14:20:17+08:00https://flcube.com/yichang-humanwell-partners-with-dp-technology-to-leverage-hermite-platform-for-drug-discovery/2025-08-26T14:09:57+08:00https://flcube.com/humanwell-healthcare-wins-nmpa-approval-for-rfus-144-in-pain-management/2025-08-26T13:57:31+08:00https://flcube.com/humanwell-healthcares-rfus-144-wins-nmpa-approval-for-pruritus-clinical-study/2025-08-26T13:57:31+08:00https://flcube.com/china-pharma-h1-2022-financials-40-of-firms-report-revenue-and-profit-growth/2025-08-26T13:57:30+08:00https://flcube.com/humanwells-generic-clobazam-approved-for-lennox-gastaut-syndrome-in-china/2025-08-26T13:57:29+08:00https://flcube.com/nmpa-approves-humanwells-generic-clobazam-for-lennox-gastaut-syndrome/2025-08-26T13:57:28+08:00https://flcube.com/humanwell-healthcares-remimazolam-receives-nmpa-approval-for-bronchoscopy-use/2025-08-26T13:57:28+08:00https://flcube.com/hengrui-pharmaceuticals-receives-new-approval-for-remimazolam-tosylate/2025-08-26T13:57:27+08:00https://flcube.com/humanwell-healthcare-initiates-phase-iia-clinical-study-for-ipf-drug-hw021199/2025-08-26T13:57:26+08:00https://flcube.com/humanwell-healthcares-innovative-drug-for-solid-tumors-gets-green-light-from-nmpa/2025-08-26T13:57:25+08:00https://flcube.com/humanwell-healthcare-receives-nmpa-approval-for-chemically-synthesized-semaglutide-clinical-trial/2025-08-26T13:57:25+08:00https://flcube.com/humanwell-healthcare-receives-nmpa-approval-for-compound-sodium-lactate-ringers-injection/2025-08-26T13:57:24+08:00https://flcube.com/humanwell-healthcares-recombinant-plasmid-hepatocyte-growth-factor-injection-accepted-for-nmpa-review/2025-08-26T13:57:23+08:00https://flcube.com/humanwells-hwh340-receives-clinical-approval-for-prostate-cancer-treatment/2025-08-26T13:57:22+08:00https://flcube.com/humanwell-healthcare-receives-nmpa-approval-for-caplyta-generic-in-schizophrenia-trial/2025-08-26T13:57:22+08:00https://flcube.com/humanwell-healthcare-gains-nmpa-clearance-for-hz-j001-cream-in-vitiligo-trial/2025-08-26T13:57:21+08:00https://flcube.com/humanwell-healthcare-gains-nmpa-approval-for-giapreza-generic-in-shock-therapy/2025-08-26T13:57:20+08:00https://flcube.com/humanwell-healthcare-receives-nmpa-approval-for-hw241045-ipf-clinical-trials/2025-08-26T13:57:19+08:00https://flcube.com/wusheng-erlunbao-sinopharms-first%e2%80%91of%e2%80%91its%e2%80%91kind-hexavalent-rotavirus-vaccine-receives-nmpa-approval/2025-08-26T13:45:31+08:00https://flcube.com/lepu-medical-secures-nmpa-approval-for-innovative-sodium-hyaluronate-dermal-filler/2025-08-26T13:37:42+08:00https://flcube.com/inxmed-secures-hk100-m-private-placement-from-trumed-health/2025-08-26T13:30:45+08:00https://flcube.com/chengdu-ucellos-uc101-car%e2%80%91t-gains-nmpa-approval/2025-08-26T11:27:58+08:00https://flcube.com/henlius-serplulimab-and-abbott-drive-robust-2025-financials/2025-08-26T11:05:09+08:00https://flcube.com/beone-secures-950-m-deal-with-royalty-pharma-for-tarlatamab-rights/2025-08-26T10:54:54+08:00https://flcube.com/remegen-reports-48-revenue-growth-in-2025-h1-driven-by-telitacicept-and-disitamab-vedotin/2025-08-25T14:54:05+08:00https://flcube.com/xuanzhu-biopharmas-xzp-3621-approved-for-alk-positive-nsclc-in-china/2025-08-25T14:43:30+08:00https://flcube.com/vibrant-therapeutics-secures-multi-million-series-a-funding-to-advance-intelligent-macromolecule-drugs/2025-08-25T14:30:24+08:00https://flcube.com/dizal-pharma-reports-74-4-revenue-growth-in-2025-semi-annual-results/2025-08-25T14:07:57+08:00https://flcube.com/daiichi-sankyos-enhertu-submitted-for-priority-review-in-china-for-her2-positive-breast-cancer/2025-08-25T14:02:09+08:00https://flcube.com/datroway-approved-in-china-for-hr-positive-her2-negative-breast-cancer/2025-08-25T13:54:34+08:00https://flcube.com/yantai-dongchengs-225ac-lnc1011-injection-gains-fda-approval-for-prostate-cancer-trial/2025-08-25T13:44:29+08:00https://flcube.com/ocumensions-ot-301-meets-primary-endpoint-in-denali-phase-iii-trial/2025-08-22T17:01:41+08:00https://flcube.com/zhejiang-medicine-receives-nmpa-approval-for-phase-1-trial-of-xc2309-injection/2025-08-22T16:44:01+08:00https://flcube.com/shanghai-bao-pharma-files-for-hong-kong-ipo-aiming-to-boost-biologics-development/2025-08-22T15:47:14+08:00https://flcube.com/zhongsheng-pharmas-onradivir-granted-drug-registration-in-macau/2025-08-22T15:37:51+08:00https://flcube.com/tianjin-lisheng-plans-rmb-1-billion-fund-with-strategic-partners/2025-08-22T15:00:26+08:00https://flcube.com/hengrui-pharmaceuticals-reports-15-88-revenue-growth-in-2025-semi-annual-results/2025-08-22T14:49:47+08:00https://flcube.com/chinas-nmpa-resumes-import-of-vasudhas-loratadine-api-after-rectifications/2025-08-22T14:35:36+08:00https://flcube.com/jazz-pharmaceuticals-secures-global-rights-to-sanionas-epilepsy-drug-san2355/2025-08-22T14:11:31+08:00https://flcube.com/kite-pharma-acquires-interius-biotherapeutics-for-350-million-to-boost-car-therapy-platform/2025-08-22T13:58:11+08:00https://flcube.com/ionis-pharmaceuticals-dawnzera-approved-by-fda-for-hae-prevention/2025-08-22T13:46:07+08:00https://flcube.com/innocare-pharmas-icp-723-joins-chinas-spark-project-for-pediatric-solid-tumors/2025-08-22T12:27:50+08:00https://flcube.com/lifetech-scientifics-pda-occluder-gains-nmpa-innovative-device-review-status/2025-08-22T12:17:28+08:00https://flcube.com/bio-thera-inks-eur-136m-deal-with-stada-for-bat1806-commercialization/2025-08-21T15:54:07+08:00https://flcube.com/3d-medicines-and-catug-biotech-forge-strategic-alliance-in-mrna-lnp-innovation/2025-08-21T15:19:27+08:00https://flcube.com/bio-thera-adjusts-bat3306-clinical-study-to-meet-regulatory-standards/2025-08-21T15:03:38+08:00https://flcube.com/novartis-atrasentan-approved-in-china-for-igan-proteinuria-reduction/2025-08-21T14:49:46+08:00https://flcube.com/suzhou-zelgens-zg005-and-gecacitinib-win-nmpa-approval-for-advanced-solid-tumors/2025-08-21T14:42:13+08:00https://flcube.com/minovas-mi078-shows-promising-results-in-postpartum-depression-trial/2025-08-21T14:32:28+08:00https://flcube.com/abbiskos-absk043-gains-ind-approval-for-kras-g12c-nsclc-in-partnership-with-allist/2025-08-21T14:18:49+08:00https://flcube.com/sino-biopharmas-zongertinib-receives-second-breakthrough-designation-for-nsclc/2025-08-21T13:33:32+08:00https://flcube.com/haohai-biotech-terminates-ok-lens-distribution-deal-with-brighten-optix-amid-carl-zeiss-acquisition/2025-08-21T13:16:38+08:00https://flcube.com/nanjing-zenshine-pharma-partners-with-cigalah-medpharm-to-advance-sebaloxavir-marboxil-in-mena/2025-08-21T12:58:19+08:00https://flcube.com/china-releases-draft-guidelines-for-single-arm-oncology-trials-to-support-drug-approvals/2025-08-21T12:50:01+08:00https://flcube.com/ascentage-pharma-reports-h1-2025-financial-results-shows-strong-growth-in-olverembatinib-sales/2025-08-21T11:27:37+08:00https://flcube.com/chongqing-genrix-bio-pharmaceuticals-gr1802-injection-receives-nmpa-approval-for-seasonal-allergic-rhinitis-in-adolescents/2025-08-20T20:46:02+08:00https://flcube.com/santhera-pharmaceuticals-signs-exclusive-agreement-with-uniphar-for-agamree-distribution-in-middle-east/2025-08-20T20:32:05+08:00https://flcube.com/vivatides-therapeutics-completes-multi-million-dollar-seed-financing-to-advance-nucleic-acid-delivery-platform/2025-08-20T15:55:56+08:00https://flcube.com/china-unveils-ten-measures-to-boost-family-doctor-contract-services/2025-08-20T15:46:07+08:00https://flcube.com/hunan-fangsheng-pharmaceutical-to-acquire-jak-inhibitor-patent-rights-for-rmb-80-million/2025-08-20T15:09:14+08:00https://flcube.com/haihe-biopharma-seeks-japan-approval-for-risovalisib-in-pik3ca-mutated-ovarian-cancer/2025-08-20T14:17:26+08:00https://flcube.com/xtalpi-collaborates-with-dong-a-st-on-ai-driven-drug-discovery-for-immunological-diseases/2025-08-20T14:05:25+08:00https://flcube.com/sino-biopharms-lm-302-shows-promising-results-in-phase-iii-trials-for-gastric-cancer/2025-08-20T13:52:44+08:00https://flcube.com/goodrx-and-novo-nordisk-introduce-499-monthly-pricing-for-semaglutide-pens/2025-08-20T13:30:25+08:00https://flcube.com/innocare-pharmas-orelabrutinib-powers-74-3-revenue-surge-in-2025-h1/2025-08-20T13:20:44+08:00https://flcube.com/chinas-zelgen-secures-fda-ind-approval-for-triple-targeted-cancer-drug-zggs34/2025-08-20T13:12:52+08:00https://flcube.com/hansohs-ameile-fuels-revenue-growth-to-rmb-7-434-billion-in-h1-2025/2025-08-20T13:01:37+08:00https://flcube.com/sichuan-kelun-biotech-reports-h1-revenue-drop-advances-key-drug-commercialization/2025-08-20T11:53:04+08:00https://flcube.com/wuxi-biologics-reports-16-1-revenue-growth-in-h1-2025-launches-wuxihigh-2-0-platform/2025-08-20T11:42:26+08:00https://flcube.com/remegens-rc148-granted-breakthrough-therapy-designation-for-nsclc-treatment/2025-08-20T11:34:13+08:00https://flcube.com/shandong-lukangs-cigb-814-starts-phase-1-trial-for-rheumatoid-arthritis-treatment/2025-08-20T11:26:34+08:00https://flcube.com/hutchmed-completes-patient-enrollment-for-orpathys-and-tagrisso-combination-study/2025-08-20T11:22:43+08:00https://flcube.com/sino-biopharmaceutical-reports-10-7-revenue-growth-and-140-2-profit-surge-in-h1-2025/2025-08-19T17:47:00+08:00https://flcube.com/kangtai-biological-gains-nmpa-approval-for-trivalent-influenza-vaccine-clinical-trial/2025-08-19T17:39:27+08:00https://flcube.com/zhifei-biologicals-adult-and-adolescent-dtap-vaccine-gains-nmpa-trial-approval/2025-08-19T17:33:30+08:00https://flcube.com/remegen-inks-licensing-deal-with-santen-china-for-rc28-e-eye-disease-drug/2025-08-19T17:27:40+08:00https://flcube.com/microport-cardioflows-alwide-plus-wins-eu-ce-mark-for-heart-valve-procedures/2025-08-19T17:19:36+08:00https://flcube.com/mabwells-innovative-cdh17-targeted-adc-7mw4911-receives-fda-clinical-trial-approval/2025-08-19T17:12:44+08:00https://flcube.com/hengrui-pharmas-hetrombopag-olamine-accepted-by-nmpa-for-chemotherapy-induced-thrombocytopenia/2025-08-19T17:04:40+08:00https://flcube.com/wuxi-xdc-reports-strong-h1-2025-growth-with-62-2-revenue-increase/2025-08-19T16:58:01+08:00https://flcube.com/genentech-to-end-2b-collaboration-with-adaptive-biotechnologies-on-t-cell-therapies/2025-08-19T16:40:06+08:00https://flcube.com/henlius-partners-with-genequantum-on-her2-targeted-adc-gq1005-development/2025-08-19T16:24:49+08:00https://flcube.com/acotec-scientifics-micro-guidewire-receives-beijing-medical-products-administration-approval/2025-08-19T14:20:27+08:00https://flcube.com/skyhawk-therapeutics-collaborates-with-merck-on-rna-targeting-small-molecules-for-neurological-diseases/2025-08-19T14:09:02+08:00https://flcube.com/sichuan-biokins-iza-bren-granted-fda-breakthrough-therapy-designation-for-nsclc/2025-08-19T14:01:48+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-gains-fda-and-ema-clearance-for-global-phase-iii-trial/2025-08-18T16:34:31+08:00https://flcube.com/novo-nordisks-wegovy-granted-fda-approval-for-metabolic-associated-steatohepatitis/2025-08-18T16:10:04+08:00https://flcube.com/livzon-announces-nmpa-acceptance-of-jp-1366-tablets-application-for-reflux-esophagitis/2025-08-18T15:02:11+08:00https://flcube.com/iregene-therapeutics-nouvneu001-receives-fda-fast-track-designation-for-parkinsons-therapy/2025-08-18T14:55:49+08:00https://flcube.com/abb-bio-techs-rsv-vaccine-gains-ind-approval-in-china-and-the-u-s/2025-08-18T14:26:50+08:00https://flcube.com/haiscos-hsk39297-gains-nmpa-approval-for-amd-and-gmg-trials/2025-08-18T14:16:58+08:00https://flcube.com/fda-accelerates-approval-of-dordaviprone-for-h3-k27m-mutant-diffuse-midline-glioma/2025-08-18T13:59:42+08:00https://flcube.com/ajinomoto-and-amphastar-ink-licensing-pact-for-oncology-and-wamd-drug-candidates/2025-08-18T13:52:18+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-shr-7782-clinical-trials-in-advanced-solid-tumors/2025-08-15T16:57:49+08:00https://flcube.com/fosuninsightec-and-shanghai-international-medical-center-establish-national-focused-ultrasound-demonstration-center/2025-08-15T16:49:16+08:00https://flcube.com/minghui-pharmaceutical-secures-131m-pre-ipo-funding-led-by-orbimed-and-qiming-ventures/2025-08-15T16:40:40+08:00https://flcube.com/fda-approves-precigens-papzimeos-for-recurrent-respiratory-papillomatosis/2025-08-15T16:35:10+08:00https://flcube.com/shanghai-pharmaceuticals-and-baxter-china-forge-strategic-partnership-for-anesthesia-products/2025-08-15T16:27:51+08:00https://flcube.com/carsgen-therapeutics-reports-2025-interim-results-and-regulatory-progress/2025-08-15T15:00:40+08:00https://flcube.com/superluminal-collaborates-with-eli-lilly-on-small-molecule-therapeutics-for-cardiometabolic-diseases/2025-08-15T14:51:07+08:00https://flcube.com/sanofis-rilzabrutinib-granted-orphan-drug-designation-for-igg4-related-disease-by-ema/2025-08-15T14:42:19+08:00https://flcube.com/chinas-nhsa-releases-interim-measures-for-medical-case-based-payment-management/2025-08-15T14:35:12+08:00https://flcube.com/pfizers-emblaveo-prescribed-in-shanghai-hospitals-for-first-time-nationwide/2025-08-15T14:27:41+08:00https://flcube.com/insilico-medicines-ism8969-nears-clinical-evaluation-for-parkinsons-disease/2025-08-15T14:18:37+08:00https://flcube.com/sineugenes-first-in-class-als-gene-therapy-snug01-gets-nmpa-clinical-trial-clearance/2025-08-15T14:11:21+08:00https://flcube.com/fosun-pharma-issues-chinas-first-private-pharma-innovation-bond-to-accelerate-rd/2025-08-15T12:23:54+08:00https://flcube.com/eli-lilly-hikes-mounjaro-price-in-uk-by-170-for-private-pay-patients/2025-08-15T12:02:26+08:00https://flcube.com/qihan-biotechs-qt-019b-gains-fda-ind-approval-for-autoimmune-diseases/2025-08-15T11:56:12+08:00https://flcube.com/qihan-biotechs-qn-019a-receives-clinical-clearance-for-gene-edited-ipsc-derived-cell-therapy-in-china/2025-08-15T11:10:36+08:00https://flcube.com/hangzhou-qihan-biotechnology-secures-over-13-8-million-in-pre-series-b-financing/2025-08-15T11:10:35+08:00https://flcube.com/novartis-ianalumab-shows-positive-results-in-phase-3-trials-for-itp-and-sjogrens-disease/2025-08-14T15:54:10+08:00https://flcube.com/everest-medicines-velsipity-nda-accepted-for-review-in-taiwan/2025-08-14T14:50:35+08:00https://flcube.com/hualan-biological-gains-nmpa-approval-for-hib-vaccine-clinical-trials/2025-08-14T14:42:55+08:00https://flcube.com/sirnaomics-partners-with-hualan-biological-to-develop-and-commercialize-rsv-mrna-vaccine-in-china/2025-08-14T14:34:24+08:00https://flcube.com/remegen-announces-positive-phase-iii-results-for-telitacicept-in-primary-sjogrens-syndrome/2025-08-14T14:29:05+08:00https://flcube.com/china-issues-guidelines-for-medical-advertisement-identification-clarifies-scenarios-and-regulations/2025-08-14T14:20:31+08:00https://flcube.com/msd-officially-launches-zerbaxa-in-china-to-tackle-drug-resistant-infections/2025-08-14T14:16:54+08:00https://flcube.com/jiangsu-hengrui-establishes-new-biopharmaceutical-unit-to-strengthen-anesthesia-and-icu-presence/2025-08-14T14:11:17+08:00https://flcube.com/jiangsu-hengruis-combo-therapy-approved-for-clinical-trials-by-nmpa/2025-08-14T12:57:50+08:00https://flcube.com/henlius-biotechs-hlx04-o-accepted-by-nmpa-for-wet-amd-treatment/2025-08-14T11:53:12+08:00https://flcube.com/tyk-medicines-asandeutertinib-shows-promising-results-in-phase-ii-trial-for-egfr-mutated-nsclc/2025-08-14T11:45:09+08:00https://flcube.com/canbridge-pharmaceuticals-secures-hk-100-million-equity-financing-from-baheal-pharma/2025-08-13T16:13:30+08:00https://flcube.com/kangji-medical-proposes-privatization-aiming-to-delist-from-hong-kong-stock-exchange/2025-08-13T16:01:31+08:00https://flcube.com/hengrui-pharmaceuticals-expands-hetrombopag-olamines-indication-for-itp-patients/2025-08-13T15:15:41+08:00https://flcube.com/ascletis-pharma-reports-positive-preclinical-results-for-asc47-in-obesity-treatment/2025-08-13T13:35:09+08:00https://flcube.com/bayer-collaborates-with-kumquat-biosciences-to-develop-kras-g12d-inhibitor/2025-08-13T13:20:36+08:00https://flcube.com/sino-biopharmaceuticals-tqb3142-ind-application-accepted-by-chinas-nmpa-for-malignant-tumor-treatment/2025-08-13T12:52:33+08:00https://flcube.com/novartis-leqvio-approved-by-fda-as-standalone-therapy-for-hypercholesterolemia/2025-08-13T12:34:30+08:00https://flcube.com/hightide-therapeutics-collaborates-with-imb-to-assess-htd1801-in-t2dm-with-ckd/2025-08-13T12:16:17+08:00https://flcube.com/fda-launches-precheck-program-to-strengthen-u-s-pharmaceutical-supply-chain/2025-08-13T12:10:07+08:00https://flcube.com/pfizer-china-restructures-oncology-and-rare-disease-units-for-enhanced-focus/2025-08-13T11:38:15+08:00https://flcube.com/chinas-nhsa-publishes-preliminary-list-for-2025-national-reimbursement-drug-list-and-commercial-insurance-innovative-drug-list/2025-08-12T16:42:04+08:00https://flcube.com/legend-biotech-reports-q2-revenue-growth-of-36-7-and-h1-growth-of-60-4/2025-08-12T16:38:05+08:00https://flcube.com/takeda-reports-q1-fy2025-revenue-dip-led-by-fx-headwinds-and-generic-competition/2025-08-12T14:49:03+08:00https://flcube.com/hengruis-trastuzumab-rezetecan-and-adebrelimab-granted-breakthrough-therapy-designation-by-chinas-nmpa/2025-08-12T14:35:47+08:00https://flcube.com/hengruis-trastuzumab-rezetecan-granted-fda-orphan-drug-designation-for-gastric-cancer-treatment/2025-08-12T14:28:49+08:00https://flcube.com/macao-drug-administration-expands-white-list-for-designated-medical-institutions-in-cooperation-zone/2025-08-12T14:23:35+08:00https://flcube.com/curevac-and-gsk-resolve-mrna-vaccine-patent-dispute-with-biontech-and-pfizer/2025-08-12T14:18:57+08:00https://flcube.com/shanghai-moyang-biotechnology-secures-hundreds-of-millions-in-funding-to-expand-global-reach/2025-08-12T12:03:06+08:00https://flcube.com/novartis-begins-shipping-next-gen-anti-vegf-drug-beovu-for-diabetic-macular-edema/2025-08-12T11:55:23+08:00https://flcube.com/arvinas-and-pfizers-vepdegestrant-nda-accepted-by-fda-for-er-her2-breast-cancer/2025-08-12T11:16:04+08:00https://flcube.com/jj-medtech-gains-china-approval-for-mentor-memorygel-xtra-breast-implants/2025-08-12T11:09:16+08:00https://flcube.com/mabwell-initiates-u-s-clinical-study-of-9mw2821-for-triple-negative-breast-cancer/2025-08-12T11:03:50+08:00https://flcube.com/fosun-pharma-inks-licensing-pact-with-expedition-for-dpp-1-inhibitor-xh-s004/2025-08-12T10:56:57+08:00https://flcube.com/huadong-medicine-inks-exclusive-deal-for-jak1-inhibitor-vc005-in-china/2025-08-12T10:48:40+08:00https://flcube.com/biocytogen-partners-with-megarobo-to-drive-intelligent-upgrading-in-antibody-rd/2025-08-12T10:40:02+08:00https://flcube.com/merck-kgaa-reports-q2-results-amid-currency-headwinds-and-springworks-acquisition/2025-08-11T14:57:16+08:00https://flcube.com/akeso-announces-enrollment-of-first-patient-in-ivonescimab-phase-3-trial-for-small-cell-lung-carcinoma/2025-08-11T13:55:28+08:00https://flcube.com/junshi-biosciences-toripalimab-receives-nmpa-acceptance-for-her2-expressing-uc-treatment/2025-08-11T12:42:42+08:00https://flcube.com/shandong-boans-boyouping-receives-nmpa-approval-for-type-2-diabetes-treatment/2025-08-11T12:34:18+08:00https://flcube.com/boehringer-ingelheims-hernexeos-receives-fda-accelerated-approval-for-nsclc-treatment/2025-08-11T12:26:19+08:00https://flcube.com/lepu-biopharma-signs-licensing-pact-with-excalipoint-for-preclinical-assets/2025-08-11T12:22:16+08:00https://flcube.com/tigermed-partners-with-africare-biopharma-to-enhance-africas-clinical-research-capabilities/2025-08-11T12:08:24+08:00https://flcube.com/johnson-johnsons-rybrevant-approved-by-chinas-nmpa-for-egfr-mutant-nsclc-treatment/2025-08-11T12:00:39+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-combination-therapy-clinical-trial-in-advanced-solid-tumors/2025-08-08T17:53:06+08:00https://flcube.com/viatris-reports-q2-revenue-drop-sees-growth-in-greater-china-amid-global-decline/2025-08-08T17:31:24+08:00https://flcube.com/jingxin-pharma-signs-patent-license-for-cariprazine-hydrochloride-with-gedeon-richter/2025-08-08T16:53:16+08:00https://flcube.com/teleflexs-rusch-ez-blocker-gets-nmpa-approval-for-china-market/2025-08-08T15:12:42+08:00https://flcube.com/tellgen-plans-acquisition-of-82-stake-in-wuhan-healthcare-biotech-for-rmb-328-million/2025-08-08T15:06:08+08:00https://flcube.com/haiscos-hsk47388-receives-nmpa-clinical-trial-approval-for-autoimmune-diseases/2025-08-08T14:54:33+08:00https://flcube.com/hutchmed-reports-9-revenue-dip-in-h1-2025-fruzaqla-sales-grow-despite-overall-decline/2025-08-08T14:46:21+08:00https://flcube.com/westgene-partners-with-bgi-huo-yan-for-mrna-drug-development-and-industrialization/2025-08-08T14:38:02+08:00https://flcube.com/henlius-hlx43-approved-by-fda-for-phase-1-trial-in-thymic-carcinoma-treatment/2025-08-08T14:32:27+08:00https://flcube.com/cryofocus-medtechs-cryoadhesion-system-gains-nmpa-approval-for-commercialization/2025-08-08T14:26:48+08:00https://flcube.com/zai-lab-announces-q2-2025-results-with-10-revenue-growth-driven-by-key-products/2025-08-08T14:20:35+08:00https://flcube.com/sino-biopharmaceuticals-lm-24c5-receives-nmpa-approval-for-phase-2-clinical-trials-in-ceacam5-positive-solid-tumors/2025-08-08T14:12:35+08:00https://flcube.com/eli-lilly-reports-strong-q2-growth-but-shares-dip-on-orforglipron-data/2025-08-08T13:53:45+08:00https://flcube.com/amgen-reports-9-revenue-growth-in-q2-2025-driven-by-key-product-sales/2025-08-07T21:28:28+08:00https://flcube.com/sunshine-lake-pharma-makes-history-with-dual-entity-restructuring-listing-on-hkex/2025-08-07T16:03:01+08:00https://flcube.com/nhsa-updates-volume-based-procurement-policy-for-medical-institutions-in-11th-vbp-tender/2025-08-07T14:47:07+08:00https://flcube.com/neowise-biotechnologys-nw-101c-receives-nmpa-clinical-trial-approval-for-prame-targeted-tcr-t-therapy/2025-08-07T14:39:26+08:00https://flcube.com/dizal-pharmas-dzd8586-granted-fda-fast-track-designation-for-cll-sll-treatment/2025-08-07T14:34:44+08:00https://flcube.com/astrazenecas-fasenra-approved-for-pediatric-severe-eosinophilic-asthma-in-china/2025-08-07T14:26:39+08:00https://flcube.com/sino-biopharmaceuticals-rovadicitinib-granted-breakthrough-therapy-designation-for-chronic-graft-versus-host-disease/2025-08-07T14:08:34+08:00https://flcube.com/guangzhou-innogen-pharmaceuticals-launches-h-share-global-offering-in-hong-kong/2025-08-07T13:03:49+08:00https://flcube.com/beone-medicines-reports-42-revenue-growth-in-q2-2025-driven-by-brukinsa-sales/2025-08-07T12:13:40+08:00https://flcube.com/sino-medical-sciences-cometiu-stent-system-and-comex-catheter-receive-fda-breakthrough-designation/2025-08-07T12:04:39+08:00https://flcube.com/novartis-evaluates-acquisition-of-avidity-biosciences-to-strengthen-rare-disease-pipeline/2025-08-07T11:50:18+08:00https://flcube.com/shanghai-issues-new-measures-to-boost-commercial-health-insurance-for-biopharmaceutical-innovation/2025-08-07T11:07:49+08:00https://flcube.com/pfizers-q2-2025-revenue-rises-10-driven-by-strong-biopharma-sales/2025-08-06T16:25:51+08:00https://flcube.com/novo-nordisk-reports-strong-h1-2025-financial-results-driven-by-semaglutide-sales/2025-08-06T16:07:17+08:00https://flcube.com/qyuns-therapeutics-qx004n-enters-phase-3-trials-for-psoriasis-and-crohns-disease/2025-08-06T14:31:36+08:00https://flcube.com/sino-biopharmaceuticals-tqc3302-approved-for-copd-maintenance-treatment-clinical-trials/2025-08-06T14:20:54+08:00https://flcube.com/everest-medicines-nefecon-granted-full-approval-by-taiwans-tfda-for-iga-nephropathy/2025-08-06T12:55:40+08:00https://flcube.com/cspc-pharmaceuticals-semaglutide-injection-nmpa-marketing-application-accepted/2025-08-06T12:44:19+08:00https://flcube.com/hebei-senlangs-senl103-car-t-therapy-approved-for-refractory-generalized-myasthenia-gravis-in-china/2025-08-06T12:17:59+08:00https://flcube.com/chempartner-and-leado-pharma-sign-strategic-agreement-to-advance-new-drug-rd/2025-08-05T14:01:35+08:00https://flcube.com/zhongheng-group-acquires-patent-for-innovative-chronic-heart-failure-drug-lz-01/2025-08-05T13:53:29+08:00https://flcube.com/gaush-meditechs-frequency-domain-biometer-gains-medical-device-registration-in-jiangsu/2025-08-05T13:45:23+08:00https://flcube.com/sichuan-huiyus-hy05350-achieves-first-patient-dosing-in-phase-i-trial-for-msln-positive-tumors/2025-08-05T13:38:43+08:00https://flcube.com/zhaoke-ophthalmologys-tono-i-gains-nmpa-approval-for-glaucoma-management-in-china/2025-08-05T13:27:57+08:00https://flcube.com/kexing-partners-with-guangdong-zhongsheng-to-commercialize-onradivir-tablets-in-macau/2025-08-05T13:22:12+08:00https://flcube.com/innovent-biologics-ibi3032-receives-ind-approval-from-fda-and-nmpa-for-glp-1ra-clinical-trials/2025-08-05T11:58:00+08:00https://flcube.com/dr-noah-biotech-collaborates-with-thermo-fisher-to-accelerate-rare-disease-treatments/2025-08-04T15:34:55+08:00https://flcube.com/tennor-therapeutics-submits-listing-application-to-hong-kong-stock-exchange-main-board/2025-08-04T15:00:50+08:00https://flcube.com/fda-clears-elevidys-gene-therapy-after-investigating-8-year-old-boys-death/2025-08-04T12:48:23+08:00https://flcube.com/mabwells-cdh17-targeted-adc-7mw4911-receives-clinical-trial-approval-in-china-and-ind-clearance-in-the-us/2025-08-04T12:07:22+08:00https://flcube.com/cutia-therapeutics-cu-40102-approved-in-hong-kong-for-androgenetic-alopecia-treatment/2025-08-04T12:00:04+08:00https://flcube.com/utc-therapeutics-gains-fda-clearance-for-car-t-therapy-uclm805-in-msln-positive-solid-tumors/2025-08-04T11:50:02+08:00https://flcube.com/fda-mandates-safety-labeling-changes-for-opioid-pain-medications-and-targets-7-oh-products/2025-08-04T11:41:42+08:00https://flcube.com/luye-pharmas-ly03021-completes-enrollment-of-first-healthy-subject-in-phase-i-trial/2025-08-04T11:35:34+08:00https://flcube.com/allianthera-partners-with-dr-falk-pharma-to-develop-atb102-for-ulcerative-colitis/2025-08-01T20:55:10+08:00https://flcube.com/grand-pharma-partners-with-ire-elit-to-distribute-68ge-68ga-generators-in-china/2025-08-01T20:49:52+08:00https://flcube.com/lees-pharmas-socazolimab-approved-by-nmpa-for-es-sclc-first-line-treatment/2025-08-01T19:44:44+08:00https://flcube.com/brightgene-and-cr-sanjiu-collaborate-on-bgm0504-injection-development-and-commercialization/2025-08-01T17:56:49+08:00https://flcube.com/abbvie-reports-strong-q2-2025-results-with-immunology-portfolio-leading-growth/2025-08-01T17:48:50+08:00https://flcube.com/bms-q2-earnings-reflect-strategic-investments-maintains-full-year-revenue-growth-outlook/2025-08-01T16:53:37+08:00https://flcube.com/chinas-nhsa-issues-rules-for-instant-settlement-of-medical-insurance-funds/2025-08-01T16:47:14+08:00https://flcube.com/hybio-and-brightgene-partner-on-peptide-raw-material-supply-for-global-drug-commercialization/2025-08-01T16:41:52+08:00https://flcube.com/beone-medicines-bgb-16673-granted-prime-designation-by-ema-for-waldenstroms-macroglobulinemia/2025-08-01T16:37:07+08:00https://flcube.com/neurodawns-subsidiary-receives-nmpa-approval-for-first-lhi-treatment-rk-4-injection/2025-08-01T16:27:08+08:00https://flcube.com/nmpa-seeks-public-feedback-on-draft-regulations-for-internet-drug-and-medical-device-information-services/2025-08-01T15:04:19+08:00https://flcube.com/haiscos-ciprofol-nda-accepted-by-fda-a-milestone-for-chinese-anesthesia-innovation/2025-08-01T14:57:42+08:00https://flcube.com/astrazenecas-ultomiris-gains-nmpa-approval-for-neuromyelitis-optica-spectrum-disorder/2025-08-01T14:35:22+08:00https://flcube.com/chipscreens-next-gen-brain-penetrant-aurora-b-inhibitor-cs231295-gains-fda-clearance-for-advanced-solid-tumors/2025-08-01T14:28:33+08:00https://flcube.com/hengrui-receives-clinical-clearance-for-hrs-5041-in-prostate-cancer-treatment/2025-08-01T11:54:50+08:00https://flcube.com/porton-pharma-partners-with-eva-pharma-to-boost-car-t-cell-therapy-in-mena/2025-07-31T16:27:06+08:00https://flcube.com/porton-advanced-and-cellstore-partner-to-optimize-cell-therapy-drug-cryopreservation/2025-07-31T16:25:38+08:00https://flcube.com/immuneonco-receives-10m-milestone-payment-from-instil-bio-for-imm2510-imm27m-collaboration/2025-07-31T15:57:46+08:00https://flcube.com/luoxin-pharmaceutical-transfers-equity-stake-to-shanghai-pharma-for-rmb-415-million/2025-07-31T14:29:05+08:00https://flcube.com/sino-biopharmaceutical-on-track-to-receive-300m-milestone-payment-for-pd-1-vegf-antibody-deal/2025-07-31T14:21:53+08:00https://flcube.com/walvax-expands-rights-to-notitias-gut-microbiota-therapy-in-greater-china/2025-07-31T12:58:15+08:00https://flcube.com/sanofis-sar446523-gains-fda-orphan-drug-status-for-relapsed-or-refractory-multiple-myeloma/2025-07-31T12:27:51+08:00https://flcube.com/sandoz-to-acquire-evotecs-biologics-unit-for-300-million-expansion/2025-07-31T12:13:11+08:00https://flcube.com/zhaoke-ophthalmologys-melphalan-granted-fda-orphan-drug-designation-for-pediatric-retinoblastoma/2025-07-31T12:05:05+08:00https://flcube.com/zhaoke-ophthalmology-partners-with-french-fareva-for-strategic-expansion/2025-07-31T11:55:24+08:00https://flcube.com/lees-pharma-partners-with-shaohe-biotech-to-translate-probiotics-into-public-health-solutions/2025-07-31T11:36:12+08:00https://flcube.com/gsk-reports-6-sales-growth-in-q2-2025-driven-by-specialty-medicine-and-vaccines/2025-07-31T11:26:46+08:00https://flcube.com/cspc-signs-exclusive-licensing-deal-with-madrigal-for-glp-1-agonist-syh2086/2025-07-31T11:16:36+08:00https://flcube.com/hrain-biotechs-hicara-approved-by-nmpa-for-relapsed-refractory-lbcl/2025-07-31T11:00:54+08:00https://flcube.com/eli-lillys-jaypirca-achieves-primary-endpoint-in-phase-iii-bruin-cll-314-trial/2025-07-30T14:41:56+08:00https://flcube.com/shanghai-pharmaceuticals-b019-injection-approved-for-sle-clinical-trials/2025-07-30T14:01:05+08:00https://flcube.com/bayers-sevabertinib-granted-priority-review-by-chinas-nmpa-for-nsclc-treatment/2025-07-30T12:58:36+08:00https://flcube.com/ltz-therapeutics-and-eli-lilly-partner-to-develop-myeloid-engager-therapeutics/2025-07-30T12:51:26+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-phase-iii-trial-of-psoriasis-cream-mc2-01/2025-07-30T12:45:24+08:00https://flcube.com/china-medical-systems-zunveyl-nda-accepted-by-chinas-nmpa-for-alzheimers-treatment/2025-07-30T12:09:53+08:00https://flcube.com/msds-q2-earnings-hit-by-gardasil-sales-decline-keytruda-growth-slows/2025-07-30T11:57:29+08:00https://flcube.com/novo-nordisk-shares-plummet-20-as-obesity-drug-competition-intensifies-and-full-year-guidance-lowered/2025-07-30T11:46:13+08:00https://flcube.com/yoltechs-yolt-203-gains-orphan-drug-designation-for-primary-hyperoxaluria-type-1-treatment/2025-07-29T16:24:47+08:00https://flcube.com/cedicine-biotechs-umbilical-cord-blood-mononuclear-cell-injection-gains-cde-approval-for-clinical-trial/2025-07-29T16:13:29+08:00https://flcube.com/alphamab-oncologys-jskn003-granted-fda-orphan-drug-designation-for-gastric-and-gastroesophageal-junction-cancer/2025-07-29T16:05:32+08:00https://flcube.com/pierre-fabres-braftovi-approved-in-china-for-braf-v600e-mutant-metastatic-colorectal-cancer/2025-07-29T15:36:52+08:00https://flcube.com/henlius-biotechs-hlx14-recommended-for-eu-approval-by-emas-chmp/2025-07-29T15:08:29+08:00https://flcube.com/fosun-pharma-secures-licensing-rights-for-ar1001-in-alzheimers-treatment/2025-07-29T14:54:00+08:00https://flcube.com/boehringer-ingelheim-and-re-vana-partner-to-develop-first-in-class-ocular-therapies/2025-07-29T14:43:23+08:00https://flcube.com/tigermed-acquires-japans-micron-cro-to-expand-imaging-expertise-in-asia-pacific/2025-07-29T14:08:45+08:00https://flcube.com/eli-lillys-mounjaro-approved-by-chinas-nmpa-for-type-2-diabetes-treatment-with-insulin/2025-07-29T12:30:05+08:00https://flcube.com/antengenes-xpovio-approved-for-new-multiple-myeloma-indication-by-chinas-nmpa/2025-07-29T12:24:37+08:00https://flcube.com/shanghai-biomedicine-ma-fund-acquires-stake-in-microport-via-share-transfer-agreement/2025-07-29T12:17:16+08:00https://flcube.com/astrazeneca-restructures-biopharm-business-to-strengthen-autoimmune-and-respiratory-therapies/2025-07-29T12:01:39+08:00https://flcube.com/wuxi-apptec-reports-strong-q2-2025-results-with-20-6-revenue-growth/2025-07-29T11:54:27+08:00https://flcube.com/bms-and-bain-capital-launch-new-autoimmune-disease-focused-biopharma-company/2025-07-29T11:17:47+08:00https://flcube.com/beone-medicines-tislelizumab-receives-positive-chmp-opinion-for-nsclc-treatment/2025-07-29T11:12:17+08:00https://flcube.com/bristol-myers-squibb-gains-nmpa-approval-for-opdivo-yervoy-combo-in-nsclc/2025-07-28T17:00:37+08:00https://flcube.com/nmpa-updates-2025-edition-of-medical-narcotic-and-psychotropic-substances-catalogs/2025-07-28T16:09:21+08:00https://flcube.com/tibet-aim-pharms-major-shareholder-transfers-stake-to-beijing-fuhao/2025-07-28T16:02:09+08:00https://flcube.com/roches-elevidys-receives-negative-chmp-opinion-for-duchenne-muscular-dystrophy/2025-07-28T15:53:36+08:00https://flcube.com/aidea-pharmas-aitribond-approved-by-zanzibar-food-and-drug-agency/2025-07-28T15:48:17+08:00https://flcube.com/mirxes-and-nagawa-launch-free-gastric-cancer-screening-project-in-japan/2025-07-28T15:34:04+08:00https://flcube.com/ascletis-pharma-doses-first-patients-in-u-s-phase-2a-trial-for-monthly-glp-1-agonist-asc30/2025-07-28T15:27:05+08:00https://flcube.com/sobi-north-americas-doptelet-approved-by-fda-for-pediatric-itp-treatment/2025-07-28T15:16:50+08:00https://flcube.com/hengrui-and-gsk-enter-global-licensing-pact-for-pde3-4-inhibitor-hrs-9821/2025-07-28T15:10:26+08:00https://flcube.com/pfizer-and-biontechs-lp-8-1-covid-19-vaccine-gets-ema-chmp-nod/2025-07-28T14:44:38+08:00https://flcube.com/sansure-biotechs-gene-polymorphism-detection-kits-receive-nmpa-class-iii-ivd-certification/2025-07-28T14:11:16+08:00https://flcube.com/nmpa-approves-ambroxol-hydrochloride-oral-drops-for-over-the-counter-sale/2025-07-28T13:46:19+08:00https://flcube.com/biogens-zurzuvae-receives-positive-chmp-opinion-for-postpartum-depression-treatment/2025-07-28T12:49:43+08:00https://flcube.com/gsks-blenrep-approved-in-eu-for-relapsed-or-refractory-multiple-myeloma/2025-07-28T12:22:42+08:00https://flcube.com/sanofis-sarclisa-approved-in-eu-for-newly-diagnosed-multiple-myeloma-2/2025-07-28T12:13:01+08:00https://flcube.com/velavigo-closes-60-million-pre-a-financing-round-to-advance-global-clinical-trials/2025-07-28T11:58:10+08:00https://flcube.com/matchpoint-therapeutics-partners-with-novartis-to-develop-oral-covalent-inhibitors-for-inflammatory-diseases/2025-07-28T11:48:18+08:00https://flcube.com/sinocelltechs-sct640c-injection-receives-nmpa-approval-for-ra-clinical-trials/2025-07-25T14:50:45+08:00https://flcube.com/hengrui-pharmaceuticals-hrs8179-and-hrs-1893-receive-nmpa-clinical-trial-approval/2025-07-25T14:37:40+08:00https://flcube.com/cryofocus-medtechs-asthma-cryoablation-system-granted-fda-breakthrough-device-designation/2025-07-25T14:26:31+08:00https://flcube.com/3sbio-and-pfizer-finalize-licensing-agreement-for-pd-1-vegf-bispecific-antibody-ssgj-707/2025-07-25T14:00:21+08:00https://flcube.com/roche-ag-reports-7-sales-growth-in-h1-2025-driven-by-pharmaceuticals-expansion/2025-07-25T13:03:03+08:00https://flcube.com/genfleet-therapeutics-announces-fast-track-designation-for-gfh375-vs-7375-in-pancreatic-cancer/2025-07-25T12:44:34+08:00https://flcube.com/leads-biolabs-lists-on-hong-kong-stock-exchange-in-189-million-ipo/2025-07-25T12:32:48+08:00https://flcube.com/everest-medicines-completes-hk1-57-billion-share-placement-to-advance-rd-and-commercialization/2025-07-25T12:27:45+08:00https://flcube.com/yangtze-river-pharmaceuticals-tadalafil-hydrochloride-tablets-approved-for-ed-treatment-in-china/2025-07-25T12:22:23+08:00https://flcube.com/ipsens-cabometyx-approved-by-european-commission-for-neuroendocrine-tumors/2025-07-25T12:11:35+08:00https://flcube.com/nhsa-announces-reforms-to-centralized-drug-procurement-policies-beyond-lowest-price/2025-07-24T17:11:08+08:00https://flcube.com/boehringer-ingelheim-reports-6-3-sales-growth-in-first-half-of-2025/2025-07-24T17:05:59+08:00https://flcube.com/kelun-biotechs-skb378-win378-enters-global-phase-ii-trial-for-asthma-treatment/2025-07-24T16:48:05+08:00https://flcube.com/sirius-therapeutics-srsd107-receives-ema-approval-for-phase-ii-clinical-trials-in-thromboembolic-diseases/2025-07-24T15:27:14+08:00https://flcube.com/akeso-enrolls-first-patient-in-phase-iii-trial-of-ivonescimab-for-pancreatic-cancer/2025-07-24T14:42:34+08:00https://flcube.com/youcare-pharmas-ykyy029-receives-fda-ind-approval-for-hypertension-treatment/2025-07-24T14:06:29+08:00https://flcube.com/national-health-commission-launches-integrated-medical-and-elder-care-demonstration-projects/2025-07-24T12:19:50+08:00https://flcube.com/kintors-kx-826-topical-solution-meets-primary-endpoint-in-aga-phase-ii-trial/2025-07-24T12:15:05+08:00https://flcube.com/ascentage-pharma-collaborates-with-major-chinese-firms-to-commercialize-lisaftoclax/2025-07-23T15:40:14+08:00https://flcube.com/shanghai-kehua-bioengineering-subsidiary-receives-two-ivd-certificates-from-nmpa/2025-07-23T15:25:09+08:00https://flcube.com/shenzhen-beimeis-twyneo-receives-nmpa-clinical-trial-approval-for-acne-treatment/2025-07-23T15:00:34+08:00https://flcube.com/chison-medical-and-gates-foundation-collaborate-on-innovative-ultrasound-equipment/2025-07-23T14:06:55+08:00https://flcube.com/shanghai-microport-ep-medtechs-icemagic-catheter-receives-eu-mdr-certification/2025-07-23T13:51:08+08:00https://flcube.com/cttq-doses-first-patient-in-china-for-tqb6411-phase-i-clinical-trial/2025-07-23T11:57:21+08:00https://flcube.com/fda-approved-smile-system-launches-in-lecheng-for-adhd-treatment/2025-07-23T10:57:12+08:00https://flcube.com/grand-pharmas-tlx591-granted-nmpa-approval-for-phase-iii-prostate-cancer-trial/2025-07-23T10:49:27+08:00https://flcube.com/abbisko-therapeutics-completes-first-patient-dosing-for-prmt5xmta-inhibitor-absk131/2025-07-23T10:28:55+08:00https://flcube.com/novatim-and-erigen-ink-licensing-pact-for-dual-target-car-t-therapy-kq-2003/2025-07-22T16:25:47+08:00https://flcube.com/ausperbio-gains-nmpa-approval-for-phase-iii-trials-of-ahb-137-in-chronic-hepatitis-b/2025-07-22T15:48:17+08:00https://flcube.com/sanofi-to-acquire-vicebio-ltd-for-up-to-usd-1-6-billion-advancing-next-gen-vaccine-development/2025-07-22T15:42:22+08:00https://flcube.com/astrazeneca-to-invest-50-billion-in-us-manufacturing-and-rd-expansion-by-2030/2025-07-22T15:32:17+08:00https://flcube.com/astrazenecas-flaura2-study-confirms-osimertinib-combos-survival-benefit-in-nsclc/2025-07-22T15:29:14+08:00https://flcube.com/genentechs-astegolimab-shows-promising-results-in-phase-iib-copd-trial/2025-07-22T15:27:03+08:00https://flcube.com/livzon-pharmas-lzm012-meets-phase-iii-endpoint-for-psoriasis-treatment/2025-07-22T14:32:53+08:00https://flcube.com/simcere-zaiming-receives-fda-clearance-for-phase-i-trial-of-fgfr2b-targeting-adc-sim0686/2025-07-22T14:20:58+08:00https://flcube.com/abbott-reports-q2-2025-sales-of-usd-11-14-billion-led-by-medical-devices-growth/2025-07-22T11:26:55+08:00https://flcube.com/dualitybios-next-generation-her3-adc-db-1310-granted-fda-fast-track-designation/2025-07-22T10:55:45+08:00https://flcube.com/shanghai-pharma-and-cutia-therapeutic-collaborate-on-codon-biopharmas-innovative-drug-distribution/2025-07-22T10:36:56+08:00https://flcube.com/bio-theras-bat4406f-gets-nmpa-nod-for-mcd-and-fsgs-clinical-trials/2025-07-22T10:19:47+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-hdm2012-clinical-trials-in-advanced-solid-tumors/2025-07-21T16:43:32+08:00https://flcube.com/optoseeker-biotech-and-biomap-collaborate-to-accelerate-antibody-therapeutics-development/2025-07-21T16:35:52+08:00https://flcube.com/wondfo-biotechs-msi-detection-kit-granted-nmpa-marketing-clearance/2025-07-21T16:26:29+08:00https://flcube.com/zhongke-yian-receives-nmpa-approval-for-innovative-sirolimus-eluting-coronary-stent/2025-07-21T16:20:43+08:00https://flcube.com/nmpa-approves-worlds-first-plant-based-human-albumin-for-liver-cirrhosis-treatment/2025-07-21T16:04:59+08:00https://flcube.com/kante-biotechs-yilijia-wins-nmpa-category-iii-license-for-pancreatic-cancer-early-detection/2025-07-21T15:58:19+08:00https://flcube.com/wuxi-biologics-passes-fda-pre-approval-inspection-with-zero-critical-findings/2025-07-21T15:48:26+08:00https://flcube.com/jumpcan-pharmaceuticals-jike-shu-approved-by-nmpa-for-influenza-a-and-b-treatment/2025-07-21T15:42:46+08:00https://flcube.com/cde-seeks-feedback-on-96th-batch-of-chemical-generic-drug-reference-standards/2025-07-21T15:29:10+08:00https://flcube.com/novo-nordisks-ozempic-approved-for-kidney-protection-in-china-pioneering-glycemic-and-renal-control/2025-07-21T15:23:29+08:00https://flcube.com/shanghai-wankexin-biotech-to-acquire-stake-in-chengdu-kanghua-biological-for-rmb-1-851-billion/2025-07-21T15:17:50+08:00https://flcube.com/hebei-implements-separate-payment-for-57-negotiated-drugs-starting-august-1-2025/2025-07-21T15:01:12+08:00https://flcube.com/bayer-and-jd-health-collaborate-on-dulcolax-lactulose-to-expand-chinas-digestive-health-market/2025-07-21T14:54:15+08:00https://flcube.com/sarepta-therapeutics-announces-500-employee-layoffs-after-fda-elevidys-trial-suspension/2025-07-21T14:42:14+08:00https://flcube.com/vivavision-biotech-closes-d2-funding-round-advancing-ophthalmic-therapies/2025-07-21T14:27:20+08:00https://flcube.com/youcare-pharma-subsidiary-gains-nmpa-clearance-for-phase-i-study-of-sirna-hypertension-drug-ykyy029/2025-07-18T23:00:14+08:00https://flcube.com/gsks-blenrep-fails-to-win-fda-advisory-committee-support-for-relapsed-multiple-myeloma/2025-07-18T22:20:45+08:00https://flcube.com/robo-medical-secures-tens-of-millions-in-funding-for-endofaster-and-endodreams-development/2025-07-18T22:15:17+08:00https://flcube.com/cansino-bio-receives-nmpa-approval-for-phase-i-ii-trial-of-recombinant-polio-vaccine/2025-07-18T22:09:27+08:00https://flcube.com/yifan-pharmas-generic-glycerol-phenylbutyrate-accepted-for-nmpa-review/2025-07-18T14:59:17+08:00https://flcube.com/hengrui-pharmaceuticals-shr-8068-gains-nmpa-approval-for-nsclc-and-colorectal-cancer-trials/2025-07-18T14:44:17+08:00https://flcube.com/fosun-pharmas-zhejiang-xinghao-unit-initiates-phase-ib-study-for-copd-dpp-1-inhibitor-xh-s004/2025-07-18T14:27:32+08:00https://flcube.com/legend-biotechs-carvykti-achieves-usd-439-million-in-q2-2025-sales/2025-07-18T14:17:15+08:00https://flcube.com/buchang-pharma-subsidiary-establishes-shaanxi-buchang-meddata-with-lingyishushu/2025-07-18T10:44:29+08:00https://flcube.com/novartis-reports-double-digit-growth-in-q2-and-1h25-driven-by-key-brands/2025-07-17T15:46:21+08:00https://flcube.com/takedas-oveporexton-meets-all-endpoints-in-phase-3-narcolepsy-type-1-trials/2025-07-17T14:15:49+08:00https://flcube.com/phase-scientific-partners-with-lumos-diagnostics-to-launch-febridx-in-us-respiratory-market/2025-07-17T13:57:45+08:00https://flcube.com/daiichi-sankyo-and-astrazeneca-submit-enhertu-application-for-her2-positive-gastric-cancer-in-china/2025-07-17T13:45:34+08:00https://flcube.com/johnson-johnson-reports-5-8-sales-growth-in-2025q2-increases-full-year-guidance/2025-07-17T12:50:10+08:00https://flcube.com/konruns-kc1036-proposed-for-cdes-spark-program-to-accelerate-pediatric-ewings-sarcoma-treatment-development/2025-07-17T12:16:29+08:00https://flcube.com/hainan-boao-research-hospital-secures-approval-for-chinas-first-medical-food-import-for-rare-metabolic-disorders/2025-07-17T12:05:41+08:00https://flcube.com/sanofis-gene-therapy-sar446597-secures-fda-fast-track-for-geographic-atrophy/2025-07-17T11:56:19+08:00https://flcube.com/tcelltech-secures-usd-40-million-series-b-funding-for-tx-103-car-t-therapy-development/2025-07-16T17:44:52+08:00https://flcube.com/hengrui-pharma-and-kailera-announce-positive-phase-iii-results-for-hrs9531-in-obesity-treatment/2025-07-16T17:39:47+08:00https://flcube.com/haisco-pharma-receives-fda-approval-for-clinical-trials-of-autoimmune-drug-hsk47388/2025-07-16T17:35:35+08:00https://flcube.com/danahers-cytiva-collaborates-with-correctsequence-on-gene-therapy-lnp-delivery-system/2025-07-16T16:46:30+08:00https://flcube.com/astrazenecas-baxdrostat-meets-primary-and-secondary-endpoints-in-phase-iii-baxhtn-trial/2025-07-16T16:41:11+08:00https://flcube.com/shanghai-sanyou-medical-receives-nmpa-marketing-license-for-jazz-spinal-fixation-system/2025-07-16T16:35:05+08:00https://flcube.com/nmpa-updates-reference-drugs-for-gqce-evaluation-42-new-additions-and-6-removals/2025-07-16T16:29:00+08:00https://flcube.com/bd-merges-biosciences-diagnostic-solutions-with-waters-corporation-in-usd-17-5-billion-deal/2025-07-16T16:24:52+08:00https://flcube.com/sino-biopharmaceutical-acquires-majority-stake-in-lanova-medicines-for-usd-950-92-million/2025-07-16T16:00:29+08:00https://flcube.com/vigonvitas-simenafil-receives-nmpa-approval-for-erectile-dysfunction-treatment/2025-07-16T15:29:22+08:00https://flcube.com/xgene-licenses-novel-non-opioid-analgesic-xg005-to-neurogen-for-greater-china-development/2025-07-16T15:19:20+08:00https://flcube.com/otsuka-to-acquire-cantargias-il-1rap-monoclonal-antibody-can10-for-autoimmune-diseases/2025-07-16T15:06:50+08:00https://flcube.com/huadong-medicine-receives-fda-approval-for-clinical-trials-of-innovative-adc-hdm2020/2025-07-15T18:10:48+08:00https://flcube.com/ningbo-health-gene-and-biofast-biotech-partner-to-advance-genetic-testing-for-hereditary-diseases/2025-07-15T18:05:12+08:00https://flcube.com/boehringer-ingelheim-licenses-spevigo-to-leo-pharma-for-global-dermatology-expansion/2025-07-15T17:58:04+08:00https://flcube.com/peijia-medical-completes-first-patient-implantation-for-monarq-ttvr-system-in-global-clinical-study/2025-07-15T17:53:38+08:00https://flcube.com/golden-age-health-secures-exclusive-rights-to-innostellars-gene-therapy-lx-101-in-china/2025-07-15T17:35:05+08:00https://flcube.com/merck-initiates-expressive-phase-iii-trial-for-once-monthly-hiv-prep-drug-mk-8527/2025-07-15T17:15:01+08:00https://flcube.com/china-medical-systems-cms-d001-gains-nmpa-approval-for-atopic-dermatitis-trials/2025-07-15T17:08:42+08:00https://flcube.com/nhsa-reports-2024-healthcare-stats-bmi-fund-reaches-rmb-3-49-trillion-income-with-95-participation-rate/2025-07-15T16:37:38+08:00https://flcube.com/sinomab-bioscience-voluntarily-withdraws-bla-for-suciraslimab-in-china-citing-need-for-additional-data/2025-07-15T16:05:00+08:00https://flcube.com/mabwell-signs-licensing-agreement-with-unilab-for-denosumab-biosimilars-in-the-philippines/2025-07-15T15:56:11+08:00https://flcube.com/innovent-biologics-and-jd-health-form-strategic-partnership-to-enhance-drug-supply-and-healthcare-services/2025-07-15T15:29:19+08:00https://flcube.com/shanghai-henlius-biotech-initiates-us-patient-dosing-in-phase-iii-trial-for-her2-positive-gastric-cancer/2025-07-15T15:11:35+08:00https://flcube.com/bayer-ags-kerendia-approved-by-fda-to-treat-adult-heart-failure-with-ejection-fraction-%e2%89%a540/2025-07-15T15:04:47+08:00https://flcube.com/sichuan-biokins-iza-bren-approved-for-phase-ii-clinical-study-in-renal-cell-carcinoma/2025-07-15T14:54:50+08:00https://flcube.com/hunan-mabgeek-biotech-files-for-hong-kong-ipo-to-expand-innovative-biologics-pipeline/2025-07-15T14:45:05+08:00https://flcube.com/gsks-arexvy-rsv-vaccine-expansion-for-adults-18-49-receives-fda-review/2025-07-15T14:26:50+08:00https://flcube.com/dizals-sunvozertinib-included-in-nccn-guidelines-for-egfr-exon20ins-nsclc-treatment/2025-07-14T15:24:31+08:00https://flcube.com/boao-super-hospital-introduces-xiaflex-for-non-surgical-peyronies-disease-treatment/2025-07-14T15:17:59+08:00https://flcube.com/lexenpharm-partners-with-aptargroup-for-single-dose-nasal-spray-services-in-greater-china/2025-07-14T15:08:27+08:00https://flcube.com/eolas-therapeutics-gains-full-rights-to-azd4041-for-opioid-use-disorder-development/2025-07-14T15:02:20+08:00https://flcube.com/royal-philips-and-suzhou-peixin-collaborate-on-ai-powered-interventional-therapy-platform-for-structural-heart-disease/2025-07-14T14:36:44+08:00https://flcube.com/yoltech-therapeutics-receives-nmpa-clearance-for-yolt-101-in-hefh-clinical-study/2025-07-14T12:21:49+08:00https://flcube.com/carsgen-therapeutics-secures-european-patent-for-gpc3-car-t-technology-after-successful-opposition-proceedings/2025-07-14T12:11:37+08:00https://flcube.com/eisai-announces-commercial-release-of-urece-dotinurad-from-suzhou-facility-in-china/2025-07-14T12:00:16+08:00https://flcube.com/innocare-pharma-receives-fda-approval-for-mesutoclax-in-myeloid-malignancies/2025-07-14T11:47:31+08:00https://flcube.com/pfizer-and-astellas-xtandi-shows-positive-results-in-phase-iii-embark-study-for-prostate-cancer/2025-07-14T11:27:14+08:00https://flcube.com/bayers-elinzanetant-granted-uk-marketing-authorization-for-menopause-related-vasomotor-symptoms/2025-07-11T16:05:54+08:00https://flcube.com/abbvie-licenses-igi-therapeutics-isb-2001-for-oncology-and-autoimmune-diseases/2025-07-11T15:45:37+08:00https://flcube.com/jiangsu-jibeier-receives-nmpa-approval-for-clinical-trials-of-jjh201601-liposome-in-advanced-hnscc/2025-07-11T15:33:59+08:00https://flcube.com/fosun-pharmaceutical-launches-phase-iii-study-for-fumaining-in-pediatric-low-grade-glioma/2025-07-11T15:26:42+08:00https://flcube.com/beone-medicines-tevimbra-approved-by-european-commission-for-nasopharyngeal-carcinoma/2025-07-11T15:21:08+08:00https://flcube.com/johnson-johnson-medtech-launches-varipulse-platform-for-atrial-fibrillation-in-asia-pacific/2025-07-11T15:16:11+08:00https://flcube.com/jcr-pharmaceuticals-signs-licensing-agreement-with-astrazenecas-alexion-for-just-aav-gene-therapy-platform/2025-07-11T15:10:30+08:00https://flcube.com/zhimeng-biopharmas-cb03-154-receives-cde-approval-for-als-phase-ii-iii-clinical-study/2025-07-11T15:00:17+08:00https://flcube.com/nhsa-finalizes-2025-drug-catalog-adjustment-plan-with-minimal-changes-from-draft/2025-07-11T14:55:58+08:00https://flcube.com/msds-once-daily-hiv-1-therapy-doravirine-islatravir-nda-accepted-by-fda-for-review/2025-07-11T14:14:29+08:00https://flcube.com/zelgens-zg006-receives-breakthrough-therapy-designation-for-advanced-small-cell-lung-cancer/2025-07-11T14:08:53+08:00https://flcube.com/cosunters-gst-hg131-granted-breakthrough-therapy-designation-for-hbv-treatment-in-china/2025-07-11T12:41:55+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-receives-nmpa-approval-for-cll-sll-treatment/2025-07-11T12:32:19+08:00https://flcube.com/allists-furmonertinib-granted-priority-review-for-egfr-exon-20-nsclc-in-china/2025-07-11T11:43:02+08:00https://flcube.com/hkym-biopharmas-km1-receives-nmpa-green-light-for-phase-ib-ii-study-in-advanced-solid-tumors/2025-07-11T11:29:56+08:00https://flcube.com/united-laboratories-receives-fda-approval-for-clinical-study-of-ubt37034-in-overweight-obesity-treatment/2025-07-11T10:49:14+08:00https://flcube.com/cstone-pharmaceuticals-receives-nmpa-approval-for-local-production-of-gavreto-in-china/2025-07-10T15:43:05+08:00https://flcube.com/biocytogen-and-beone-medicines-deepen-partnership-with-global-antibody-licensing-agreement/2025-07-10T15:36:41+08:00https://flcube.com/eli-lillys-kisunla-donanemab-receives-fda-label-update-with-new-dosing-schedule-for-alzheimers-treatment/2025-07-10T15:28:01+08:00https://flcube.com/jiangsu-chia-tai-tianqings-culmerciclib-receives-nmpa-review-for-expanded-breast-cancer-indication/2025-07-10T15:20:05+08:00https://flcube.com/sironax-partners-with-novartis-on-brain-delivery-module-platform-for-cns-drugs/2025-07-10T15:01:07+08:00https://flcube.com/novo-nordisk-invests-111-million-in-tianjin-quality-control-lab-expansion/2025-07-10T14:55:05+08:00https://flcube.com/simcere-and-connect-biopharmas-rademikibart-nda-accepted-by-chinas-nmpa-for-atopic-dermatitis/2025-07-10T14:46:48+08:00https://flcube.com/anke-bio-secures-exclusive-rights-to-bao-pharmas-long-acting-fsh-ctp-for-china-market/2025-07-10T14:07:29+08:00https://flcube.com/shuwen-biotech-completes-rmb100-million-series-c1-round-to-advance-womens-health-diagnostics/2025-07-10T14:01:05+08:00https://flcube.com/iaso-biotherapeutics-receives-orphan-drug-designation-in-south-korea-for-fucaso-in-multiple-myeloma/2025-07-10T13:57:05+08:00https://flcube.com/msd-to-acquire-verona-pharma-for-10-billion-expanding-respiratory-portfolio/2025-07-10T13:52:36+08:00https://flcube.com/guangdong-taienkang-submits-marketing-application-for-generic-vuity-to-chinas-nmpa/2025-07-09T16:22:28+08:00https://flcube.com/pascal-qian-appointed-general-manager-of-bms-china-unit/2025-07-09T15:49:29+08:00https://flcube.com/adagene-collaborates-with-conjugatebio-to-develop-bispecific-antibody-drug-conjugates/2025-07-09T15:30:31+08:00https://flcube.com/zhaoke-ophthalmology-partners-with-somerset-therapeutics-to-accelerate-us-expansion/2025-07-09T15:18:21+08:00https://flcube.com/lakeshore-biopharma-secures-15-million-in-private-placement-to-fuel-growth/2025-07-09T14:29:11+08:00https://flcube.com/innovents-dabote-becomes-first-china-originated-kras-g12c-inhibitor-approved-in-macau/2025-07-09T14:12:52+08:00https://flcube.com/nk-celltech-secures-14-million-in-series-a-financing-to-advance-nk-cell-therapies/2025-07-09T14:01:29+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-clearance-for-shr-2173-in-primary-membranous-nephropathy/2025-07-09T13:33:13+08:00https://flcube.com/jj-submits-snda-to-fda-for-caplyta-to-prevent-schizophrenia-relapse/2025-07-09T13:27:55+08:00https://flcube.com/novartis-coartem-baby-approved-by-swissmedic-for-newborns-and-young-infants/2025-07-09T13:20:16+08:00https://flcube.com/jiangsu-hengrui-gains-nmpa-clinical-clearance-for-hrs-9821-in-copd-treatment/2025-07-09T13:12:36+08:00https://flcube.com/nmpa-updates-review-procedures-for-conditional-drug-marketing-approval-applications/2025-07-09T12:40:22+08:00https://flcube.com/boston-scientifics-farapulse-gains-fda-approval-for-expanded-use-in-persistent-atrial-fibrillation/2025-07-09T11:42:42+08:00https://flcube.com/hutchmed-announces-first-commercial-shipments-of-tazverik-across-china/2025-07-09T11:00:43+08:00https://flcube.com/shenzhen-concemed-medtech-secures-hundreds-of-millions-in-series-a-funding-for-endoscopy-expansion/2025-07-08T16:25:26+08:00https://flcube.com/concemed-raises-pre-series-a-funding-to-expand-digestive-endoscope-pipeline/2025-07-08T16:15:15+08:00https://flcube.com/remegen-submits-new-indication-application-for-disitamab-vedotin-in-urothelial-carcinoma/2025-07-08T15:33:58+08:00https://flcube.com/grand-pharmas-sir-spheres-y-90-gets-fda-accelerated-approval-for-unresectable-hcc/2025-07-08T14:51:29+08:00https://flcube.com/boehringer-ingelheim-starts-phase-iii-thulite-study-for-bi-1815368-in-diabetic-macular-edema/2025-07-08T14:43:24+08:00https://flcube.com/gsk-completes-acquisition-of-boston-pharmas-bp-asset-ix-for-efimosfermin-alpha/2025-07-08T14:06:14+08:00https://flcube.com/qilu-pharmaceutical-partners-with-sagent-pharmaceuticals-to-expand-us-market-presence/2025-07-08T13:49:45+08:00https://flcube.com/nmpa-releases-93rd-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2025-07-08T13:32:40+08:00https://flcube.com/roches-chugai-pharmaceutical-partners-with-gero-to-develop-therapies-for-age-related-diseases/2025-07-08T13:23:45+08:00https://flcube.com/cstone-pharmaceuticals-licenses-cejemly-to-istituto-gentili-for-23-countries-in-europe-and-the-uk/2025-07-08T13:05:40+08:00https://flcube.com/jiangsu-cttqs-tqb2102-receives-breakthrough-therapy-designation-for-her2-breast-cancer/2025-07-08T12:29:19+08:00https://flcube.com/wepon-medical-receives-nmpa-clinical-approval-for-wp107-in-generalized-myasthenia-gravis/2025-07-08T12:17:06+08:00https://flcube.com/chinas-cde-announces-95th-batch-of-reference-preparations-for-public-comment/2025-07-07T15:21:45+08:00https://flcube.com/china-ministry-of-finance-restricts-eu-imported-medical-devices-in-government-procurement-over-rmb45-million/2025-07-07T15:01:02+08:00https://flcube.com/scg-cell-therapy-obtains-nmpa-approval-for-scg101v-in-chronic-hbv-study/2025-07-07T14:43:54+08:00https://flcube.com/bgi-genomics-launches-mini-breast-cancer-76-gene-detection-system-for-personalized-treatment/2025-07-07T14:14:26+08:00https://flcube.com/astrazenecas-imfinzi-approved-in-eu-for-perioperative-treatment-of-muscle-invasive-bladder-cancer/2025-07-07T14:04:39+08:00https://flcube.com/modella-ai-collaborates-with-astrazeneca-to-accelerate-oncology-drug-development-with-ai/2025-07-07T13:35:46+08:00https://flcube.com/cstone-pharmaceuticals-announces-phase-iii-trial-progress-for-nofazinlimab-in-hepatocellular-carcinoma/2025-07-07T13:12:14+08:00https://flcube.com/micot-raises-over-rmb-100-million-in-series-d-funding-led-by-zheshang-venture-capital/2025-07-07T12:59:08+08:00https://flcube.com/nmpa-unveils-measures-to-support-high-end-medical-device-innovation-with-full-lifecycle-regulation/2025-07-07T12:51:22+08:00https://flcube.com/astrazeneca-in-talks-for-15b-licensing-deal-for-ivonescimab-with-summit-therapeutics/2025-07-07T12:47:43+08:00https://flcube.com/jiangsu-vcare-pharmatechs-vc004-nda-accepted-for-review-by-chinas-nmpa/2025-07-04T18:21:17+08:00https://flcube.com/novartis-cosentyx-fails-to-meet-primary-endpoint-in-gcaptain-study-for-giant-cell-arteritis/2025-07-04T18:17:15+08:00https://flcube.com/eli-lillys-mounjaro-approved-by-chinas-nmpa-for-obstructive-sleep-apnea-in-obese-adults/2025-07-04T18:13:33+08:00https://flcube.com/akeso-biopharma-initiates-phase-ia-clinical-study-for-trop2-nectin4-bispecific-adc-ak146d1/2025-07-04T18:09:52+08:00https://flcube.com/jiangsu-kanion-receives-nmpa-approval-for-kys2301-gel-in-atopic-dermatitis-clinical-study/2025-07-04T18:03:49+08:00https://flcube.com/sino-biopharmaceuticals-recombinant-factor-viia-n01-approved-by-nmpa-for-hemophilia-treatment/2025-07-04T17:58:39+08:00https://flcube.com/thermo-fishers-oncomine-dx-express-test-approved-by-fda-as-companion-diagnostic-for-dizals-zegfrovy/2025-07-04T17:52:52+08:00https://flcube.com/jiangsu-hengrui-announces-nmpa-approval-for-miebo-in-dry-eye-disease-treatment/2025-07-04T17:44:16+08:00https://flcube.com/chinas-weimai-plans-hong-kong-ipo-to-expand-ai-powered-healthcare-services/2025-07-04T17:23:08+08:00https://flcube.com/msds-winrevair-accepted-for-priority-review-by-fda-for-pulmonary-arterial-hypertension/2025-07-04T17:10:06+08:00https://flcube.com/hangzhou-jiuyuan-announces-nmpa-approval-for-generic-doptelet-in-thrombocytopenia-treatmen/2025-07-04T17:03:49+08:00https://flcube.com/betta-pharmaceuticals-kangmeina-approved-by-nmpa-for-advanced-breast-cancer-treatment/2025-07-04T16:40:28+08:00https://flcube.com/bioversys-partners-with-shionogi-to-advance-bv500-for-non-tuberculous-mycobacterial-infections/2025-07-04T16:30:11+08:00https://flcube.com/regenerons-lynozyfic-granted-fda-accelerated-approval-for-relapsed-refractory-multiple-myeloma/2025-07-04T16:07:50+08:00https://flcube.com/sumitomo-pharmas-xenleta-approved-in-china-for-community-acquired-pneumonia-treatment/2025-07-04T15:42:21+08:00https://flcube.com/bebt-908-receives-conditional-nmpa-approval-for-relapsed-refractory-dlbcl/2025-07-04T15:23:03+08:00https://flcube.com/fosun-pharma-subsidiary-launches-co-developed-biochemical-reagent-with-siemens-healthineers/2025-07-04T14:47:25+08:00https://flcube.com/cspc-pharma-receives-nmpa-approval-for-hydroxocobalamine-in-pediatric-mma-treatment/2025-07-04T13:52:03+08:00https://flcube.com/kanion-pharma-and-space-peptides-submit-ind-for-ai-enabled-ccr8-peptide-inhibitor-kys2301/2025-07-04T13:01:12+08:00https://flcube.com/cr-medical-holdings-partners-with-shanghai-haohai-bio-in-medical-aesthetics-sector/2025-07-04T11:51:47+08:00https://flcube.com/haohai-bio-acquires-additional-stake-in-sznimo-for-ophthalmic-expansion/2025-07-04T11:44:34+08:00https://flcube.com/haohai-biotechs-sodium-hyaluronate-gel-receives-nmpa-approval-for-aesthetic-treatments/2025-07-04T11:41:16+08:00https://flcube.com/brii-biosciences-licenses-brii-693-to-joincare-pharma-for-development-in-greater-china/2025-07-04T11:28:44+08:00https://flcube.com/astrazeneca-ceo-soriot-explores-us-stock-listing-move-potentially-impacting-london-exchange/2025-07-03T22:05:26+08:00https://flcube.com/shanghai-henlius-biotech-earns-gmp-certification-for-prolia-xgeva-biosimilar-hlx14-and-perjeta-biosimilar-hlx11/2025-07-03T17:08:17+08:00https://flcube.com/dizals-sunvozertinib-receives-fda-accelerated-approval-for-egfr-exon20ins-nsclc/2025-07-03T17:01:29+08:00https://flcube.com/serviers-voranigo-approved-for-idh-mutant-diffuse-glioma-in-beijing/2025-07-03T16:56:12+08:00https://flcube.com/sichuan-biokins-iza-bren-meets-primary-endpoint-in-phase-iii-npc-trial/2025-07-03T16:52:01+08:00https://flcube.com/genrix-bio-receives-nmpa-clearance-for-gr1803-in-relapsed-refractory-multiple-myeloma/2025-07-03T16:45:18+08:00https://flcube.com/simcere-pharmas-suvemcitug-approved-by-chinas-nmpa-for-platinum-resistant-ovarian-cancer/2025-07-03T16:36:27+08:00https://flcube.com/china-resources-double-crane-announces-nmpa-clinical-approval-for-j002-dry-eye-syndrome-treatment/2025-07-03T16:28:08+08:00https://flcube.com/sun-novo-pharma-collaborates-with-lekuang-huilin-on-stc007-for-post-abdominal-surgery-pain/2025-07-03T15:23:36+08:00https://flcube.com/abbvies-venclexta-approved-by-chinas-nmpa-for-cll-sll-patients-with-17p-deletion/2025-07-03T15:12:27+08:00https://flcube.com/changchun-genesciences-firsekibart-receives-nmpa-approval-for-acute-gouty-arthritis/2025-07-03T14:53:51+08:00https://flcube.com/xtalpi-completes-pre-seed-investment-in-foundry-biosciences-to-advance-ai-driven-longevity-therapeutics/2025-07-03T14:36:36+08:00https://flcube.com/canbridges-geruining-approved-for-gaucher-disease-treatment-first-domestically-developed-ert/2025-07-03T14:26:23+08:00https://flcube.com/innocare-pharma-receives-nmpa-clinical-approval-for-innovative-adc-b7-h3/2025-07-03T14:17:45+08:00https://flcube.com/anhui-anke-biotechnology-receives-nmpa-clearance-for-ak2024-in-her2-positive-solid-tumors/2025-07-02T23:21:02+08:00https://flcube.com/chengdu-kanghong-receives-nmpa-approval-for-clinical-trials-of-kh813-in-metastatic-nsq-nsclc/2025-07-02T23:08:11+08:00https://flcube.com/takeda-pharmaceutical-gains-fda-approval-for-gammagard-liquid-erc-in-primary-immunodeficiency/2025-07-02T23:01:55+08:00https://flcube.com/3sbio-partners-with-thermo-fisher-to-advance-cell-and-gene-therapy-solutions/2025-07-02T17:58:35+08:00https://flcube.com/jacobio-pharma-initiates-first-patient-dosing-in-u-s-phase-i-iia-study-for-pan-kras-inhibitor-jab-23e73/2025-07-02T17:51:49+08:00https://flcube.com/shanghai-pharmaceuticals-meditrust-health-files-for-ipo-in-hong-kong-amidst-ai-powered-healthcare-payment-transformation/2025-07-02T17:41:47+08:00https://flcube.com/hisun-pharmaceuticals-receives-nmpa-approval-for-hs387-clinical-trials-in-advanced-solid-tumors/2025-07-02T16:56:14+08:00https://flcube.com/china-isotope-radiation-corporation-showcases-c-14-barium-carbonate-at-international-symposium/2025-07-02T16:43:16+08:00https://flcube.com/merck-kgaa-completes-3-4-billion-acquisition-of-springworks-therapeutics-boosting-rare-oncology-portfolio/2025-07-02T16:07:29+08:00https://flcube.com/allergan-aesthetics-skinvive-by-juvederm-accepted-for-fda-review-to-reduce-neck-lines/2025-07-02T15:55:12+08:00https://flcube.com/hybio-and-icarbonx-enter-crdmo-service-pact-and-strategic-investment-to-advance-peptide-drug-pipeline/2025-07-02T15:43:56+08:00https://flcube.com/enchannel-medical-acquires-acqmap-platform-assets-from-acutus-medical-to-strengthen-non-contact-mapping-tech/2025-07-02T15:40:07+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-partners-with-nsfc-to-establish-private-enterprise-innovation-fund/2025-07-02T15:31:42+08:00https://flcube.com/sanofi-invests-25-million-in-chinas-adagene-to-advance-safebody-program/2025-07-02T12:16:17+08:00https://flcube.com/nhsa-unveils-plans-for-2025-national-drug-list-adjustments-and-commercial-insurance-drug-list/2025-07-02T11:37:37+08:00https://flcube.com/esteve-to-acquire-sanofis-caprelsa-rights-in-over-50-countries-for-medullary-thyroid-cancer-treatment/2025-07-02T11:33:00+08:00https://flcube.com/abbvie-to-acquire-capstan-therapeutics-for-its-first-in-class-car-t-candidate/2025-07-01T22:59:45+08:00https://flcube.com/chia-tai-tianqings-anlotinib-granted-nmpa-approval-for-soft-tissue-sarcoma/2025-07-01T18:02:31+08:00https://flcube.com/huadong-medicines-first-in-class-adc-hdm2012-gains-fda-phase-i-trial-clearance/2025-07-01T17:56:07+08:00https://flcube.com/china-unveils-measures-to-boost-innovative-drug-development-with-insurance-data-support/2025-07-01T17:44:37+08:00https://flcube.com/hutchmeds-orpathys-approved-in-china-for-egfr-met-co-mutation-nsclc/2025-07-01T17:23:43+08:00https://flcube.com/recbio-partners-with-biological-e-for-hpv-vaccinerec603s-india-and-global-expansion/2025-07-01T17:16:35+08:00https://flcube.com/astellas-pharmas-vyloy-gains-first-prescriptions-across-china-for-gastric-cancer/2025-07-01T17:07:30+08:00https://flcube.com/guangdong-announces-first-batch-of-approved-innovative-drugs-and-medical-devices/2025-07-01T16:59:09+08:00https://flcube.com/santens-tapcom-administered-to-first-patient-in-gba-via-drug-access-policy/2025-07-01T16:54:51+08:00https://flcube.com/zhaoke-ophthalmology-partners-with-jamjoom-pharma-for-cyclosporine-eye-gel-distribution-in-middle-east/2025-07-01T16:40:59+08:00https://flcube.com/ascletis-faces-patent-challenge-from-cspc-subsidiary-conjupro-bio/2025-07-01T16:33:04+08:00https://flcube.com/fosun-pharma-secures-licensing-deal-for-hcb101-sirp%ce%b1-fc-fusion-protein/2025-07-01T15:26:57+08:00https://flcube.com/zai-labs-bemarituzumab-meets-phase-iii-endpoint-in-gastric-cancer-trial/2025-07-01T15:14:24+08:00https://flcube.com/hengrui-pharmaceuticals-aihengping-gains-nmpa-approval-for-regional-analgesia/2025-07-01T14:57:27+08:00https://flcube.com/avistones-vebreltinib-wins-nmpa-approval-for-met-amplified-nsclc/2025-07-01T14:46:54+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-aisuda-in-severe-alopecia-areata/2025-07-01T14:33:27+08:00https://flcube.com/microport-neurotechs-numen-nest-gains-fda-marketing-approval/2025-07-01T00:48:37+08:00https://flcube.com/bms-secures-fda-approval-for-updated-labels-of-breyanzi-and-abecma/2025-07-01T00:35:58+08:00https://flcube.com/genscript-receives-213-8m-payment-from-lanova-for-pd-1-antibody-license/2025-06-30T23:20:54+08:00https://flcube.com/ucbs-fenfluramine-shows-positive-results-in-phase-iii-gemz-study-for-cdkl5-deficiency-disorder/2025-06-30T22:52:49+08:00https://flcube.com/sunshine-lake-pharma-lists-on-hkex-via-introduction-method/2025-06-30T22:37:59+08:00https://flcube.com/mgi-tech-partners-with-italys-negedia-to-advance-genomic-sequencing-and-spatial-transcriptomics/2025-06-30T16:30:45+08:00https://flcube.com/china-proposes-healthcare-security-law-to-strengthen-medical-insurance-system/2025-06-30T16:14:19+08:00https://flcube.com/quantumpharm-and-pfizer-expand-collaboration-on-advanced-molecular-simulation-platform/2025-06-30T15:59:38+08:00https://flcube.com/blissbio-inc-files-for-hong-kong-ipo-to-advance-oncology-focused-adc-pipeline/2025-06-30T15:50:06+08:00https://flcube.com/fda-removes-rems-requirements-for-bcma-and-cd19-targeted-car-t-therapies/2025-06-30T15:38:49+08:00https://flcube.com/profound-therapeutics-and-novartis-forge-four-year-partnership-for-cardiovascular-drug-targets/2025-06-30T15:32:32+08:00https://flcube.com/diagens-biotechs-ai-imaging-platform-imedimage-makes-hong-kong-ipo-debut/2025-06-30T15:20:43+08:00https://flcube.com/pfizers-emblaveo-approved-by-chinas-nmpa-for-complex-infections/2025-06-30T15:12:07+08:00https://flcube.com/gileads-lenacapavir-approved-in-hainan-for-hiv-1-pre-exposure-prophylaxis/2025-06-30T15:05:26+08:00https://flcube.com/genfleet-therapeutics-files-for-hong-kong-ipo-amid-kras-inhibitor-success/2025-06-30T14:58:07+08:00https://flcube.com/dk-medtech-partners-with-mozarc-medical-to-enhance-hemodialysis-access-solutions/2025-06-28T00:25:22+08:00https://flcube.com/acip-recommends-msds-enflonsia-for-infants-under-8-months-to-prevent-rsv/2025-06-27T17:15:47+08:00https://flcube.com/viatris-announces-positive-results-in-vega-3-trial-for-mr-141-presbyopia-treatment/2025-06-27T17:07:41+08:00https://flcube.com/jenscares-lux-valve-plus-shows-promising-results-in-global-trinity-study/2025-06-27T16:58:47+08:00https://flcube.com/innovent-biologics-mazdutide-gets-nmpa-nod-for-weight-management/2025-06-27T16:43:33+08:00https://flcube.com/mabwell-bioscience-partners-with-calico-life-sciences-on-9mw3811-development/2025-06-27T16:35:37+08:00https://flcube.com/china-raises-subsidy-for-basic-public-health-services-targets-vulnerable-groups/2025-06-27T16:18:34+08:00https://flcube.com/hua-dong-medicines-hdm2020-gains-nmpa-approval-for-clinical-trials/2025-06-27T16:06:56+08:00https://flcube.com/cutia-therapeutics-phase-iii-results-for-lidocaine-tetracaine-cream-to-be-presented-at-csd-meeting/2025-06-27T16:00:23+08:00https://flcube.com/novartis-completes-acquisition-of-regulus-therapeutics-for-adpkd-treatment/2025-06-27T15:51:53+08:00https://flcube.com/sino-biopharmaceuticals-lm-108-gains-cde-btd-for-gastric-adenocarcinoma/2025-06-27T15:40:46+08:00https://flcube.com/mabwell-bioscience-grants-qilu-pharma-exclusive-rights-to-mailisheng-in-greater-china/2025-06-27T15:24:33+08:00https://flcube.com/fosun-pharmas-serplulimab-approved-for-es-sclc-in-the-uk-and-india/2025-06-26T23:03:59+08:00https://flcube.com/sanofis-riliprubart-granted-orphan-drug-status-for-antibody-mediated-rejection-treatment/2025-06-26T22:53:01+08:00https://flcube.com/bio-thera-solutions-initiates-phase-iii-trial-of-bat8006-for-platinum-resistant-ovarian-cancer/2025-06-26T22:46:57+08:00https://flcube.com/astrazeneca-restructures-to-form-gastrointestinal-oncology-business-unit/2025-06-26T22:38:07+08:00https://flcube.com/ema-panel-recommends-brukinsa-tablet-formulation-for-approval/2025-06-26T22:33:23+08:00https://flcube.com/sinocelltech-wins-nmpa-clearance-for-triab-sctb39g-in-solid-tumors/2025-06-26T17:46:09+08:00https://flcube.com/carsgens-satri-cel-nda-accepted-by-chinas-nmpa-for-gastric-adenocarcinoma/2025-06-26T17:38:01+08:00https://flcube.com/lepu-biopharma-gains-ema-approval-for-mrg003-hnscc-clinical-trial/2025-06-26T16:39:17+08:00https://flcube.com/remegen-inks-global-licensing-pact-with-vor-biopharma-for-telitacicept/2025-06-26T16:29:59+08:00https://flcube.com/angel-pharma-gains-nmpa-approval-for-soquelitinib-in-atopic-dermatitis-trial/2025-06-26T16:16:50+08:00https://flcube.com/biogens-phase-i-results-highlight-salanersens-potential-in-spinal-muscular-atrophy/2025-06-26T16:04:12+08:00https://flcube.com/kymera-and-sanofi-advance-irak4-program-with-selection-of-kt-485-for-clinical-development/2025-06-26T15:56:56+08:00https://flcube.com/lg-chems-cross-linked-sodium-hyaluronate-gel-gains-nmpa-approval-for-midface-use/2025-06-26T15:49:15+08:00https://flcube.com/eli-lillys-amyvid-sees-fda-approved-label-update-for-alzheimers-diagnosis/2025-06-26T15:33:44+08:00https://flcube.com/gilead-signs-licensing-pact-with-kymera-therapeutics-for-cdk2-targeted-mgd/2025-06-26T15:22:53+08:00https://flcube.com/sineugenes-als-gene-therapy-snug01-granted-fda-orphan-drug-designation/2025-06-26T15:14:25+08:00https://flcube.com/acotec-scientific-wins-nmpa-approval-for-armoni-hp-balloon-catheter/2025-06-26T15:00:19+08:00https://flcube.com/immvira-bioscience-files-for-hong-kong-ipo-to-advance-oncolytic-immunotherapy-pipeline/2025-06-26T14:41:48+08:00https://flcube.com/immvira-partners-with-china-resources-biopharmaceutical-on-oncolytic-virus-mvr-c5252-for-gliomas/2025-06-26T14:02:21+08:00https://flcube.com/immviras-oncolytic-virus-mvr-c5252-receives-fda-orphan-drug-designation-for-glioma/2025-06-26T14:02:20+08:00https://flcube.com/immvira-secures-series-c-financing-to-advance-oncolytic-virus-and-exosome-programs/2025-06-26T14:02:19+08:00https://flcube.com/immviras-mvr-t3011-it-shows-efficacy-in-melanoma-treatment/2025-06-26T14:02:18+08:00https://flcube.com/immviras-mvr-c5252-receives-nmpa-approval-for-glioma-treatment-development/2025-06-26T14:02:17+08:00https://flcube.com/obio-technology-and-immvira-partner-on-oncolytic-virus-project-for-bla-filing-and-commercialization/2025-06-26T14:02:16+08:00https://flcube.com/immviras-mvr-t3011-iv-achieves-positive-outcomes-in-us-phase-i-clinical-study/2025-06-26T14:02:15+08:00https://flcube.com/immvira-commences-phase-ii-trial-for-mvr-t3011-in-high-risk-nmibc/2025-06-26T14:02:14+08:00https://flcube.com/genevectors-jwk002-gains-nmpa-ind-approval-for-xlrs-gene-therapy/2025-06-26T12:24:30+08:00https://flcube.com/xtalpi-signs-loi-with-dovetree-for-ai-powered-drug-development/2025-06-26T12:12:39+08:00https://flcube.com/cms-plans-secondary-listing-on-singapore-exchange-to-enhance-shareholder-base-and-liquidity/2025-06-25T23:07:31+08:00https://flcube.com/livzons-yjh-012-sirna-drug-gets-nmpa-green-light-for-gout-trials/2025-06-25T22:54:27+08:00https://flcube.com/ge-healthcare-wins-fda-approval-for-vizamyl-label-update-in-alzheimers-detection/2025-06-25T22:44:16+08:00https://flcube.com/nhsa-emphasizes-management-of-designated-medical-institutions-for-healthcare-quality/2025-06-25T22:32:53+08:00https://flcube.com/suzhou-porton-biologics-partners-with-future-biotechnology-to-expand-viral-vector-services/2025-06-25T16:55:32+08:00https://flcube.com/lundbecks-lu-ag13909-wins-orphan-drug-designations-for-congenital-adrenal-hyperplasia/2025-06-25T15:51:42+08:00https://flcube.com/henlius-biotech-doses-first-patient-in-japanese-bridging-trial-of-serplulimab-for-es-sclc/2025-06-25T15:45:15+08:00https://flcube.com/c-q-pharmas-prasugrel-clinical-filing-accepted-by-chinas-nmpa/2025-06-25T15:37:41+08:00https://flcube.com/beone-medicines-launches-ziihera-for-her2-high-biliary-tract-cancer-in-china/2025-06-25T14:47:35+08:00https://flcube.com/bio-thera-partners-with-steincares-for-biosimilar-commercialization-in-latin-america/2025-06-25T14:32:25+08:00https://flcube.com/tingsn-technology-secures-rmb-100m-in-series-b-round-for-4d-intracardiac-ultrasound-rd/2025-06-25T13:03:49+08:00https://flcube.com/bayer-and-tsinghua-university-renew-strategic-research-pact-for-drug-innovation/2025-06-25T12:55:57+08:00https://flcube.com/dynamiker-bios-aspergillus-detection-kit-wins-nmpa-marketing-approval/2025-06-25T12:46:59+08:00https://flcube.com/gsk-gains-fda-clearance-for-benlysta-autoinjector-in-pediatric-lupus-nephritis/2025-06-25T12:38:33+08:00https://flcube.com/medilink-therapeutics-yl201-wins-fda-breakthrough-therapy-designation-for-sclc/2025-06-25T12:33:33+08:00https://flcube.com/siemens-healthineers-collaborates-with-mgh-to-advance-theranostics-applications/2025-06-25T00:31:21+08:00https://flcube.com/fda-approves-astrazenecas-datopotamab-deruxtecan-for-egfr-mutated-nsclc/2025-06-25T00:26:38+08:00https://flcube.com/transthera-sciences-tinengotinib-gains-fda-fast-track-for-mcrpc-treatment/2025-06-25T00:19:14+08:00https://flcube.com/mercks-prevymis-approved-in-china-for-pediatric-cmv-prevention/2025-06-25T00:01:14+08:00https://flcube.com/sansure-biotech-wins-nmpa-approval-for-fungal-infection-detection-kit/2025-06-24T23:54:53+08:00https://flcube.com/broncus-medical-wins-nmpa-approval-for-broncablate-rfa-system-console/2025-06-24T23:45:31+08:00https://flcube.com/nhsa-implements-region-based-pricing-system-for-medical-services/2025-06-24T23:35:57+08:00https://flcube.com/insilico-medicine-partners-with-uaeu-to-drive-biotech-innovation-in-the-middle-east/2025-06-24T23:27:41+08:00https://flcube.com/vcanbio-submits-clinical-trial-application-for-vum02-in-severe-pneumonia-treatment/2025-06-24T23:18:22+08:00https://flcube.com/simcere-halts-rd-on-alzheimers-drug-candidates-amid-pipeline-setbacks/2025-06-24T23:10:29+08:00https://flcube.com/yifan-pharma-wins-nmpa-approval-for-norditropin-biosimilar-trial/2025-06-24T22:59:05+08:00https://flcube.com/gsks-linerixibat-accepted-for-ema-review-for-cholestatic-pruritus-in-pbc/2025-06-24T22:53:08+08:00https://flcube.com/sanofis-sarclisa-recommended-for-eu-approval-in-newly-diagnosed-multiple-myeloma/2025-06-24T21:18:15+08:00https://flcube.com/beijing-tightens-price-risk-management-for-scarce-medications/2025-06-24T21:04:32+08:00https://flcube.com/cloudbreak-pharmas-ipo-raises-hkd-522m-for-ophthalmic-drug-development/2025-06-24T17:57:21+08:00https://flcube.com/formation-bio-licenses-gusacitinib-to-sanofi-for-novel-indication-study/2025-06-24T17:41:50+08:00https://flcube.com/astrazenecas-oncology-executive-mike-la-to-leave-company-in-june/2025-06-24T16:33:53+08:00https://flcube.com/novo-nordisks-ozempic-gets-positive-chmp-opinion-for-peripheral-artery-disease/2025-06-24T16:20:35+08:00https://flcube.com/illumina-to-acquire-somalogic-for-350m-to-expand-proteomics-tech-integration/2025-06-24T15:17:31+08:00https://flcube.com/denovo-biopharma-inks-licensing-deal-with-chuang-yi-for-db104-in-taiwan/2025-06-24T12:26:59+08:00https://flcube.com/hengrui-pharmaceuticals-wins-nmpa-approval-for-six-novel-solid-tumor-drugs/2025-06-23T21:20:54+08:00https://flcube.com/gan-lee-pharmaceuticals-presents-phase-ii-results-of-gzr18-and-gzr4-at-ada-scientific-sessions/2025-06-23T21:10:46+08:00https://flcube.com/ema-panel-recommends-bio-theras-usymro-for-autoimmune-diseases/2025-06-23T20:54:53+08:00https://flcube.com/jjs-darzalex-sc-recommended-by-chmp-for-high-risk-smoldering-multiple-myeloma/2025-06-23T20:43:59+08:00https://flcube.com/eli-lillys-efsitora-meets-key-endpoints-in-phase-iii-trials-for-type-2-diabetes/2025-06-23T20:39:18+08:00https://flcube.com/johnson-johnsons-imbruvica-secures-chmp-recommendation-for-expanded-mcl-use/2025-06-23T20:33:35+08:00https://flcube.com/bayers-nubeqa-receives-positive-chmp-opinion-for-mhspc-treatment/2025-06-23T20:25:50+08:00https://flcube.com/boao-lecheng-partners-with-china-national-center-for-neurological-diseases-to-establish-translational-center/2025-06-23T20:21:22+08:00https://flcube.com/sichuan-huiyus-cdcp1-targeted-adc-hy0001a-gets-nmpa-clinical-trial-approval/2025-06-23T17:54:04+08:00https://flcube.com/changshan-biochemical-receives-nmpa-clearance-for-albenatide-in-weight-loss-trials/2025-06-23T17:38:50+08:00https://flcube.com/immuneonco-receives-nmpa-approval-for-imc-003-imm72-in-pulmonary-arterial-hypertension-trial/2025-06-23T17:30:37+08:00https://flcube.com/united-imaging-intelligence-closes-rmb-1b-series-a-round-to-boost-ai-in-healthcare/2025-06-23T17:24:19+08:00https://flcube.com/mgi-techs-dnbseq-t1-gains-ce-ivdr-certification-for-eu-market-entry/2025-06-23T16:19:12+08:00https://flcube.com/jiangxi-rimag-to-acquire-70-stake-in-guangzhou-gaomai-for-rmb-54-million/2025-06-23T16:15:05+08:00https://flcube.com/simcere-pharmas-quviviq-receives-nmpa-approval-for-insomnia-treatment/2025-06-23T16:06:20+08:00https://flcube.com/sanofi-and-regeneron-win-fda-approval-for-dupixent-in-bullous-pemphigoid-treatment/2025-06-23T15:57:47+08:00https://flcube.com/zai-labs-partner-argenx-secures-eu-approval-for-vygart-in-cidp-treatment/2025-06-23T15:38:58+08:00https://flcube.com/harbour-biomed-and-otsuka-pharma-collaborate-globally-on-bcmaxcd3-bispecific-t-cell-engager/2025-06-23T15:03:07+08:00https://flcube.com/cansino-biologics-pcv13i-vaccine-gains-nmpa-approval/2025-06-23T13:00:15+08:00https://flcube.com/zhongsheng-pharmas-ray1225-enters-phase-iii-trial-for-obesity-overweight-treatment/2025-06-20T23:11:20+08:00https://flcube.com/dizals-phase-iii-trial-completes-enrollment-for-shuwozhe-in-egfr-exon20ins-nsclc/2025-06-20T23:01:01+08:00https://flcube.com/shanghai-pharmaceuticals-receives-thai-fda-approval-for-pregabalin-capsules/2025-06-20T17:38:39+08:00https://flcube.com/wantai-biological-launches-phase-iii-trial-for-vzv-7d-varicella-vaccine/2025-06-20T16:03:32+08:00https://flcube.com/msd-initiates-ideate-prostate01-phase-iii-trial-of-ifinatamab-deruxtecan-for-mcrpc/2025-06-20T15:57:16+08:00https://flcube.com/changchun-bcht-gains-nmpa-approval-for-bk-01-adjuvanted-influenza-vaccine/2025-06-20T15:50:53+08:00https://flcube.com/nmpas-cde-reports-4900-clinical-trial-filings-for-innovative-drugs-in-2024/2025-06-20T15:41:58+08:00https://flcube.com/beijing-science-sun-pharma-inks-rmb20m-drug-tech-transfer-pact-for-neoab33-project/2025-06-20T15:37:38+08:00https://flcube.com/cde-issues-new-requirements-for-ind-applications-of-innovative-drugs/2025-06-20T15:31:40+08:00https://flcube.com/advanz-pharma-acquires-bayers-testoviron-commercial-rights-in-key-markets/2025-06-20T15:23:11+08:00https://flcube.com/medtides-ipo-raises-hkd-514-million-to-expand-global-peptide-crdmo-services/2025-06-20T15:15:02+08:00https://flcube.com/shanghai-innogens-diabetes-drug-patent-for-efsubaglutide-alfa-fully-invalidated/2025-06-20T15:05:44+08:00https://flcube.com/shandong-xinhua-pharma-initiates-phase-ii-study-of-oab-14-for-alzheimers-disease/2025-06-20T14:36:14+08:00https://flcube.com/bayer-wins-beijing-mpa-approval-for-medrad-stellant-d-ce-medical-device/2025-06-20T14:17:47+08:00https://flcube.com/joincare-pharma-gets-nmpa-green-light-for-pediatric-influenza-drug-jkn2301/2025-06-20T14:13:13+08:00https://flcube.com/sanofi-and-abu-dhabi-department-of-health-collaborate-to-accelerate-vaccine-development/2025-06-20T12:35:03+08:00https://flcube.com/abbott-partners-with-abu-dhabi-department-of-health-to-localize-pharma-production-and-digital-health-solutions/2025-06-20T12:33:34+08:00https://flcube.com/platinum-life-biotechs-ruibosheng-first-prescribed-in-china-for-agvhd-treatment/2025-06-20T12:26:13+08:00https://flcube.com/mindranks-mdr-001-phase-iib-study-achieves-clinical-endpoints-for-weight-loss/2025-06-20T12:18:58+08:00https://flcube.com/eccogene-announces-first-patient-dosing-in-phase-ib-study-of-azd5004-ecc5004-in-china/2025-06-19T15:18:43+08:00https://flcube.com/simcere-zaiming-initiates-us-phase-i-study-of-sim0500-for-relapsed-refractory-multiple-myeloma/2025-06-19T15:06:06+08:00https://flcube.com/fda-launches-elsa-ai-tool-to-enhance-staff-efficiency-in-regulatory-processes/2025-06-19T14:52:45+08:00https://flcube.com/fda-launches-immediate-review-of-clinical-trials-involving-cell-transfer-to-hostile-countries/2025-06-19T14:37:42+08:00https://flcube.com/gileads-yeztugo-approved-by-fda-as-first-six-monthly-injectable-hiv-prep/2025-06-19T14:33:36+08:00https://flcube.com/fosun-pharmas-fumaining-launches-clinically-for-rare-disease-treatment-in-china/2025-06-19T14:28:03+08:00https://flcube.com/fda-launches-commissioners-national-priority-voucher-program-for-accelerated-drug-reviews/2025-06-19T14:12:38+08:00https://flcube.com/hengrui-pharmas-ruitanning-enters-clinical-use-for-chemo-induced-nausea-and-vomiting/2025-06-19T14:06:52+08:00https://flcube.com/mercks-clesrovimab-gears-up-for-priority-review-in-china-for-rsv-prevention/2025-06-19T14:01:33+08:00https://flcube.com/sanofis-tzield-prescribed-in-boao-lecheng-to-delay-onset-of-type-1-diabetes/2025-06-18T22:26:36+08:00https://flcube.com/allgens-medicals-skuheal-artificial-bone-repair-material-gains-vietnam-marketing-approval/2025-06-18T21:44:26+08:00https://flcube.com/clover-biopharmaceuticals-completes-enrollment-for-phase-i-trial-of-rsv-hmpv-combination-vaccines/2025-06-18T21:28:42+08:00https://flcube.com/shanghai-henlius-biotech-partners-with-shanghai-chest-hospital-for-clinical-research-and-talent-development/2025-06-18T21:22:34+08:00https://flcube.com/remegens-telitacicept-receives-orphan-drug-designation-for-myasthenia-gravis-in-europe/2025-06-18T18:07:46+08:00https://flcube.com/yunnan-baiyaos-jz-14-gets-nmpa-clinical-clearance-for-ulcerative-colitis-trial/2025-06-18T17:08:13+08:00https://flcube.com/johnson-johnson-submits-sbla-to-expand-stelara-use-for-pediatric-crohns-disease/2025-06-18T16:58:03+08:00https://flcube.com/suzhou-zelgen-gains-nmpa-approval-for-zg005-and-zg006-combination-trial-in-advanced-cancers/2025-06-18T16:53:38+08:00https://flcube.com/mindray-bio-medical-expands-north-american-warehouse-to-enhance-operational-efficiency/2025-06-18T16:46:56+08:00https://flcube.com/gsk-launches-linked-by-lupus-initiative-to-support-lupus-care-with-1m-funding/2025-06-18T16:42:55+08:00https://flcube.com/bayer-files-nda-for-gadoquatrane-aiming-to-offer-lowest-dose-gbca-in-the-u-s/2025-06-18T16:36:40+08:00https://flcube.com/epimab-biotherapeutics-submits-hong-kong-ipo-application-as-biotech-expands/2025-06-18T16:30:11+08:00https://flcube.com/sinocelltech-gains-nmpa-clearance-for-sctb39-1-clinical-study-in-advanced-solid-tumors/2025-06-18T16:25:12+08:00https://flcube.com/santens-ryjunea-gets-eu-approval-to-slow-myopia-progression-in-children/2025-06-18T16:17:24+08:00https://flcube.com/takedas-shan-guohong-departs-to-join-beone-medicines-as-next-career-move/2025-06-18T00:22:43+08:00https://flcube.com/novo-nordisk-partners-with-alibaba-health-to-launch-weight-management-hub/2025-06-18T00:14:46+08:00https://flcube.com/legend-biotech-plans-to-disband-china-sales-team-amid-carvykti-commercialization-challenges/2025-06-18T00:06:02+08:00https://flcube.com/pierre-fabre-acquires-global-rights-to-egfr-inhibitors-pfl-721-and-pfl-241-from-antares-therapeutics/2025-06-17T23:16:03+08:00https://flcube.com/hasten-biopharmaceutical-accelerates-asia-pacific-expansion-with-11-mat-transfers/2025-06-17T23:03:20+08:00https://flcube.com/sino-biopharmaceuticals-tdi01-receives-breakthrough-therapy-designation-for-cgvhd-treatment/2025-06-17T22:03:11+08:00https://flcube.com/3d-medicines-partners-with-mgi-tech-for-precision-medicine-solutions-in-oncology-and-infectious-diseases/2025-06-17T21:57:05+08:00https://flcube.com/fosun-pharma-collaborates-with-teva-on-development-of-tev-56278-in-china-and-southeast-asia/2025-06-17T17:57:24+08:00https://flcube.com/biomerieux-set-to-acquire-day-zero-diagnostics-to-boost-infectious-disease-rd-pipeline/2025-06-17T16:42:53+08:00https://flcube.com/suzhou-genassists-gen6050x-gains-fda-orphan-drug-status-for-duchenne-muscular-dystrophy/2025-06-17T16:28:47+08:00https://flcube.com/biotroy-therapeutics-secures-usd-28m-in-series-a-funding-for-cd3l1-anti-tumor-drug-development/2025-06-17T16:04:19+08:00https://flcube.com/glycot-therapeutics-partners-with-innovent-biologics-to-advance-adc-technology/2025-06-17T15:57:49+08:00https://flcube.com/shanghai-escugen-and-sunrock-biopharma-collaborate-on-first-in-class-ccr9-targeted-adc/2025-06-17T15:45:13+08:00https://flcube.com/abbvies-venclexta-fails-to-meet-overall-survival-endpoint-in-hr-mds-trial/2025-06-17T15:36:07+08:00https://flcube.com/harbour-biomed-wins-cnipa-validation-of-binding-molecule-patent-amid-dispute/2025-06-17T15:31:32+08:00https://flcube.com/roche-advances-prasinezumab-to-phase-iii-for-early-parkinsons-disease/2025-06-17T15:24:53+08:00https://flcube.com/simcere-and-nextcure-forge-strategic-alliance-to-co-develop-sim0505-adc-for-solid-tumors/2025-06-17T15:11:11+08:00https://flcube.com/eli-lilly-close-to-acquiring-verve-therapeutics-for-up-to-usd-1-3-billion/2025-06-17T14:42:08+08:00https://flcube.com/pediatrix-therapeutics-wins-macau-approval-for-neffy-epinephrine-nasal-spray/2025-06-17T14:28:40+08:00https://flcube.com/minova-pharmaceuticals-launches-rongzhi-chinas-first-injectable-adipocytolytic-drug/2025-06-17T00:51:36+08:00https://flcube.com/remegen-secures-1827-day-patent-extension-for-telitacicept-in-china/2025-06-17T00:41:19+08:00https://flcube.com/fujian-cosunter-gains-ethics-approval-for-phase-iii-study-of-neracorvir-in-chb-patients/2025-06-17T00:35:39+08:00https://flcube.com/cde-accepts-nda-for-ark-bios-azstarys-a-priority-reviewed-adhd-treatment/2025-06-17T00:27:12+08:00https://flcube.com/ascentage-pharma-highlights-hematology-advances-at-eha-2025-focus-on-olverembatinib-and-apg-5918/2025-06-17T00:18:46+08:00https://flcube.com/clover-biopharmaceuticals-terminates-adimmune-influenza-vaccine-pact-over-market-shifts/2025-06-17T00:12:31+08:00https://flcube.com/fosun-pharmas-serplulimab-approved-in-singapore-and-malaysia-for-es-sclc-treatment/2025-06-17T00:02:20+08:00https://flcube.com/chinas-nhc-unveils-2025-healthcare-reforms-to-tackle-procurement-and-service-irregularities/2025-06-16T23:56:48+08:00https://flcube.com/thermo-fisher-mulls-4b-diagnostic-business-sale-amid-healthcare-sector-turbulence/2025-06-16T21:46:36+08:00https://flcube.com/changchun-high-tech-subsidiary-gains-nmpa-approval-for-cinv-drug-trial/2025-06-16T21:38:37+08:00https://flcube.com/novo-nordisk-advances-amycretin-for-weight-management-in-phase-iii-trials/2025-06-16T21:30:18+08:00https://flcube.com/fda-oks-msds-keytruda-for-perioperative-head-and-neck-cancer-treatment-with-pd-l1-expression/2025-06-16T17:49:21+08:00https://flcube.com/gsk-seeks-ema-approval-to-expand-rsv-vaccine-arexvy-use-to-adults-aged-18/2025-06-16T17:31:25+08:00https://flcube.com/ucb-announces-investment-in-u-s-biologics-production-facility/2025-06-16T17:21:03+08:00https://flcube.com/gene-solutions-partners-with-shenzhen-usk-bio-to-advance-precision-oncology-in-southern-china/2025-06-16T17:15:31+08:00https://flcube.com/mri-and-astellas-alliance-to-boost-japanese-drug-discovery-startups/2025-06-16T16:39:27+08:00https://flcube.com/msd-wins-nmpa-approval-for-keytruda-lenvima-combo-in-hepatocellular-carcinoma/2025-06-16T15:33:41+08:00https://flcube.com/xuanzhu-biopharma-files-for-hong-kong-ipo-to-advance-innovative-drug-pipeline/2025-06-16T15:21:35+08:00https://flcube.com/roche-imposes-new-dosing-restrictions-on-elevidys-for-non-ambulatory-dmd-patients/2025-06-16T15:14:09+08:00https://flcube.com/innovent-biologics-initiates-phase-iii-trial-for-mazdutide-in-osa-and-obesity/2025-06-16T15:06:59+08:00https://flcube.com/abbisko-therapeutics-launches-clinical-study-of-fgfr4-inhibitor-in-advanced-hepatocellular-carcinoma/2025-06-16T14:24:16+08:00https://flcube.com/dessight-biomedical-secures-rmb-100m-series-a-funding-for-surgical-robot-development/2025-06-16T14:19:20+08:00https://flcube.com/astrazeneca-launches-truqap-in-china-for-pik3ca-akt1-pten-altered-breast-cancer/2025-06-16T12:55:40+08:00https://flcube.com/cr-sanjiu-partners-with-help-therapeutics-to-advance-ipsc-based-heart-failure-therapy/2025-06-16T12:44:11+08:00https://flcube.com/raffles-medical-partners-with-cqmu-first-hospital-to-enhance-healthcare-services/2025-06-16T12:18:28+08:00https://flcube.com/astrazeneca-and-cspc-pharma-collaborate-on-novel-oral-drug-discovery/2025-06-16T12:08:58+08:00https://flcube.com/cf-pharmtech-files-for-hong-kong-ipo-to-expand-respiratory-disease-treatments/2025-06-16T12:04:11+08:00https://flcube.com/cloudbreak-pharma-files-for-hong-kong-ipo-amid-ophthalmic-drug-development/2025-06-16T11:51:34+08:00https://flcube.com/nona-biosciences-licenses-hcab-technology-to-visterra-for-biologic-development/2025-06-13T16:28:56+08:00https://flcube.com/biontech-in-deal-to-acquire-curevac-for-1-25b-to-boost-cancer-mrna-therapies/2025-06-13T16:16:33+08:00https://flcube.com/abbvies-mavyret-gains-fda-approval-for-acute-hcv-in-children-and-adults/2025-06-13T16:07:47+08:00https://flcube.com/zhaoke-ophthalmologys-tab014-receives-bla-review-for-wamd-treatment/2025-06-13T16:00:03+08:00https://flcube.com/gsk-licenses-shigella-vaccine-to-bharat-biotech-for-low-and-middle-income-countries/2025-06-13T15:51:19+08:00https://flcube.com/merck-launches-phase-iii-trial-for-quadrivalent-dengue-vaccine-v181/2025-06-13T15:43:00+08:00https://flcube.com/nvidia-and-novo-nordisk-collaborate-to-accelerate-ai-driven-drug-discovery/2025-06-13T15:36:49+08:00https://flcube.com/sanofis-rilzabrutinib-shows-promise-in-igg4-related-disease-trial/2025-06-13T15:26:42+08:00https://flcube.com/bayer-extends-genomics-partnership-with-broad-institute-for-cardiology-research/2025-06-13T15:20:42+08:00https://flcube.com/bayzed-health-launches-hk-ipo-to-expand-cancer-care-services/2025-06-13T15:00:27+08:00https://flcube.com/transthera-sciences-sets-hong-kong-ipo-at-hkd13-15-per-share/2025-06-13T14:50:17+08:00https://flcube.com/beone-medicines-wins-fda-approval-for-brukinsa-tablet-across-all-five-indications/2025-06-13T13:33:36+08:00https://flcube.com/gene-solutions-partners-with-topgen-biopharm-to-advance-precision-oncology-in-asia/2025-06-13T13:28:39+08:00https://flcube.com/suzhous-mei-medical-secures-rmb-100m-funding-for-eptfe-innovation/2025-06-13T13:22:17+08:00https://flcube.com/bms-reports-positive-poetyk-psa-1-results-for-sotyktu-in-psoriatic-arthritis/2025-06-13T13:11:38+08:00https://flcube.com/lilly-launches-mounjaro-multi-dose-pen-in-china-for-diabetes-and-weight-management/2025-06-13T13:07:42+08:00https://flcube.com/xtalpi-acquires-liverpool-chirochem-to-boost-ai-driven-drug-discovery/2025-06-12T16:12:56+08:00https://flcube.com/shandong-boan-partners-with-shanghai-pharma-for-ba5101-diabetes-drug/2025-06-12T15:53:54+08:00https://flcube.com/gccf-and-cttq-explore-collaboration-to-expand-innovative-drug-access-in-hong-kong/2025-06-12T15:46:52+08:00https://flcube.com/escugen-partners-with-sovranbio-to-accelerate-development-of-antibody-drug-conjugates/2025-06-12T15:26:08+08:00https://flcube.com/varian-medical-systems-secures-nmpa-approval-for-ethos-2-0-ai-radiotherapy-platform/2025-06-12T15:11:00+08:00https://flcube.com/novo-nordisk-china-restructures-to-form-new-obesity-and-diabetes-department/2025-06-12T15:00:44+08:00https://flcube.com/eli-lilly-partners-with-juvena-therapeutics-on-muscle-health-ai-platform/2025-06-12T14:38:09+08:00https://flcube.com/daiichi-sankyo-launches-phase-i-trial-for-enhertu-subcutaneous-formulation/2025-06-12T14:16:58+08:00https://flcube.com/nmpa-issues-immediate-guidelines-for-ngs-related-ivd-reagent-classification/2025-06-12T13:53:19+08:00https://flcube.com/china-updates-class-3-hospital-accreditation-standards-for-2025/2025-06-12T13:49:45+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-phase-iii-trial-of-roflumilast-foam/2025-06-11T23:26:55+08:00https://flcube.com/chinas-sichuan-kelun-biotech-wins-btd-for-sac-tmt-in-non-squamous-nsclc/2025-06-11T23:11:37+08:00https://flcube.com/chinas-cde-seeks-feedback-on-advanced-therapy-medicinal-products-guidelines/2025-06-11T23:05:18+08:00https://flcube.com/philochem-grants-rayzebio-global-rights-to-oncoacp3-for-prostate-cancer/2025-06-11T23:00:58+08:00https://flcube.com/henlius-biotech-starts-global-phase-ii-trial-for-pd-l1-adc-hlx43/2025-06-11T22:18:01+08:00https://flcube.com/tawada-healthcare-secures-series-a-funding-led-by-highlight-capital/2025-06-11T21:45:21+08:00https://flcube.com/mercks-pimicotinib-nda-accepted-for-review-by-chinas-cde/2025-06-11T15:35:32+08:00https://flcube.com/cspc-pharmas-sys6040-adc-gains-fda-clinical-trial-approval/2025-06-11T14:56:36+08:00https://flcube.com/state-council-issues-opinions-to-advance-shenzhens-healthcare-reforms/2025-06-11T14:24:17+08:00https://flcube.com/eisais-urece-arrives-in-shanghai-poised-for-chinese-market-entry/2025-06-11T12:56:49+08:00https://flcube.com/sanofi-to-ship-beyfortus-ahead-of-rsv-season-ensuring-global-availability/2025-06-11T12:49:16+08:00https://flcube.com/boai-nkys-lyc001-receives-clinical-approval-in-china-for-advanced-solid-tumors/2025-06-11T12:39:29+08:00https://flcube.com/sino-biopharmaceuticals-tqb2868-approved-for-phase-iii-trial-in-metastatic-pancreatic-cancer/2025-06-11T12:18:33+08:00